Novel type vi crispr originogs and systems
Through the VI-B type CRISPR-Cas system, the specific degradation of RNA in eukaryotic cells is achieved using Cas13b effector protein and crRNA, solving the reliability problem of RNA targeting technology in mammalian systems and providing an efficient genome Editing and distraction tools.
Patent Information
- Application Number
- CN202410945478.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-10-04
- Filing Date
- 2018-04-11
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to achieve effective targeting and editing of nucleic acids or polynucleotides in eukaryotic systems, especially in mammalian systems, and there is a lack of reliable systems and tools for the application of RNA targeting technology.
A VI-B type CRISPR-Cas system was developed, which uses the Cas13b effector protein to bind to crRNA, and realizes specific degradation of RNA by guiding the complementary binding of the sequence to the target RNA, and regulates the activity of Cas13b through the auxiliary protein Csx27 or Csx28. , CRISPR complexes are formed to edit and interfere with targeted RNA.
Provides a reliable RNA targeting system that can effectively detect, analyze and manipulate RNA in eukaryotic cells, realize interference or editing of specific target sites, and is suitable for genomic engineering and biotechnology applications, improving system flexibility Sex and extensibility.
Smart Images

Figure CN118995694A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of April 11, 2018, application number 201880038907.3, and invention name “Novel Type VI CRISPR Orthologs and Systems”.
[0002] Related Applications and Incorporation by Reference
[0003] This application claims priority to U.S. Provisional Application No. 62 / 484,791, filed on April 12, 2017, U.S. Provisional Application No. 62 / 561,662, filed on September 21, 2017, and U.S. Provisional Application No. 62 / 568,129, filed on October 4, 2017, each of which is incorporated herein by reference in its entirety.
[0004] Reference is made to PCT applications filed on October 21, 2016, including application number PCT / US2016 / 058302 when specifically designating the United States. Reference is made to U.S. Provisional Patent Application 62 / 245,270 filed on October 22, 2015, U.S. Provisional Patent Application 62 / 296,548 filed on February 17, 2016, and U.S. Provisional Patent Applications 62 / 376,367 and 62 / 376,382 filed on August 17, 2016. Further reference is made to US 62 / 471,792 filed on March 15, 2017. Further reference is made to U.S. Provisional Patent Application 62 / 471,170 filed on March 17, 2017. Further reference is made to U.S. Provisional Patent Application 62 / 484,791 filed on April 12, 2017. Further reference is made to U.S. Provisional Patent Application 62 / 561,662 filed on September 21, 2017. The following references are mentioned: Smargon et al. (2017), “Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28,” Molecular Cell 65, 618-630 (February 16, 2017) doi:10.1016 / j.molcel.2016.12.023. (Epub January 5, 2017) and Smargon et al. (2017), “Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28,” bioRxiv 092577; doi:https: / / doi.org / 10.1101 / 092577. (Released December 9, 2017). Each of the foregoing applications and literature citations is hereby incorporated herein by reference.
[0005] All documents cited or referenced in the documents cited herein, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated by reference and may be used in the practice of the present invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
[0006] Statement Regarding Federally Funded Research
[0007] This invention was made with U.S. Government support under Grant Nos. MH100706 and MH110049 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Technical Field
[0008] The present invention generally relates to systems, methods and compositions for controlling gene expression involving sequence targeting (such as gene transcription interference or nucleic acid editing), which systems, methods and compositions can use vector systems related to clustered regularly interspaced short palindromic repeats (CRISPR) and its components. Background Art
[0009] Recent advances in genome sequencing technologies and analytical methods have significantly accelerated the ability to catalog and map genetic factors associated with various biological functions and diseases. Precise genome targeting technologies are needed to achieve systematic reverse engineering of causal genetic variation and advance synthetic biology, biotechnology and medical applications by selectively perturbing single genetic elements. Although genome editing technologies (such as designer zinc fingers, transcription activator-like effectors (TALEs) or homing meganucleases) can be used to generate targeted genome perturbations, new genome and transcriptome engineering technologies that employ novel strategies and molecular mechanisms and are affordable, easy to establish, scalable, and convenient for targeting multiple locations within the eukaryotic genome and transcriptome are still needed. This will provide a major resource for new applications in genome engineering and biotechnology.
[0010] CRISPR-Cas systems of bacterial and archaeal adaptive immunity show extreme diversity in protein composition and genomic locus structure. CRISPR-Cas system loci have more than 50 gene families and no strictly universal genes exist, indicating that locus structure evolves rapidly and is extremely diverse. To date, a multi-pronged approach has been used to comprehensively characterize cas genes for 93 Cas proteins, resulting in approximately 395 maps. The classification includes labeling gene maps plus labeling of locus structure. A new classification of CRISPR-Cas systems is proposed, in which these systems are roughly divided into two categories: Class 1 with multi-subunit effector complexes and Class 2 with single-subunit effector modules exemplified by the Cas9 protein. Novel effector proteins associated with Class 2 CRISPR-Cas systems can be developed as powerful genome engineering tools, and it is important to predict putative novel effector proteins and their engineering and optimization.
[0011] The CRISPR-Cas adaptive immune system protects microorganisms from foreign genetic elements through DNA or RNA-DNA interference. 2 types of single-component CRISPR-Cas effectors target RNA. One such effector is Cas13a (also known as C2c2; see Shmakov et al. (2015) "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems"; Molecular Cell 60:1-13; doi: http: / / dx.doi.org / 10.1016 / j.molcel.2015.10.008), which is characterized as an RNA-guided RNase (Abudayyeh et al. (2016), Science, [Electronic version before print], June 2; "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector"; doi: 10.1126 / science.aaf5573). According to the current classification, Cas13a is a Class 2 VI-A type CRISPR-Cas system. Cas13b provides another option, which is a Class 2 VI-B type effector protein. Class 2 VI-B type effector proteins include two subgroups, namely VI-B1 type and VI-B2 type, also known as 29 group proteins and 30 group proteins, and its members include RNA programmable nucleases, RNA interferons and may involve bacterial adoptive immunity to RNA bacteriophages. (See Smargon A et al., "Cas13b is a Type VI-BCRISPR-associated RNA-Guided RNAse differentially regulated by accessoryproteins Csx27 and Csx28" Molecular Cell (online) January 5, 2017. DOI: 10.1016 / j.molcel.2016.12.023).
[0012] Group 29 and 30 systems include a large effector (about 1100 amino acids in length, called Cas13b) and one or neither of two small putative accessory proteins (about 200 amino acids in length, called Csx27 and Csx28, respectively) near the CRISPR array. Depending on the small proteins nearby, the systems are classified as type VI-B1 (Csx27) or type VI-B2 (Csx28). No other proteins are conserved between species for each locus, either upstream or downstream of the array out to 25 kilobase pairs. With a few exceptions, the CRISPR array contains direct repeats of 36 nucleotides in length and spacers of 30 nucleotides in length. Direct repeats are generally well conserved, especially at the ends, with GTTG / GUUG at the 5' end being reverse complementary to CAAC at the 3' end. This conservation indicates strong base pairing for RNA loop structures that may interact with one or more proteins in the locus. A search for motifs complementary to the direct repeats revealed no candidate tracrRNAs near the array, suggesting only one crRNA similar to that found in the Cpf1 locus.
[0013] Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention. Summary of the invention
[0014] There is an urgent need for optional and reliable systems and techniques for targeting nucleic acids or polynucleotides (e.g., DNA or RNA or any hybrid or derivative thereof) with wide application, particularly in eukaryotic systems, more particularly in mammalian systems. The present invention meets this need and provides related advantages. The addition of the novel RNA targeting system of the present application to the genome, transcriptome and epigenome targeting technology library can be used to transform research and interference or editing of specific target sites by direct detection, analysis and manipulation, particularly in eukaryotic systems, more particularly in mammalian systems (including cells, organs, tissues or organisms). In order to effectively utilize the RNA targeting system of the present application for RNA targeting without harmful effects, it is crucial to understand the engineering and optimization aspects of these RNA targeting tools.
[0015] Class 2 VI-B type effector protein Cas13b is an RNA-guided RNase that can be effectively programmed to degrade ssRNA. The inventors have performed screening to identify a representative number of Cas13b orthologs from different species and determine the efficacy of these orthologs in eukaryotic cell environments. In various embodiments, the present invention relates to, includes or utilizes a VI-B type CRISPR-Cas effector protein or a Cas13b effector protein; and nucleic acids encoding such proteins.
[0016] In some embodiments, the effector protein has at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity to a wild-type Cas13b effector protein of a prokaryotic organism selected from Porphyromonas, Prevotella, Bacteroides, Riemerella, Bergeyella, Alistipes, Myroides, Capnocytophaga, and Flavobacterium. In some embodiments, the effector protein binds to an agent selected from Porphyromonas gulae, Prevotella sp., Porphyromonas gingivalis, Bacteroides pyogenes, Riemerella anatipestifer, Bergeyella zoohelcum, Prevotella intermedia, Prevotella buccae, Alistipes sp., Prevotella aurantiaca, Myroides odoratimimus, Capnocytophaga canimorsus, Flavobacterium branchiophilum, and Flavobacterium columnaris. The wild-type Cas13b effector protein of a prokaryotic organism of columnare has at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity.In a preferred embodiment, the effector protein is selected from oral Porphyromonas Cas13b (accession number WP_039434803), Prevotella P5-125 The wild-type Cas13b effector proteins of Cas13b (accession number WP_044065294), Porphyromonas gingivalis Cas13b (accession number WP_053444417), Porphyromonas COT-052OH4946Cas13b (accession number WP_039428968), Bacteroides pyogenes Cas13b (accession number WP_034542281), and Riemerella anatipestifer Cas13b (accession number WP_004919755) have at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity. The most preferred effector protein is selected from oral Porphyromonas Cas13b (Accession No. WP_039434803), Prevotella P5-125 Cas13b (Accession No. WP_044065294), gingival Porphyromonas Cas13b (Accession No. WP_053444417), Porphyromonas COT-052OH4946 Cas13b (Accession No. WP_039428968); and most particularly preferred is oral Porphyromonas Cas13b (Accession No. WP_039434803) or Prevotella P5-125 The wild-type Cas13b effector protein of Cas13b (Accession No. WP_044065294) has at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity to the effector protein. The complete amino acid sequence of each of these Cas13b effector proteins and other effector proteins is as follows. Figure 1 shown.
[0017] In some embodiments, the Cas13b effector protein (a) comprises 900-1800 amino acids and two HEPN domains, (b) is naturally present in the prokaryotic genome and is located within 10 kb upstream or downstream of the CRISPR array, (c) is the only encoded protein comprising more than 700 amino acids within 10 kb upstream or downstream of the CRISPR array, and / or (d) there is no Cas1 gene or Cas2 gene within 10 kb upstream or downstream of the CRISPR array. In some embodiments, at least one of Csx27 or Csx28 is also present within 10 kb upstream or downstream of the CRISPR array.
[0018] In certain embodiments, the Cas13b effector protein has a modified sequence compared to the wild-type protein. In certain embodiments, the effector protein is identical to the wild-type Cas13b effector protein in at least one or more common motifs shared between two or more Cas13b effector proteins. Common motifs can be determined by standard sequence alignment tools to identify consensus sequences. In a specific embodiment, the Cas13b effector protein is a protein comprising a sequence having at least 70% sequence identity with one or more of the sequences consisting of DKHXFGAFLNLARHN (SEQ ID NO: 1), GLLFFVSLFLDK (SEQ ID NO: 2), SKIXGFK (SEQ ID NO: 3), DMLNELXRCP (SEQ ID NO: 4), RXZDRFPYFALRYXD (SEQ ID NO: 5) and LRFQVBLGXY (SEQ ID NO: 6). In another specific embodiment, the Cas13b effector protein comprises a sequence having at least 70% sequence identity with at least 2, 3, 4, 5 or all 6 of these sequences. In other specific embodiments, the sequence identity to these sequences is at least 75%, 80%, 85%, 90%, 95% or 100%. In other specific embodiments, the Cas 13b effector protein is a protein comprising a sequence having 100% sequence identity to GLLFFVSLFL (SEQ ID NO: 7) and RHQXRFPYF (SEQ ID NO: 8). In other specific embodiments, the Cas13b effector is a Cas13b effector protein comprising a sequence having 100% sequence identity to RHQDRFPY (SEQ ID NO: 9).
[0019] It will be understood that the terms "Cas enzyme," "CRISPR enzyme," "CRISPR protein," "Cas protein," and "CRISPR Cas" are generally used interchangeably and all references herein similarly refer to the CRISPR effector proteins further described in this application, unless otherwise clearly indicated, such as specific reference to Cas9.
[0020] In an embodiment of the present invention, the VI-B type system comprises a Cas13b effector protein and optionally a small auxiliary protein encoded upstream or downstream of the Cas13b effector protein. In certain embodiments, the small auxiliary protein enhances the ability of the Cas13b effector to target RNA.
[0021] In certain embodiments of the invention, the VI-B type system comprises a Cas13b effector protein and optionally a small auxiliary protein encoded upstream or downstream of the Cas13b effector protein. In certain embodiments, the small auxiliary protein suppresses the ability of the Cas13b effector to target RNA.
[0022] The present invention provides a non-naturally occurring or engineered composition comprising: i) a VI-B type CRISPR-Cas effector protein, and ii) a VI-B type CRISPR-Cas crRNA, wherein the crRNA comprises a) a guide sequence capable of hybridizing with a target RNA sequence, and b) a forward repeat sequence. The VI-B type CRISPR-Cas effector protein forms a complex with the crRNA, and the guide sequence guides the complex to perform sequence-specific binding with the target RNA sequence, thereby forming a CRISPR complex comprising a VI-B type CRISPR-Cas effector protein complexed with the guide sequence, and the guide sequence hybridizes with the target RNA sequence. The complex formed when the guide sequence hybridizes with the target RNA sequence includes the interaction (recognition) of the original spacer flanking sequence (PFS).
[0023] In some embodiments, the non-naturally occurring or engineered compositions of the invention may comprise a Type VI-B CRISPR-Cas accessory protein that enhances the activity of a Type VI-B CRISPR-Cas effector protein. In certain such embodiments, the accessory protein that enhances the activity of a Type VI-B CRISPR-Cas effector protein is a csx28 protein. In such embodiments, the Type VI-B CRISPR-Cas effector protein and the Type VI-B CRISPR-Cas accessory protein may be from the same source or from different sources.
[0024] In some embodiments, the non-naturally occurring or engineered composition of the invention comprises a Type VI-B CRISPR-Cas accessory protein that represses the activity of a Type VI-B CRISPR-Cas effector protein. In certain such embodiments, the accessory protein that represses the activity of a Type VI-B CRISPR-Cas effector protein is a csx27 protein. In such embodiments, the Type VI-B CRISPR-Cas effector protein and the Type VI-B CRISPR-Cas accessory protein may be from the same source or from different sources.
[0025] In some embodiments, the non-naturally occurring or engineered compositions of the invention comprise two or more Type VI-B CRISPR-Cas crRNAs.
[0026] In some embodiments, the non-naturally occurring or engineered compositions of the present invention comprise a guide sequence that hybridizes with a target RNA sequence in a prokaryotic cell. In some embodiments, the non-naturally occurring or engineered compositions of the present invention comprise a guide sequence that hybridizes with a target RNA sequence in a eukaryotic cell. The CRISPR system provided herein can utilize crRNA or similar polynucleotides comprising a guide sequence, wherein the polynucleotide is a mixture of RNA, DNA, or RNA and DNA, and / or wherein the polynucleotide comprises one or more nucleotide analogs. The sequence may comprise any structure, including but not limited to the structure of natural crRNA, such as a bulge, a hairpin, or a stem-loop structure. In certain embodiments, the polynucleotide comprising a guide sequence forms a duplex with a second polynucleotide sequence, and the second polynucleotide sequence may be an RNA or DNA sequence.
[0027] In certain embodiments, these methods utilize chemically modified guide RNAs. Examples of chemical modifications of guide RNAs include, but are not limited to, incorporation of 2'-O-methyl (M), 2'-O-methyl 3' phosphorothioate (MS), or 2'-O-methyl 3' thiophosphonoacetate (MSP) at one or more terminal nucleotides. Such chemically modified guide RNAs may have increased stability and activity compared to unmodified guide RNAs, but on-target and off-target specificity cannot be predicted. (See Hendel, 2015, Nat Biotechnol. 33 (9): 985-9, doi: 10.1038 / nbt.3290, published online on June 29, 2015). Chemically modified guide RNAs also include, but are not limited to, RNAs having phosphorothioate bonds and locked nucleic acid (LNA) nucleotides containing a methylene bridge between the 2' and 4' carbons of the ribose ring.
[0028] In some embodiments, the Type VI-B CRISPR-Cas effector protein comprises one or more nuclear localization signals (NLS).
[0029] In contrast to the catalytic mechanisms of other known RNases found in CRISPR-Cas systems, Cas13b achieves RNA cleavage through conserved basic residues within its two HEPN domains. Mutations in the HEPN domains, such as substitutions (e.g., alanine) of any of the four predicted HEPN domain catalytic residues, can convert Cas13b into an inactive programmable RNA-binding protein (dCas13b, similar to dCas9).
[0030] The ability of dCas13b to bind specific sequences can be used according to several aspects of the invention to (i) introduce effector modules into specific transcripts to modulate function or translation, which can be used for large-scale screening, construction of synthetic regulatory circuits, and other purposes; (ii) fluorescently label specific RNAs to visualize their transport and / or localization; (iii) alter RNA localization through domains with affinity for specific subcellular compartments; and (iv) capture specific transcripts (by directly pulling down dCas13b or using dCas13b to localize biotin ligase activity to specific transcripts) to enrich for proximal molecular chaperones including RNA and proteins.
[0031] Active Cas13b should also have many applications. One aspect of the present invention relates to targeting specific transcripts for destruction. In addition, once Cas13b is triggered by homologous targets, other (non-complementary) RNA molecules can be cleaved in vitro and cell growth can be inhibited in vivo. Biologically, this mixed RNase activity can reflect the protection mechanism based on programmed cell death / dormancy (PCD / D) of the VI-B type CRISPR-Cas system. Therefore, in one aspect of the present invention, it can be used to trigger PCD or dormancy in specific cells, such as cancer cells expressing specific transcripts, neurons of a given class, cells infected by specific pathogens, or other abnormal cells or other cells that are not desired to exist.
[0032] The present invention provides a method for modifying a nucleic acid sequence associated with or at a target locus of interest, particularly in a eukaryotic cell, tissue, organ or organism, more particularly in a mammalian cell, tissue, organ or organism, the method comprising delivering a non-naturally occurring or engineered composition comprising a VI-B type CRISPR-Cas locus effector protein and one or more nucleic acid components to the locus, wherein the effector protein forms a complex with the one or more nucleic acid components, and when the complex binds to the target locus, the effector protein induces modification of a sequence associated with or at the target locus of interest. In a preferred embodiment, the modification is the introduction of a strand break. In a preferred embodiment, the sequence associated with or at the target locus of interest comprises RNA, and the effector protein is encoded by a VI-B type CRISPR-Cas locus. The complex can be formed in vitro or ex vivo and introduced into a cell or contacted with RNA; or it can be formed in vivo.
[0033] The present invention provides a method for targeting (such as modifying) a sequence associated with a target locus or at a target locus, the method comprising delivering a non-naturally occurring or engineered composition comprising a Cas13b locus effector protein (which may be catalytically active, or alternatively inactive) and one or more nucleic acid components to the sequence associated with the locus or at the locus, wherein the Cas13b effector protein forms a complex with the one or more nucleic acid components, and when the complex binds to the target locus, the effector protein induces modification of the sequence associated with the target locus or at the target locus. In a preferred embodiment, the modification is the introduction of a strand break. In a preferred embodiment, the Cas13b effector protein forms a complex with a nucleic acid component, advantageously with an engineered or non-naturally occurring nucleic acid component. The complex can be formed in vitro or ex vivo and introduced into a cell or contacted with RNA; or it can be formed in vivo. The induction of modification of a sequence associated with a target locus or at a target locus can be guided by a Cas13b effector protein-nucleic acid. In a preferred embodiment, a nucleic acid component is CRISPR RNA (crRNA). In a preferred embodiment, a nucleic acid component is a mature crRNA or a guide RNA, wherein the mature crRNA or the guide RNA comprises a spacer sequence (or a guide sequence) and a forward repeat sequence or a derivative thereof. In a preferred embodiment, the spacer sequence or a derivative thereof comprises a seed sequence, wherein the seed sequence is essential for identification and / or hybridization of the sequence at the target locus.
[0034] Aspects of the present invention relate to Cas13b effector protein complexes with one or more non-naturally occurring or engineered or modified or optimized nucleic acid components. In a preferred embodiment, the nucleic acid component of the complex may include a guide sequence connected to a forward repeat sequence, wherein the forward repeat sequence includes one or more stem loops or optimized secondary structures. In one embodiment, the length of the forward repeat sequence may be about 36 nucleotides. In a specific embodiment, the forward repeat sequence includes GTTG / GUUG at the 5' end, which is reversely complementary to the CAAC at the 3' end. In certain embodiments, the minimum length of the forward repeat sequence is 16nt, such as at least 28nt, and has a single stem loop. In another embodiment, the length of the forward repeat sequence is greater than 16nt, preferably greater than 17nt, such as at least 28nt, and has more than one stem loop or optimized secondary structure. In a specific embodiment, the forward repeat sequence has 25 or more nt, such as 26nt, 27nt, 28nt or more, and one or more stem loop structures. In a preferred embodiment, the forward repeat sequence can be modified to include one or more protein-bound RNA aptamers. In a preferred embodiment, one or more aptamers may be included, such as a portion of an optimized secondary structure. Such aptamers may be able to bind to a bacteriophage coat protein. The bacteriophage coat protein may be selected from Qβ, F2, GA, fr, JP501, MS2, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, φCb5, φCb8r, φCb12r, φCb23r, 7s and PRR1. In a preferred embodiment, the bacteriophage coat protein is MS2. The present invention also provides a nucleic acid component of the complex having a length of 30 or more, 40 or more, or 50 or more nucleotides.
[0035] The present invention provides cells comprising a Cas13b effector protein and / or its guide and / or a complex with a target nucleic acid, including cells comprising a transiently expressed or introduced Cas13b effector protein and / or its guide and / or complex. In certain embodiments, the cell is a eukaryotic cell, including but not limited to a yeast cell, a plant cell, a mammalian cell, an animal cell or a human cell.
[0036] The present invention provides a method for modifying a target locus, particularly in a eukaryotic cell, tissue, organ or organism, more particularly in a mammalian cell, tissue, organ or organism, comprising delivering a non-naturally occurring or engineered composition comprising a Cas13b locus effector protein and one or more nucleic acid components to the locus, wherein the Cas13b effector protein forms a complex with the one or more nucleic acid components, and when the complex binds to the target locus, the effector protein induces modification of the target locus. In a preferred embodiment, the modification is the introduction of a strand break. The complex can be formed in vitro or ex vivo and introduced into a cell or contacted with RNA; or it can be formed in vivo.
[0037] In such methods, the target locus of interest may be contained in an RNA molecule. Moreover, the target locus of interest may be contained in a DNA molecule, and in certain embodiments, may be contained in a transcribed DNA molecule. In such methods, the target locus of interest may be contained in an in vitro nucleic acid molecule.
[0038] In such methods, the target locus can be included in a nucleic acid molecule in a cell, particularly a eukaryotic cell such as a mammalian cell or a plant cell. The mammalian cell can be a non-human primate, bovine, porcine, rodent or mouse cell. The cell can be a non-mammalian eukaryotic cell, such as poultry, fish or shrimp. The plant cell can be a crop plant, such as cassava, corn, sorghum, wheat or rice. The plant cell can also be algae, trees or vegetables. The modification introduced into the cell by the present invention can be to change the cell and the cell progeny for improving the output of a bioproduct such as an antibody, starch, alcohol or other desired cell output. The modification introduced into the cell by the present invention can be to make the cell and the cell progeny include a change in the bioproduct produced by the change.
[0039] The mammalian cell can be a non-human mammal (e.g., a primate, bovine, ovine, porcine, canine, rodent, lagomorph, such as a monkey, cow, sheep, pig, dog, rabbit, rat, or mouse) cell. The cell can be a non-mammalian eukaryotic cell, such as a bird (e.g., chicken), a vertebrate fish (e.g., salmon), or a shellfish (e.g., oyster, clam, lobster, shrimp) cell. The cell can also be a plant cell. The plant cell can be a monocot or a dicot, and can also be a crop or grain plant, such as cassava, corn, sorghum, soybean, wheat, oat, or rice. The plant cell can also be an algae, a tree, or a production plant, a fruit, or a vegetable (e.g., a tree such as a citrus tree, e.g., an orange, grapefruit, or lemon tree; a peach or nectarine tree; an apple or pear tree; a nut tree such as an almond, walnut, or pistachio tree; a nightshade; a Brassica; a Lactuca; a Spinacia; a Capsicum; cotton, tobacco, asparagus, carrot, cabbage, broccoli, cauliflower, tomato, eggplant, pepper, lettuce, spinach, strawberries, blueberries, raspberries, blackberries, grapes, coffee, cocoa, etc.).
[0040] The present invention provides a method for modifying a target locus of interest, the method comprising delivering a non-naturally occurring or engineered composition comprising a Type VI-B CRISPR-Cas locus effector protein and one or more nucleic acid components to the locus, wherein the effector protein forms a complex with the one or more nucleic acid components, and when the complex binds to the target locus, the effector protein induces modification of the target locus of interest. In a preferred embodiment, the modification is the introduction of a strand break.
[0041] The present invention provides a method for modifying a target locus of interest, the method comprising delivering a non-naturally occurring or engineered composition comprising a Cas13b locus effector protein and one or more nucleic acid components to the locus, wherein the Cas13b effector protein forms a complex with the one or more nucleic acid components, and when the complex binds to the target locus, the effector protein induces modification of the target locus of interest. In a preferred embodiment, the modification is the introduction of a strand break.
[0042] In such methods, the target locus of interest may be contained in an in vitro nucleic acid molecule. In such methods, the target locus of interest may be contained in a nucleic acid molecule in a cell. Preferably, in such methods, the target locus of interest may be contained in an in vitro RNA molecule. Also preferably, in such methods, the target locus of interest may be contained in an RNA molecule in a cell. The cell may be a prokaryotic cell or a eukaryotic cell. The cell may be a mammalian cell. The cell may be a rodent cell. The cell may be a mouse cell.
[0043] In any of the methods described, the target locus of interest can be a genomic or epigenomic locus of interest. In any of the methods described, the complex can be delivered with multiple guides for multiplexed use. In any of the methods described, more than one protein can be used.
[0044] In other aspects of the invention, the nucleic acid component may comprise a CRISPR RNA (crRNA) sequence. Without limitation, the applicant assumes that in this case, the pre-crRNA may comprise a secondary structure sufficient to process the mature crRNA and the crRNA loaded onto the effector protein. By way of example and not limitation, such a secondary structure may comprise, consist essentially of, or consist of a stem loop within the pre-crRNA, more particularly within a direct repeat sequence.
[0045] In any of the methods described, the effector protein and nucleic acid components may be provided by one or more polynucleotide molecules encoding the protein and / or one or more nucleic acid components, and wherein the one or more polynucleotide molecules may be operably configured to express the protein and / or one or more nucleic acid components. One or more polynucleotide molecules may contain one or more regulatory elements that are operably configured to express the protein and / or one or more nucleic acid components. One or more polynucleotide molecules may be contained in one or more vectors. In any of the methods described, the target locus may be a target genome or epigenomic locus. In any of the methods described, the complex may be delivered with a variety of guides for multiple uses. In any of the methods described, more than one protein may be used.
[0046] The regulatory element may comprise an inducible promoter. The polynucleotide and / or vector system may comprise an inducible system.
[0047] In any of the methods described, one or more polynucleotide molecules may be included in the delivery system, or one or more vectors may be included in the delivery system.
[0048] In any of the methods described, the non-naturally occurring or engineered composition can be delivered via liposomes, particles including nanoparticles, exosomes, microvesicles, a gene gun, or one or more viral vectors.
[0049] The invention also provides a non-naturally occurring or engineered composition having the characteristics discussed herein or defined in any method described herein.
[0050] Thus, in certain embodiments, the present invention provides a non-naturally occurring or engineered composition, such as a composition that is particularly capable of or configured to modify a target locus of interest, the composition comprising a Type VI-B CRISPR-Cas locus effector protein and one or more nucleic acid components, wherein the effector protein forms a complex with the one or more nucleic acid components, and when the complex binds to the target locus, the effector protein induces modification of the target locus of interest. In certain embodiments, the effector protein may be a Cas13b locus effector protein.
[0051] In another aspect, the present invention also provides a non-naturally occurring or engineered composition, such as a composition that is particularly capable of or configured to modify a target locus of interest, comprising: (a) a guide RNA molecule (or a combination of guide RNA molecules, such as a first guide RNA molecule and a second guide RNA molecule, such as for multiplexing) or a nucleic acid encoding the guide RNA molecule (or one or more nucleic acids encoding a combination of guide RNA molecules); (b) a Type VI-B CRISPR-Cas locus effector protein or a nucleic acid encoding the Type VI-B CRISPR-Cas locus effector protein. In certain embodiments, the effector protein can be a Cas13b locus effector protein.
[0052] On the other hand, the present invention also provides a non-naturally occurring or engineered composition comprising: (a) a guide RNA molecule (or a combination of guide RNA molecules, such as a first guide RNA molecule and a second guide RNA molecule) or a nucleic acid encoding the guide RNA molecule (or one or more nucleic acids encoding a combination of guide RNA molecules); (b) a Cas13b locus effector protein.
[0053] The present invention also provides a vector system comprising one or more vectors comprising one or more polynucleotide molecules encoding components of a non-naturally occurring or engineered composition, wherein the composition is a composition having the characteristics defined in any method described herein.
[0054] The present invention also provides a delivery system comprising one or more vectors or one or more polynucleotide molecules, wherein the one or more vectors or polynucleotide molecules comprise one or more polynucleotide molecules encoding components of a non-naturally occurring or engineered composition, wherein the composition is a composition having the characteristics defined in any method discussed herein or described herein.
[0055] The present invention also provides a non-naturally occurring or engineered composition for use in a therapeutic method, or one or more polynucleotides encoding components of the composition, or a vector or delivery system comprising one or more polynucleotides encoding components of the composition. The therapeutic method may include gene or transcriptome editing or gene therapy.
[0056] The present invention also provides methods and compositions in which one or more amino acid residues of an effector protein, such as an engineered or non-naturally occurring effector protein or Cas13b, can be modified. In one embodiment, the modification may include mutations of one or more amino acid residues of the effector protein. One or more mutations may be in one or more catalytically active domains of the effector protein. The nuclease activity of the effector protein may be reduced or even eliminated compared to the effector protein lacking the one or more mutations. The effector protein may not guide the cleavage of the RNA chain at the target locus. In a preferred embodiment, the one or more mutations may include two mutations. In a preferred embodiment, one or more amino acid residues are modified in a Cas13b effector protein, such as an engineered or non-naturally occurring effector protein or Cas13b. In certain embodiments, the effector protein comprises one or more of the following mutations: R116A, H121A, R1177A, H1182A (wherein the amino acid position corresponds to a mutation derived from Bergey's bacterium ATCC 43767 of Cas13b protein), such as R116A, H121A, R1177A and H1182A; R116A, H121A and R1177A; R116A, H121A and H1182A; R116A, R1177A and H1182A; H121A, R1177A and H1182A; R116A and H121A; R116A and R1177A; R116A and H1182A; H121A and R1177A; H121A and H1182A; R1177A and H1182A; R116A; H121A; R1177A; H1182A. The skilled person will understand that the corresponding amino acid positions in different Cas13b proteins can be mutated to achieve the same effect. In certain embodiments, one or more of the mutations R116A, H121A, R1177A, H1182A completely or partially eliminate the catalytic activity of the protein (e.g., change in cleavage rate, change in specificity, etc.), such as R116A, H121A, R1177A and H1182A; R116A, H121A and R1177A; R116A, H121A and H1182A; R116A, R1177A, and H1182A; H121A, R1177A, and H1182A; R116A and H121A; R116A and R1177A; R116A and H1182A; H121A and R1177A; H121A and H1182A; R1177A and H1182A; R116A; H121A; R1177A; H1182A. In certain embodiments, wherein the amino acid positions correspond to the amino acid positions of the Cas13b protein derived from Prevotella P5-125, the effector protein comprises H133A and H1058A mutations.In certain embodiments, the effector protein described herein is a "death" effector protein, such as a dead Cas13b effector protein (i.e., dCas13b). In certain embodiments, the effector protein has one or more mutations in HEPN domain 1. In certain embodiments, the effector protein has one or more mutations in HEPN domain 2. In certain embodiments, the effector protein has one or more mutations in HEPN domain 1 and HEPN domain 2. The effector protein may include one or more heterologous functional domains. One or more heterologous functional domains may include one or more nuclear localization signal (NLS) domains. One or more heterologous functional domains may include at least two or more NLS domains. One or more NLS domains may be positioned at or near the end of the effector protein (e.g., Cas13b effector protein) or close to the end, and if there are two or more NLSs, each of the two may be positioned at or near the end of the effector protein (e.g., Cas13b effector protein) or close to the end. One or more heterologous functional domains may include one or more transcriptional activation domains. In a preferred embodiment, the transcriptional activation domain may include VP64. The one or more heterologous functional domains may include one or more transcriptional repression domains. In a preferred embodiment, the transcriptional repression domain includes a KRAB domain or a SID domain (e.g., SID4X). The one or more heterologous functional domains may include one or more nuclease domains. In a preferred embodiment, the nuclease domain includes Fok1.
[0057] The present invention also provides one or more heterologous functional domains to have one or more of the following activities: methylase activity, demethylase activity, translation activation activity, translation repression activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-stranded RNA cleavage activity, double-stranded RNA cleavage activity, single-stranded DNA cleavage activity, double-stranded DNA cleavage activity and nucleic acid binding activity. At least one or more heterologous functional structural domains may be at or near the amino terminus of the effector protein, and / or at least one or more heterologous functional domains are at or near the carboxyl terminus of the effector protein. One or more heterologous functional domains may be fused to the effector protein. One or more heterologous functional domains may be connected to the effector protein. One or more heterologous functional domains may be connected to the effector protein via a linker portion.
[0058] In certain embodiments of the present invention, one or more heterologous functional domains may include an epitope tag or a reporter. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporters include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) β-galactosidase, β-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
[0059] The present invention also provides the following effector protein: it comprises an effector protein having at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity with a wild-type Cas13b effector protein of a prokaryotic genus selected from Porphyromonas, Prevotella, Bacteroides, Riemerella, Bergeyella, Another Branch, Fragrant Fungus, Capnocytophaga and Flavobacterium. The present invention also provides the following effector protein: it comprises an effector protein having at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity with a wild-type Cas13b effector protein of a prokaryotic species selected from Porphyromonas oralis, Prevotella species, Porphyromonas gingivalis, Bacteroides pyogenes, Riemerella anatipestifer, Bergeyella zooulcerans, Prevotella intermedia, Prevotella buccal, another Mycobacterium species, Prevotella aurantiaca, Aromatic fungi, Capnocytophaga canimorsus, Flavobacterium branchiophyllum and Flavobacterium columnaris. The present invention also provides the following effector protein: it comprises an effector protein selected from oral Porphyromonas Cas13b (accession number WP_039434803), Prevotella species P5-125Cas13b (accession number WP_044065294), gingival Porphyromonas Cas13b (accession number WP_053444417), Porphyromonas species COT-052OH4946 The wild-type Cas13b effector protein of Cas13b (accession number WP_039428968), Bacteroides pyogenes Cas13b (accession number WP_034542281), and Riemerella anatipestifer Cas13b (accession number WP_004919755) has an effector protein with at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater homology or identity.The most preferred effector protein is selected from oral Porphyromonas Cas13b (accession number WP_039434803), Prevotella species P5-125 Cas13b (accession number WP_044065294), gingival Porphyromonas Cas13b (accession number WP_053444417), Porphyromonas species COT-052OH4946 The wild-type Cas13b effector protein of Cas13b (Accession No. WP_039428968) has at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology or identity; and most particularly preferred are effector proteins having at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology or identity with wild-type oral Porphyromonas Cas13b (Accession No. WP_039434803) or Prevotella sp. P5-125 Cas13b (Accession No. WP_044065294). The effector protein may comprise a chimeric effector protein comprising a first fragment from a first effector protein ortholog and a second fragment from a second effector protein ortholog, and wherein the first effector protein ortholog and the second effector protein ortholog are different.
[0060] In certain embodiments, the effector protein may be at least 700 amino acids in length. In preferred embodiments, the effector protein may be about 900 to about 1500 amino acids in length, such as about 900 to about 1000 amino acids, about 1000 to about 1100 amino acids, about 1100 to about 1200 amino acids, or about 1200 to about 1300 amino acids, or about 1300 to about 1400 amino acids, or about 1400 to about 1500 amino acids, such as about 900, about 1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, or about 1800 amino acids.
[0061] In some embodiments, the Cas13b effector protein (a) comprises 900-1800 amino acids and two HEPN domains, (b) is naturally present in the prokaryotic genome and is located within 10 kb upstream or downstream of the CRISPR array, (c) is the only protein comprising more than 700 amino acids within 10 kb upstream or downstream of the CRISPR array, and / or (d) there is no Cas1 gene or Cas2 gene within 10 kb upstream or downstream of the CRISPR array. In some embodiments, Csx27 or Csx28 is also present within 10 kb upstream or downstream of the CRISPR array.
[0062] In certain embodiments, the effector protein, in particular the type VI-B locus effector protein, more particularly Cas13b, comprises at least one and preferably at least two, such as more preferably exactly two, conserved RxxxxH motifs. The catalytic RxxxxH motif exhibits the characteristics of a HEPN (higher eukaryotic and prokaryotic nucleotide-binding) domain. Thus, in certain embodiments, the effector protein comprises at least one and preferably at least two, such as more preferably exactly two, HEPN domains. In certain embodiments, the HEPN domain may have RNAse activity. In other embodiments, the HEPN domain may have DNAse activity.
[0063] In certain embodiments, the Cas13b effector protein as contemplated herein may be associated with a locus comprising a short CRISPR repeat sequence having a length between 30 and 40 bp, more typically between 34 and 38 bp, even more typically between 36 and 37 bp, for example 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 bp. In certain embodiments, the CRISPR repeat sequence is a long repeat sequence or a double repeat sequence having a length between 80 and 350 bp, such as between 80 and 200 bp, even more typically between 86 and 88 bp, for example 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90 bp.
[0064] In certain embodiments, the protospacer adjacent motif (PAM) or PAM-like motif guides the effector protein (e.g., Cas13b effector protein) complex disclosed herein to bind to the target locus. PAM may be referred to as PFS or protospacer flanking site. In some embodiments, PAM may be a 5'PAM (i.e., upstream of the 5' end of the protospacer sequence). In other embodiments, PAM may be a 3'PAM (i.e., downstream of the 5' end of the protospacer sequence). In other embodiments, both 5'PAM and 3'PAM are required. In certain embodiments of the present invention, guiding effector protein (e.g., Cas13b effector protein) binding may not require PAM or PAM-like motifs. In certain embodiments, 5'PAM is D (i.e., A, G, or U). In certain embodiments, for type VI-B1 effectors, 5'PAM is D. See Example 1 of Table 2. There is a method for determining the common 5' and 3'PAMs of a given Cas13b system. In certain embodiments of the invention, cleavage at the repeat sequence can produce a crRNA (e.g., a short crRNA or a long crRNA) comprising a complete spacer sequence flanked at the 5' end by a short nucleotide (e.g., 5, 6, 7, 8, 9 or 10 nt or longer if it is a double repeat sequence) repeat sequence (which can be referred to as a crRNA "tag") and flanked at the 3' end by the remaining repeat sequence. In certain embodiments, targeting by the effector protein described herein may require a lack of homology between the crRNA tag and the target 5' flanking sequence. This requirement may be similar to the requirement further described by Samai et al. in "Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity" Cell 161, 1164-1174, May 21, 2015, where the requirement is believed to be used to distinguish between the true target on the invading nucleic acid and the CRISPR array itself, and the presence of the repeat sequence will result in complete homology with the crRNA tag and prevent autoimmunity.
[0065] In certain embodiments, the Cas13b effector protein is engineered and may include one or more mutations that reduce or eliminate nuclease activity, thereby reducing or eliminating RNA interference activity. Mutations may also be made at adjacent residues, for example, at amino acids near amino acids involved in nuclease activity. In some embodiments, one or more putative catalytic nuclease domains are inactivated, and the effector protein complex lacks cleavage activity and acts as an RNA binding complex. In a preferred embodiment, the resulting RNA binding complex may be connected to one or more functional domains described herein.
[0066] In certain embodiments, the effector protein (CRISPR enzyme; Cas13; effector protein) according to the present invention described herein is a catalytically inactive or dead Cas13 effector protein (dCas13). In some embodiments, the dCas13 effector comprises a mutation in the nuclease domain. In some embodiments, the dCas13 effector protein has been truncated. In some embodiments, in order to reduce the size of the fusion protein of the Cas13b effector and one or more functional domains, the C-terminus of the Cas13b effector can be truncated while still maintaining the RNA binding function of the Cas13b effector. For example, the C-terminus of the Cas13b effector can be truncated by at least 20 amino acids, at least 50 amino acids, at least 80 amino acids, or at least 100 amino acids, or at least 150 amino acids, or at least 200 amino acids, or at least 250 amino acids, or at least 300 amino acids, or at least 350 amino acids, or at most 120 amino acids, or at most 140 amino acids, or at most 160 amino acids, or at most 180 amino acids, or at most 200 amino acids, or at most 250 amino acids, or at most 300 amino acids, or at most 350 amino acids, or at most 400 amino acids. Specific examples of Cas13b truncations include C-terminal Δ984-1090, C-terminal Δ1026-1090 and C-terminal Δ1053-1090, C-terminal Δ934-1090, C-terminal Δ884-1090, C-terminal Δ834-1090, C-terminal Δ784-1090 and C-terminal Δ734-1090, wherein the amino acid positions correspond to the amino acid positions of the Prevotella P5-125 Cas13b protein. See Fig.15 B.
[0067] In certain embodiments, one or more functional domains are controllable, ie, inducible.
[0068] In certain embodiments of the present invention, the guide RNA or mature crRNA comprises a forward repeat sequence and a guide sequence or a spacer sequence, is essentially composed of the sequence or is composed of the sequence. In certain embodiments, the guide RNA or mature crRNA comprises a forward repeat sequence connected to a guide sequence or a spacer sequence, is essentially composed of the forward repeat sequence or is composed of the forward repeat sequence. In a preferred embodiment of the present invention, the mature crRNA comprises a stem loop or an optimized stem loop structure or an optimized secondary structure. In a preferred embodiment, the mature crRNA comprises a stem loop or an optimized stem loop structure in the forward repeat sequence, wherein the stem loop or the optimized stem loop structure is important for cleavage activity. In certain embodiments, the mature crRNA preferably comprises a single stem loop. In certain embodiments, the forward repeat sequence preferably comprises a single stem loop. In certain embodiments, the cleavage activity of the effector protein complex is modified by introducing mutations that affect the stem loop RNA duplex structure. In a preferred embodiment, mutations that maintain the RNA duplex of the stem loop can be introduced, thereby maintaining the cleavage activity of the effector protein complex. In other preferred embodiments, mutations that destroy the RNA duplex structure of the stem loop can be introduced, thereby completely eliminating the cleavage activity of the effector protein complex.
[0069] The present invention also provides nucleotide sequences encoding effector proteins that are codon-optimized for expression in eukaryotic organisms or eukaryotic cells in any method or composition described herein. In one embodiment of the invention, the codon-optimized nucleotide sequence encoding the effector protein encodes any Cas13b discussed herein, and is codon-optimized for operability in eukaryotic cells or organisms such as such cells or organisms mentioned elsewhere herein (e.g., but not limited to yeast cells or mammalian cells or organisms, including mouse cells, rat cells, and human cells or non-human eukaryotic organisms, such as plants).
[0070] In certain embodiments of the invention, at least one nuclear localization signal (NLS) is attached to the nucleic acid sequence encoding the Cas13b effector protein. In a preferred embodiment, at least one or more C-terminal or N-terminal NLS is attached (therefore, one or more nucleic acid molecules encoding the Cas13b effector protein may include encoding one or more NLS, so that the expressed product is attached or connected to the one or more NLS). In certain embodiments of the invention, at least one nuclear export signal (NES) is attached to the nucleic acid sequence encoding the Cas13b effector protein. In a preferred embodiment, at least one or more C-terminal or N-terminal NES is attached (therefore, one or more nucleic acid molecules encoding the Cas13b effector protein may include encoding one or more NES, so that the expressed product is attached or connected to the one or more NES). In a preferred embodiment, a C-terminal and / or N-terminal NLS or NES is attached for optimal expression and nuclear targeting in eukaryotic cells, preferably human cells. In a preferred embodiment, the codon-optimized effector protein is Cas13b, and the spacer sequence length of the guide RNA is 15 to 35nt. In certain embodiments, the spacer length of the guide RNA is at least 16 nucleotides, such as at least 17 nucleotides, preferably at least 18nt, such as preferably at least 19nt, at least 20nt, at least 21nt or at least 22nt. In certain embodiments, the spacer length is 15 to 17nt, 17 to 20nt, 20 to 24nt (e.g., 20, 21, 22, 23 or 24nt), 23 to 25nt (e.g., 23, 24 or 25nt), 24 to 27nt, 27 to 30nt, 30 to 35nt or 35nt or longer. In certain embodiments of the invention, the codon-optimized effector protein is Cas13b, and the forward repeat length of the guide RNA is at least 16 nucleotides. In certain embodiments, the codon-optimized effector protein is Cas13b, and the forward repeat length of the guide RNA is 16 to 20nt, for example, 16, 17, 18, 19 or 20 nucleotides. In certain preferred embodiments, the direct repeat sequence of the guide RNA is 19 nucleotides in length.
[0071] The present invention also includes a method for delivering multiple nucleic acid components, wherein each nucleic acid component is specific to a different target locus, thereby modifying multiple target loci. The nucleic acid component of the complex may include one or more protein-binding RNA aptamers. One or more aptamers may be able to bind to a phage coat protein. The phage coat protein may be selected from Qβ, F2, GA, fr, JP501, MS2, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, φCb5, φCb8r, φCb12r, φCb23r, 7s and PRR1. In a preferred embodiment, the phage coat protein is MS2. The present invention also provides a nucleic acid component of the complex having a length of 30 or more, 40 or more, or 50 or more nucleotides.
[0072] In another aspect, the present invention provides a eukaryotic cell comprising a modified target locus of interest, wherein the target locus of interest has been modified according to any of the methods described herein. In another aspect, a cell line of the cell is provided. In another aspect, a multicellular organism comprising one or more of the cells is provided.
[0073] In certain embodiments, modification of the target locus of interest can result in: a eukaryotic cell comprising an altered expression of at least one gene product; a eukaryotic cell comprising an altered expression of at least one gene product, wherein the expression of the at least one gene product is increased; a eukaryotic cell comprising an altered expression of at least one gene product, wherein the expression of the at least one gene product is decreased; or a eukaryotic cell comprising genome editing.
[0074] In certain embodiments, the eukaryotic cell can be a mammalian cell or a human cell.
[0075] In additional embodiments, the non-naturally occurring or engineered compositions, vector systems, or delivery systems described in this specification can be used for: site-specific gene knockout; site-specific genome editing; RNA sequence-specific interference; or multiplex genome engineering.
[0076] Also provided is a gene product from a cell, cell line, or organism as described herein. In certain embodiments, the amount of the gene product expressed may be greater or less than the amount of the gene product from a cell with unaltered expression or unedited genome. In certain embodiments, the gene product may be altered compared to a gene product from a cell with unaltered expression or unedited genome.
[0077] Also provided is an engineered and non-naturally occurring eukaryotic cell comprising at least one of the following: (i) a Cas13b effector protein as described herein, or (ii) a guide RNA capable of forming a CRISPR-Cas complex with a Cas13b effector protein. In some embodiments, (i) and / or (ii) are transiently expressed or introduced into a cell. Also provided is an organism comprising such a cell, cell line, progeny of the cell line or organism. The organism may be a vertebrate, such as a mammal. Alternatively, the organism may be a plant or a fungus.
[0078] In another aspect, the present invention provides a eukaryotic cell comprising a nucleotide sequence encoding a CRISPR system as described herein, which system ensures the production of a modified target locus of interest, wherein the target locus of interest is modified according to any method described herein. In another aspect, a cell line of the cell is provided. In another aspect, a multicellular organism comprising one or more of the cells is provided.
[0079] In certain embodiments, modification of the target locus may result in: a eukaryotic cell comprising an altered (protein) expression of at least one gene product; a eukaryotic cell comprising an altered (protein) expression of at least one gene product, wherein the (protein) expression of the at least one gene product is increased; a eukaryotic cell comprising an altered (protein) expression of at least one gene product, wherein the (protein) expression of the at least one gene product is decreased; or a eukaryotic cell comprising transcriptome editing.
[0080] In certain embodiments, the eukaryotic cell can be a mammalian cell or a human cell.
[0081] In additional embodiments, the non-naturally occurring or engineered compositions, vector systems, or delivery systems described in this specification can be used for RNA sequence-specific interference, RNA sequence-specific expression (including isoform-specific expression) regulation, stability, localization, functionality (e.g., ribosomal RNA or miRNA), etc.; or multiplexing of such processes.
[0082] In other embodiments, the non-naturally occurring or engineered compositions, vector systems, or delivery systems described in this specification can be used for RNA detection and / or quantification in samples such as biological samples. In certain embodiments, RNA detection is performed in cells. In one embodiment, the present invention provides a method for detecting a target RNA in a sample, comprising (a) incubating the sample with: i) a type VI-B CRISPR-Cas effector protein capable of cleaving RNA, ii) a guide RNA capable of hybridizing with the target RNA, and iii) an RNA-based cleavage-inducible reporter that can be non-specifically and detectably cleaved by the effector protein, (b) detecting the target RNA based on a signal generated by cleaving the RNA-based cleavage-inducible reporter.
[0083] In one embodiment, the VI-B type CRISPR-Cas effector protein is a Cas13b effector protein; e.g., a Cas13b effector protein described herein. In one embodiment, an RNA-based cleavage-inducible reporter construct comprises a fluorescent dye and a quencher. In certain embodiments, the sample comprises a cell-free biological sample. In other embodiments, the sample comprises a cell sample, such as, but not limited to, a plant cell or an animal cell. In one embodiment of the invention, the target RNA comprises a pathogen RNA, including, but not limited to, a target RNA from a virus, a bacterium, a fungus, or a parasite. In one embodiment, the guide RNA is designed to detect a target RNA comprising a single nucleotide polymorphism or a splice variant of an RNA transcript. In one embodiment, the guide RNA comprises one or more nucleotides that are mismatched with the target RNA. In certain embodiments, the guide RNA hybridizes with a target molecule for diagnosing a disease state such as, but not limited to, cancer or an immune disease.
[0084] The present invention provides a ribonucleic acid (RNA) detection system, comprising: a) a VI-B type CRISPR-Cas effector protein capable of cleaving RNA, b) a guide RNA capable of binding to a target RNA, and c) an RNA-based cleavage-inducible reporter capable of being non-specifically and detectably cleaved by the effector protein. In addition, the present invention provides a kit for RNA detection, comprising: a) a VI-B type CRISPR-Cas effector protein capable of cleaving RNA, and b) an RNA-based cleavage-inducible reporter capable of being non-specifically and detectably cleaved by the effector protein. In certain embodiments, the RNA-based cleavage-inducible reporter construct comprises a fluorescent dye and a quencher.
[0085] In other embodiments, the non-naturally occurring or engineered compositions, vector systems, or delivery systems described in this specification can be used to generate disease models and / or screening systems.
[0086] In additional embodiments, the non-naturally occurring or engineered compositions, vector systems, or delivery systems described in this specification can be used for: site-specific transcriptome editing or interference; nucleic acid sequence-specific interference; or multiplex genome engineering.
[0087] In various aspects of the present invention, the Cas13b effector protein or system described herein can be used to treat, prevent, prevent or inhibit viral onset, infection or propagation in mammalian subjects. Aspects of the present invention provide a Cas13b CRISPR system for treating, preventing, inhibiting and / or alleviating viral onset, infection and / or propagation in subjects, comprising (a) Cas13b CRISPR effector protein and / or polynucleic acid encoding Cas13b CRISPR effector protein, and (b) one or more guide RNAs and / or one or more polynucleic acids encoding one or more guide RNAs, wherein the one or more guide RNAs are designed to bind to one or more target molecules of the virus. The Cas13b effector protein may be as defined herein, including aspects regarding preferred wild-type Cas13b proteins and preferred derivatives and modifications thereof.
[0088] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit the onset, infection or spread of Lassa virus in a mammalian subject. Lassa virus is associated with DC and vascular endothelial cells (see Kunz, S. et al. 2005. Journal of Virology).
[0089] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, prevent, prevent or inhibit the onset, infection or spread of Ebola virus in mammalian subjects. Ebola virus is associated with many tissues and cell types, including DC, macrophages, hepatocytes, etc. (see Martines, RB et al. 2015. Journal of Pathology).
[0090] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit SARS-CoV pathogenesis, infection or transmission in mammalian subjects. SARS-CoV is associated with lung tissue and cells (see To, KF. et al. 2004. Journal of Pathology).
[0091] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, prevent, prevent or inhibit the onset, infection or spread of Zika virus in mammalian subjects. Zika virus is associated with many tissues and cell types, including body fluids, placenta, brain, etc. (see Miner, JJ and Diamond, MS 2017. Cell Host & Microbe).
[0092] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, prevent, prevent or inhibit the onset, infection or spread of dengue virus in mammalian subjects. Dengue virus is associated with many tissues and cell types, including DC, macrophages, liver, etc. (see Flipse, J. et al. 2016. Journal of General Virology).
[0093] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, prevent, prevent or inhibit the onset, infection or spread of Chikungunya virus in mammalian subjects. Chikungunya virus is associated with many tissues and cell types, including immune cells, liver, central nervous system, etc. (see Schwartz, O. and Albert, ML, 2010. Nature Reviews).
[0094] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit influenza virus pathogenesis, infection or transmission in mammalian subjects. Influenza virus is associated with lung epithelial cells and macrophages (see Medina, RA and Garcia-Sastre A. 2011 Nature Reviews).
[0095] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit HIV virus pathogenesis, infection or transmission in mammalian subjects. HIV virus is associated with T cells and macrophages (see Weiss, RA 2002. IUBMB Life).
[0096] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit rotavirus pathogenesis, infection or transmission in mammalian subjects. Rotavirus is associated with intestinal tissues and cells (see Lopez, S and Arias, CF2006.CTMI).
[0097] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit the onset, infection or spread of herpes simplex (HSV-1) in mammalian subjects. HSV-1 is associated with epithelial cells and neuronal cells (see Schelhaas, M. et al. 2003. Journal of General Virology).
[0098] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit HCV onset, infection or transmission in mammalian subjects. HCV is associated with liver tissue and cells (see Ding, Q et al. 2014. Cell Host & Microbe).
[0099] In some embodiments, the Cas13b effector protein or system described herein can be used to treat, control, prevent or inhibit HBV pathogenesis, infection or transmission in mammalian subjects. HBV is associated with liver tissue and cells (see Schieck, A. et al. 2013. Hepatology).
[0100] Also provided is a gene product from a cell, cell line, or organism as described herein. In certain embodiments, the amount of the gene product expressed may be greater or less than the amount of the gene product from a cell with unaltered expression or unedited genome. In certain embodiments, the gene product may be altered compared to a gene product from a cell with unaltered expression or unedited genome.
[0101] These and other embodiments are disclosed or become apparent from and are encompassed by the following Detailed Description.
[0102] Therefore, it is an object of the present invention not to include any previously known product, process of making the product, or method of using the product within the present invention, so that the applicant reserves the right and hereby discloses a disclaimer of any previously known product, process, or method. It should also be noted that the present invention is not intended to include any product, process, method of making the product, or method of using the product within the scope of the present invention, which does not meet the written description and implementation requirements of the USPTO (35 U.SC § 112, first paragraph) or the EPO (Article 83 of the EPC), so that the applicant reserves the right and hereby discloses a disclaimer of any previously described product, process of making the product, or method of using the product. In the practice of the present invention, it may be advantageous to fully comply with Article 53(c) of the EPC and Rules 28(b) and (c) of the EPC. Nothing herein shall be considered a commitment.
[0103] It should be noted that in this disclosure, particularly in the claims and / or paragraphs, terms such as "comprising" may have the meaning ascribed to them in U.S. patent law; for example, it may mean "including"; and terms such as "consisting essentially of..." have the meaning ascribed to them in U.S. patent law, for example, it allows elements not expressly recited but excludes elements found in the prior art or that affect the basic or novel characteristics of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0104] The novel features of the invention are set forth with particularity in the appended claims. The features and advantages of the invention will be better understood by reference to the following detailed description which sets forth illustrative embodiments in which the principles of the invention are utilized, and to the accompanying drawings, in which:
[0105] Figure 1 A list of wild-type Cas13b orthologs and their amino acid sequences are shown, along with the source organism and protein accession number.
[0106] Figure 2 Shows Figure 1 A classification of each Cas13b ortholog and their relative efficacy in knocking down luciferase expression in mammalian cell culture.
[0107] Figure 3 The activity of each active Cas13b ortholog was compared against the guide sequence control.
[0108] Figure 4 The activities of two Cas13b orthologs, Porphyromonas oralis WP_039434803 and Prevotella P5-125 WP_044065294, and the activity of C2c2 / Cas13a were compared among various guide sequences.
[0109] Figure 5:Characterization of RNA knockdown of highly active Cas13b orthologs. (A) Schematic diagram of stereotyped Cas13 loci and corresponding crRNA structures. (B) Luciferase knockdown of 19 Cas13a, 15 Cas13b and 7 Cas13c orthologs was evaluated using two different guides. Orthologs effectively knocked down using two guides are marked with their host organism names. (C) PspCas13b and LwaCas13a knockdown activity are compared by tiling guides for Gluc and measuring luciferase expression. (D) PspCas13b and LwaCas13a knockdown activity are compared by tiling guides for Cluc and measuring luciferase expression. (E) Expression levels of all genes detected in the RNA-seq library of the non-targeted control (x-axis) compared to the Gluc targeting conditions (y-axis) of LwaCas13a (red) and shRNA (black) (expressed in log2 (transcripts per million (TPM)) values). Shown are the averages of three biological replicates. Gluc transcript data points are labeled. (F) Expression levels (expressed as log2(transcripts per million (TPM) values) of all genes detected in RNA-seq libraries of non-targeted controls (x-axis) compared to Gluc targeting conditions (y-axis) for PspCas13b (blue) and shRNA (black). Shown are the averages of three biological replicates. Gluc transcript data points are labeled. (G) Number of significant off-targets of Gluc knockdown by LwaCas13a, PspCas13b, and shRNA derived from whole transcriptome analysis in E and F.
[0110] Figure 6 : Engineering dCas13b-ADAR fusions for RNA editing. (A) Schematic diagram of RNA editing of dCas13b-ADAR fusion proteins. (B) Schematic diagram of the design of the target and targeting guide for Cypridina luciferase W85X. (C) Quantification of luciferase activity recovery of Cas13b-dADAR1 (left) and Cas13b-ADAR2-cd (right) using tiled guides of 30, 50, 70, or 84 nt in length. (D) Schematic diagram of the target site for targeting Cypridina luciferase W85X. (E) Sequencing quantification of A->I editing of a 50nt guide targeting Cypridina luciferase W85X.
[0111] Figure 7: Measuring sequence flexibility of RNA editing by REPAIRv1. (A) Schematic diagram of the screen used to determine protospacer flanking site (PFS) preferences for RNA editing by REPAIRv1. (B) Distribution of RNA editing efficiencies for all 4-NPFS combinations at two different editing sites (C) Quantification of the percentage of REPAIRv1 editing for all possible 3-mer motifs at Cluc W85. (D) Heatmap of 5' and 3' base preferences for RNA editing for all possible 3-mer motifs at Cluc W85
[0112] Figure 8 : Correction of disease-associated mutations using REPAIRv1. (A) Schematic representation of the target and guide design for targeting AVPR2 878G>A. (B) Correction of the 878G>A mutation in AVPR2 to different percentages using REPAIRv1 with three different guide designs. (C) Schematic representation of the target and guide design for targeting FANCC 1517G>A. (D) Correction of the 1517G>A mutation in FANCC to different percentages using REPAIRv1 with three different guide designs. (E) Quantification of the editing percentage of 34 disease-associated G>A mutations using REPAIRv1. (F) Analysis of all possible G>A mutations that can be corrected as annotated by the ClinVar database. (G) The distribution of editing motifs for all G>A mutations in ClinVar is shown relative to the REPAIRv1 editing efficiency of each motif (as quantified on Gluc transcripts).
[0113] Fig. 9 : Characterization of the specificity of REPAIRv1. (A) Schematic diagram of KRAS target site and guide design. (B) Quantification of the editing percentage of the tiled KRAS targeted guide. The editing percentage is shown at the target and adjacent adenosine sites. For each guide, the area of duplex RNA is represented by a red rectangle. (C) Full transcriptome sites with significant RNA editing by REPAIRv1 using Cluc targeted guides. Cluc sites (254A>G) at the target site are highlighted in orange. (D) Full transcriptome sites with significant RNA editing by REPAIRv1 using non-targeted guides.
[0114] Fig.10:Adara2 is rationally mutagenized to improve the specificity of REPAIRv1. (A) Quantification of the recovery of luciferase signals by various dCas13-ADAR2 mutants, and their specificity scores, which are drawn along the contact schematic diagram between the key ADAR2 deaminase residues and the dsRNA target. The specificity score is defined as the ratio of the luciferase signal between the targeted guide and the non-targeted guide conditions. (B) Quantification of the recovery of luciferase signals by various dCas13-ADAR2 mutants, and their specificity scores. (C) The on-target editing score of each dCas13-ADAR2 mutant and the number of significant off-targets are measured by whole transcriptome sequencing of mRNA. (D) Whole transcriptome sites of important RNA editing by REPAIRv1 and REPAIRv2 using guides targeting pre-termination sites in Cluc. The target Cluc site (254A>G) is highlighted in orange. (E) RNA sequencing reads around the target Cluc editing site (254A>G), highlighting the off-target editing differences between REPAIRv1 and REPAIRv2. All A>G edits are highlighted in red, while sequencing errors are highlighted in blue. (F) RNA editing was performed by REPAIRv1 and REPAIRv2 using guides targeting out-of-frame UAG sites in endogenous KRAS and PPIB transcripts. The on-target editing scores for each condition row are shown as horizontal bars on the right. The duplex region formed by the guide RNA is shown by a red outline box.
[0115] Fig.11 : Bacterial screening of Cas13b orthologs for in vivo efficiency and PFS determination. (A) Schematic diagram of bacterial assay for determining PFS of Cas13b orthologs. Cas13b orthologs with β-lactamase targeting spacer sequences were co-transformed with β-lactamase expression plasmids and double selected. (B) Quantification of the interference activity of Cas13b orthologs targeting β-lactamases, measured by colony forming units (cfu). (C) PFS signature of Cas13b orthologs, determined by depletion sequences in bacterial assays.
[0116] Fig.12: Optimization of Cas13b knockdown and further characterization of mismatch specificity. (A) Gluc knockdown using two different guides was measured using the first 2 Cas13a and first 4 Cas13b orthologs fused to various nuclear localization and nuclear export tags. (B) LwaCas13a, RanCas13b, PguCas13b and PspCas13b were measured for knockdown of KRAS using four different guides, and compared with shRNA controls matched to four positions. (C) Schematic diagram of single mismatch and double mismatch plasmid libraries for evaluating LwaCas13a and PspCas13b knockdown specificity. There are each possible single mismatch and double mismatch in the target sequence and in the 3 positions at the 5' and 3' ends of the forward flanking target site. (D) For both LwaCas13a and PspCas13b conditions, the depletion level of the transcript with the indicated single mismatch is plotted as a heat map. (E) Depletion levels of transcripts with the indicated double mismatches are plotted as a heat map for both LwaCas13a and PspCas13b conditions.
[0117] Fig.13 : Characterization of design parameters for dCas13-ADAR2 RNA editing. (A) Gluc-targeted knockdown efficiency of wild-type Cas13b and catalytically inactive H133A / H1058A Cas13b (dCas13b). (B) Quantification of luciferase recovery by dCas13b fused to the wild-type ADAR2 catalytic domain or the hyperactive E488Q mutant ADAR2 catalytic domain, tested with tiled Cluc targeting guides. (C) Guide design and sequencing quantification for A->I editing of a 30nt guide targeting Pyralis luciferase W85X. (D) Guide design and sequencing quantification for A->I editing of a 50nt guide targeting PPIB. (E) Effect of linker selection on REPAIRv1 recovery of luciferase activity. (F) Effect of base identification relative to the target adenosine on REPAIRv1 recovery of luciferase activity.
[0118] Fig.14 : ClinVar motif distribution of G>A mutations. The number of each possible triplet motif for all G>A mutations observed in the ClinVar database.
[0119] Fig.15 : (A) Truncations of dCas13b still have RNA editing function. Various N-terminal and C-terminal truncations of dCas13b allow RNA editing, as measured by restoration of luciferase signal. Fig.15 : (B) Other examples of dCas13b-ADAR constructs with different C-terminal truncations of dCas13b.
[0120] Fig.16 : Comparison of other programmable ADAR systems with the dCas13-ADAR2 editor. (A) Schematic diagram of two programmable ADAR schemes: BoxB-based targeting and full-length ADAR2 targeting. In the BoxB scheme (top), the ADAR2 deaminase domain (ADAR2 DD (E488Q)) with the lambda N The small bacterial virus protein is fused to a protein called Then, it contains two Hairpin guide RNA can guide ADAR2 DD (E488Q), Site-specific editing. In the full-length ADAR2 scheme (bottom), the dsRNA binding domain of ADAR2 binds to the hairpin in the guide RNA, allowing programmable ADAR2 editing. (B) BoxB-ADAR2 using guides targeting Cluc and non-targeting guides DD (E488Q) Transcriptome-wide sites of significant RNA edits. The target Cluc site (254A>G) is highlighted in orange. (C) Transcriptome-wide sites of significant RNA edits by ADAR2 using guides targeting Cluc and non-targeting guides. The target Cluc site (254A>G) is highlighted in orange. (D) Transcriptome-wide sites of significant RNA edits by REPAIRv1 using guides targeting Cluc and non-targeting guides. The target Cluc site (254A>G) is highlighted in orange. (E) DD Quantification of the percentage of on-target editing by (E488Q), ADAR2, and REPAIRv1 against the Cluc-targeted guide. (F) Overlap of off-target sites between different targeting and non-targeting conditions for the programmable ADAR system.
[0121] Fig.17 : Efficiency and specificity of dCas13b-ADAR2 mutants. (A) Cluc-targeting and non-targeting guides were activated by dCas13b-ADAR2 DD Quantification of restored luciferase activity of the (E488Q) mutant. (B) Relationship between the ratio of targeted and non-targeted guides and the number of RNA editing off-targets as quantified by whole transcriptome sequencing. (C) DD The number of off-target RNA editing sites in the whole transcriptome of the (E488Q) mutant was quantified along with the on-target Cluc editing efficiency.
[0122] Fig.18 :dCas13b-ADAR2 DD (E488Q) mutants for RNA editing transcriptome-wide specificity. (A) dCas13b-ADAR2 DD (E488Q) mutant uses Cluc-targeted guides to perform significant RNA editing transcriptome-wide. The target Cluc site (254A>G) is highlighted in orange. (B) dCas13b-ADAR2 DD The (E488Q) mutant utilizes non-targeting guides for transcriptome-wide sites of significant RNA editing.
[0123] Fig.19 : dCas13b-ADAR2 DD Characterization of motif bias in off-target editing of (E488Q). (A) For each dCas13b-ADAR2 DD (E488Q) mutants, showing the motifs present in all A>G off-target edits in the transcriptome. (B) Shows the distribution of off-target A>G edits per motif identity for REPAIRv1 using targeted and non-targeting guides. (C) Shows the distribution of off-target A>G edits per motif identity for REPAIRv2 using targeted and non-targeting guides.
[0124] Fig. 20 : Further characterization of off-targets of REPAIRv1 and REPAIRv2. (A) Histogram of the number of off-targets per transcript for REPAIRv1. (B) Histogram of the number of off-targets per transcript for REPAIRv2. (C) Prediction of variant effects of off-targets for REPAIRv1. (D) Distribution of potential oncogenic effects of off-targets for REPAIRv1. (E) Prediction of variant effects of off-targets for REPAIRv2. (F) Distribution of potential oncogenic effects of off-targets for REPAIRv2.
[0125] Fig.21 : RNA editing efficiency and specificity of REPAIRv1 and REPAIRv2. (A) Quantification of the percentage of KRAS edited at the target adenosine and adjacent sites using KRAS targeting guide 1 for REPAIRv1 and REPAIRv2. (B) Quantification of the percentage of KRAS edited at the target adenosine and adjacent sites using KRAS targeting guide 3 for REPAIRv1 and REPAIRv2. (C) Quantification of the percentage of PPIB edited at the target adenosine and adjacent sites using PPIB targeting guide 2 for REPAIRv1 and REPAIRv2.
[0126] Fig. 22: Including AG, a display of all potential codon changes with A>G RNA editors. Among them, (A) a table of all potential codon conversions achieved by A>I editing. (B) a codon table showing all potential codon conversions achieved by A>I editing.
[0127] The drawings herein are for illustrative purposes only and are not necessarily drawn to scale. DETAILED DESCRIPTION
[0128] In general, CRISPR-Cas or CRISPR systems used in the aforementioned documents such as WO 2014 / 093622 (PCT / US2013 / 074667) collectively refer to transcripts and other elements involved in the expression of a CRISPR-associated ("Cas") gene or directing the activity of the gene, including sequences encoding the Cas gene, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr-mate sequences (in the case of an endogenous CRISPR system, comprising a "direct repeat sequence" and a partial direct repeat sequence processed by tracrRNA), a guide sequence (in the case of an endogenous CRISPR system, also referred to as a "spacer sequence"), or the term "one or more RNAs" used herein (e.g., one or more RNAs for guiding Cas such as Cas9, e.g., CRISPR RNA and trans-activating (tracr) RNA or a single guide RNA (sgRNA) (chimeric RNA)), or other sequences and transcripts from a CRISPR locus. In general, CRISPR systems are characterized by having elements that promote the formation of a CRISPR complex at the site of a target sequence (also called a protospacer sequence in the case of an endogenous CRISPR system).
[0129] When the CRISPR protein is a Class 2 VI-B type effector (e.g., Cas13b effector protein), tracrRNA is not required. In the engineered system of the present invention, the forward repeat sequence may include a naturally occurring sequence or a non-naturally occurring sequence. The forward repeat sequence of the present invention is not limited to the length and sequence of naturally occurring. The length of the forward repeat sequence may be 36nt, but longer or shorter forward repeat sequences may vary. For example, the forward repeat sequence may be 30nt or longer, such as 30-100nt or longer. For example, the length of the forward repeat sequence may be 30nt, 40nt, 50nt, 60nt, 70nt, 80nt, 90nt, 100nt or longer. In some embodiments, the forward repeat sequence of the present invention may include a synthetic nucleotide sequence inserted between the 5' end and the 3' end of the naturally occurring forward repeat sequence. In certain embodiments, the inserted sequence may be self-complementary, such as 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% self-complementary. In addition, the direct repeat sequence of the present invention may include an insertion sequence of nucleotides, such as an aptamer or a sequence that binds to an adapter protein (for associating with a functional domain). In certain embodiments, one end of the direct repeat sequence containing such an insertion sequence is approximately the first half of the short DR, and the other end is approximately the second half of the short DR.
[0130] In the case of forming a CRISPR complex, a "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, wherein hybridization between the target sequence and the guide sequence promotes the formation of a CRISPR complex. The target sequence may comprise an RNA polynucleotide. In some embodiments, the target sequence is located in the nucleus or cytoplasm of the cell. In some embodiments, direct repeat sequences can be identified in silico by searching for repeat motifs that meet any or all of the following criteria: 1. Found in a 2Kb genomic sequence window flanking the CRISPR locus; 2. A span of 20 to 50 bp; and 3. An interval of 20 to 50 bp. In some embodiments, 2 of these criteria may be used, such as 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.
[0131] In embodiments of the present invention, the terms guide sequence and guide RNA (i.e., RNA capable of directing Cas13b to the target genomic locus) are used interchangeably, as in the literature cited above such as WO 2014 / 093622 (PCT / US2013 / 074667). Generally speaking, a guide sequence is any polynucleotide sequence that has sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and guide the CRISPR complex to sequence-specific binding with the target sequence. In some embodiments, when optimally aligned using a suitable alignment algorithm, the degree of complementarity between a guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or more. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler transformation (e.g., Burrows WheelerAligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available from www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available from soap.genomics.org.cn), and Maq (available from maq.sourceforge.net). In some embodiments, the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the length of the guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or less nucleotides. Preferably, the length of the guide sequence is 10-40 nucleotides, such as 20-30 or 20-40 nucleotides or longer, such as 30 nucleotides or about 30 nucleotides. In certain embodiments, for Cas13b effectors, the length of the guide sequence is 10-30 nucleotides, such as 20-30 or 20-40 nucleotides or longer, such as 30 nucleotides or about 30 nucleotides. In certain embodiments, for the Cas13b effectors derived from Bergey's bacterium (such as Bergey's bacterium ATCC 43767), the length of the guide sequence is 10-30 nucleotides, such as 20-30 nucleotides, such as 30 nucleotides or about 30 nucleotides.The ability of the guide sequence to guide the CRISPR complex to bind sequence-specifically to the target sequence can be assessed by any suitable assay. For example, the preferential cleavage within the target sequence can be assessed by transfecting a vector encoding a component of the CRISPR sequence, and then assessing the preferential cleavage within the target sequence, such as by the Surveyor assay described herein, and providing CRISPR system components (including the guide sequence to be tested) sufficient to form a CRISPR complex to a host cell having a corresponding target sequence. Similarly, the cleavage of the target polynucleotide sequence can be assessed in a test tube by providing a target sequence, components of the CRISPR complex (including a guide sequence to be tested and a control guide sequence different from the test guide sequence), and comparing the binding or cleavage rate at the target sequence between the test guide sequence and the control guide sequence reaction. Other assays are also possible and are conceivable to those skilled in the art.
[0132] In a classical CRISPR-Cas system, the degree of complementarity between a guide sequence and its corresponding target sequence can be about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or 100% or more; the length of the guide or RNA or sgRNA can be about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75 or more nucleotides; or the length of the guide or RNA or sgRNA can be less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or less nucleotides. However, in certain aspects of the invention, off-target interactions can be reduced, such as reducing the interaction of the guide with a target sequence with low complementarity. Indeed, certain mutations may result in the CRISPR-Cas system being able to distinguish between target sequences and off-target sequences having a complementarity greater than 80% to about 95%, such as 83%-84% or 88-89% or 94-95% complementarity (e.g., distinguishing a target having 18 nucleotides from an off-target having 18 nucleotides with 1, 2 or 3 mismatches). Thus, in the context of the present invention, the degree of complementarity between a guide sequence and its corresponding target sequence may be greater than 94.5%, or 95%, or 95.5%, or 96%, or 96.5%, or 97%, or 97.5%, or 98%, or 98.5%, or 99%, or 99.5%, or 99.9% or 100%. Off-targets have less than 100%, or 99.9%, or 99.5%, or 99%, or 99%, or 98.5%, or 98%, or 97.5%, or 97%, or 96.5%, or 96%, or 95.5%, or 95%, or 94.5%, or 94%, or 93%, or 92%, or 91%, or 90%, or 89%, or 88%, or 87% complementarity between the sequence and the guide. %, or 86%, or 85%, or 84%, or 83%, or 82%, or 81% or 80%, and advantageously the off-target has 100%, or 99.9%, or 99.5%, or 99%, or 99%, or 98.5%, or 98%, or 97.5%, or 97%, or 96.5%, or 96%, or 95.5%, or 95% or 94.5% complementarity between the sequence and the guide.
[0133] In certain embodiments, the regulation of cleavage efficiency can be utilized by introducing mismatches, such as 1 or more mismatches, such as 1 or 2 mismatches between the spacer sequence and the target sequence, including the mismatch position along the spacer sequence / target. For example, the more centered the double mismatch is (i.e., not at 3' or 5'), the greater the impact on cleavage efficiency. Therefore, by selecting the mismatch position along the spacer sequence, the cleavage efficiency can be regulated. For example, if it is desired that the cleavage of the target is less than 100% (e.g., in a cell population), 1 or more, such as preferably 2 mismatches, between the spacer sequence and the target sequence can be introduced into the spacer sequence. The more centered the spacer sequence along the mismatch position, the lower the cleavage percentage.
[0134] The methods according to the invention described herein include inducing one or more nucleotide modifications in eukaryotic cells (in vitro, i.e., in isolated eukaryotic cells) as discussed herein, including delivering the vector to the cell as discussed herein. One or more mutations may include introducing, deleting, or replacing one or more nucleotides at each target sequence of one or more cells via one or more guide RNAs or sgRNAs. Mutations may include introducing, deleting, or replacing 1-75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. Mutations may include introducing, deleting, or replacing 1, 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. The mutations may comprise introducing, deleting or substituting 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. The mutations comprise introducing, deleting or substituting 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. The mutation may comprise introducing, deleting or substituting 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. The mutation may comprise introducing, deleting or substituting 40, 45, 50, 75, 100, 200, 300, 400 or 500 nucleotides at each target sequence of the one or more cells via one or more guide RNAs.
[0135] In order to minimize toxicity and off-target effects, it is very important to control the concentration of the delivered Cas mRNA or protein and guide RNA. The optimal concentration of Cas mRNA or protein and guide RNA can be determined by testing different concentrations in cells or non-human eukaryotic animal models and using deep sequencing to analyze the degree of modification at potential off-target genomic loci.
[0136] Typically, in the case of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from the target sequence), but may depend, for example, on secondary structure, particularly in the case of RNA targets.
[0137] The nucleic acid molecule encoding Cas is advantageously a codon-optimized Cas. In this case, an example of a codon-optimized sequence is a sequence optimized for expression in eukaryotes such as humans (i.e., optimized for expression in humans), or a sequence optimized for expression in another eukaryote, animal, or mammal discussed herein. See, for example, WO 2014 / 093622 (PCT / US2013 / 074667) for sequences optimized by SaCas9 human codons. Although this example is preferred, it should be understood that other examples are also possible, and codon optimization for host species other than humans or codon optimization for specific organs is known. In some embodiments, the enzyme coding sequence encoding Cas is codon-optimized for expression in specific cells such as eukaryotic cells. Eukaryotic cells can be cells of specific organisms such as mammals or cells derived from the specific organisms, and the mammals include but are not limited to humans or non-human eukaryotes or animals or mammals discussed herein, such as mice, rats, rabbits, dogs, livestock, or non-human mammals or primates. In some embodiments, processes for modifying human germline genetic identity and / or processes for modifying animal genetic identity that may cause animals to suffer without any substantial medical benefit to humans or animals, as well as animals produced by these processes, are excluded. Generally speaking, codon optimization refers to the process of modifying a nucleic acid sequence to enhance expression in a host cell by replacing at least one codon (e.g., about or greater than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) of a native sequence with codons that are more commonly used or most commonly used in the genes of a target host cell while maintaining the native amino acid sequence. Various species exhibit specific biases for certain codons for specific amino acids. Codon bias (differences in codon usage between organisms) is generally associated with the translation efficiency of messenger RNA (mRNA), which in turn is believed to depend, inter alia, on the properties of the codons being translated and the availability of specific transfer RNA (tRNA) molecules. The advantage of the selected tRNA in a cell generally reflects the codons that are most commonly used in peptide synthesis. Therefore, genes can be customized based on codon optimization to perform optimal gene expression in a given organism. Codon usage tables are readily available, for example, in the "Codon Usage Database" at www.kazusa.orjp / codon / , and can be adapted in a variety of ways. See Nakamura, Y. et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000).Computer algorithms for codon optimization of specific sequences for expression in specific host cells are also available, such as Gene Forge (Aptagen; Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more or all codons) in the sequence encoding Cas correspond to the most frequently used codons for a specific amino acid.
[0138] In certain embodiments, the methods described herein may include providing a Cas transgenic cell, in which one or more nucleic acids encoding one or more guide RNAs are provided or introduced, and the one or more guide RNAs are operably connected in the cell using a regulatory element comprising a promoter of one or more target genes. As used herein, the term "Cas transgenic cell" refers to a cell, such as a eukaryotic cell, in which the Cas gene genome has been integrated. According to the present invention, the nature, type or source of the cell is not particularly limited. Similarly, the manner in which the Cas transgene is introduced into the cell may also be different and may be any method known in the art. In certain embodiments, the Cas transgenic cell is obtained by introducing the Cas transgene into an isolated cell. In certain other embodiments, the Cas transgenic cell is obtained by isolating cells from a Cas transgenic organism. For example, but not limited to, the Cas transgenic cell referred to herein may be derived from a Cas transgenic eukaryotic organism, such as a Cas knock-in eukaryotic organism. Reference is made to WO 2014 / 093622 (PCT / US13 / 74667), which is incorporated herein by reference. The methods of U.S. Patent Publication Nos. 20120017290 and 20110265198 for targeting the Rosa locus assigned to Sangamo BioSciences, Inc. can be modified to utilize the CRISPR Cas system of the present invention. The methods of U.S. Patent Publication No. 20130236946 for targeting the Rosa locus assigned to Cellectis can also be modified to utilize the CRISPR Cas system of the present invention. For further example, reference is made to Platt et al. (Cell; 159(2):440-455(2014)), which describes Cas9 knock-in mice and is incorporated herein by reference. The Cas transgene can also include a Lox-Stop-polyA-Lox (LSL) box so that Cas expression can be induced by the Cre recombinase. Alternatively, Cas transgenic cells can be obtained by introducing the Cas transgene into isolated cells. Transgenic delivery systems are well known in the art. For example, the Cas transgene can be delivered in, for example, eukaryotic cells, via vector (e.g., AAV, adenovirus, lentivirus) and / or particle and / or nanoparticle delivery as described elsewhere herein.
[0139] It will be understood by those skilled in the art that cells referred to herein, such as Cas transgenic cells, may contain additional genomic alterations in addition to an integrated Cas gene or mutations caused by the sequence-specific action of Cas when complexed with RNA capable of directing Cas to a target locus, such as one or more oncogenic mutations, for example but not limited to those described in Platt et al. (2014), Chen et al. (2014) or Kumar et al. (2009).
[0140] In some embodiments, the Cas sequence is fused to one or more nuclear localization sequences (NLS) or nuclear export signals (NES), such as about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS or NES. In some embodiments, Cas comprises about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS or NES at or near the amino terminus, about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS or NES at or near the carboxyl terminus, or a combination of these situations (e.g., comprising zero or at least one or more NLS or NES at the amino terminus, and zero or at least one or more NLS or NES at the carboxyl terminus). When more than one NLS or NES is present, each NLS or NES can be selected independently of one another so that a single NLS or NES can exist in more than one copy and / or exist in combination with one or more other NLS or NES present in one or more copies. In a preferred embodiment of the invention, Cas comprises up to 6 NLSs. In some embodiments, an NLS or NES is considered to be near the N-terminus or C-terminus when the nearest amino acid of the NLS or NES is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more amino acids along the polypeptide chain from the N-terminus or C-terminus.Non-limiting examples of NLSs include NLS sequences derived from the following: the NLS of the SV40 virus large T antigen, the amino acid sequence of PKK KRKV (SEQ ID NO: X); an NLS from a nucleoplasmin (e.g., a nucleoplasmin bipartite NLS of the sequence KR PAATKKAGQAKKKK) (SEQ ID NO: X); a c-myc NLS of the amino acid sequence PAAKRVKLD (SEQ ID NO: X) or RQRRNELKRSP (SEQ ID NO: X); an hRNPA1 M9 NLS of the sequence NQSSNFGPMKGGNFGGRSSG PYGGGGQYFAKPRNQGGY (SEQ ID NO: X); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: X) from the IBB domain of importin-α; the sequences VSRKRPRP (SEQ ID NO: X) and PPKKARED (SEQ ID NO: X) of myoma T protein. NO: X); the sequence of human p53 POPKKKPL (SEQ ID NO: X); the sequence of mouse c-abl IV SALIKKKKKMAP (SEQ ID NO: X); the sequences of influenza virus NS1 DRLRR (SEQ ID NO: X) and PKQKKRK (SEQ ID NO: X); the sequence of hepatitis virus delta antigen RKLKKKIKKL (SEQ ID NO: X); the sequence of mouse Mx1 protein REKKKFLKRR (SEQ ID NO: X); the sequence of human poly (ADP-ribose) polymerase KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: X); the sequence of steroid hormone receptor (human) glucocorticoid RKCLQAGMNLEARKTKK (SEQ ID NO: X). Non-limiting examples of NES include the NES sequence LYPERLRRILT (ctgtaccctgagcgg ctgcggcggatcctgacc). Generally speaking, one or more NLS or NES have sufficient strength to drive Cas to accumulate in the nucleus or cytoplasm of eukaryotic cells in a detectable amount, respectively. Generally speaking, the intensity of nuclear localization / export activity can be derived from the number of NLS / NES in Cas, the one or more specific NLS or NES used, or a combination of these factors. Detection of accumulation in the nucleus / cytoplasm can be performed by any suitable technique. For example, a detectable marker can be fused to Cas so that the position within the cell is visualized, such as in combination with a means for detecting the position of the nucleus or cytoplasm (e.g., a stain specific to the nucleus, such as DAPI).The nucleus can also be isolated from the cell, and its contents can then be analyzed by any suitable method for detecting proteins, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulations in the nucleus can also be determined indirectly, such as by measuring the effect of CRISPR complex formation (e.g., measuring DNA cleavage or mutation at the target sequence, or measuring altered gene expression activity and / or Cas enzyme activity affected by CRISPR complex formation) compared to controls that are not exposed to Cas or complexes or exposed to Cas lacking one or more NLS or NES. In certain embodiments, other localization tags can be fused to the Cas protein, such as but not limited to localizing Cas to a specific site in the cell, such as an organelle, such as mitochondria, plastids, chloroplasts, vesicles, Golgi (nuclear or cell) membranes, ribosomes, nucleoli, endoplasmic reticulum, cytoskeleton, vacuoles, centrosomes, nucleosomes, particles, centrioles, etc.
[0141] In certain aspects, the present invention relates to vectors, for example, for delivering or introducing Cas and / or RNA capable of directing Cas to a target locus (i.e., guide RNA) in a cell, and also for propagating these components (e.g., in a prokaryotic cell). As used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. A vector is a replicon, such as a plasmid, a phage, or a cosmid, into which another DNA fragment can be inserted to achieve replication of the inserted fragment. In general, a vector is capable of replication when combined with appropriate control elements. In general, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been connected. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules comprising one or more free ends, not comprising free ends (e.g., in a circular shape); nucleic acid molecules comprising DNA, RNA, or both; and other polynucleotide variants known in the art. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which other DNA fragments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, in which a DNA or RNA sequence of viral origin is present in the vector to be packaged into a virus (e.g., a retrovirus, a replication-defective retrovirus, an adenovirus, a replication-defective adenovirus, and an adeno-associated virus (AAV)). Viral vectors also include polynucleotides carried by viruses for transfection into host cells. Some vectors can replicate autonomously in the host cells into which they are introduced (e.g., bacterial vectors and free-type mammalian vectors with bacterial replication origins). Other vectors (e.g., non-free-type mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome. In addition, some vectors can guide the expression of genes operably connected thereto. Such vectors are referred to herein as "expression vectors". Practical universal expression vectors in recombinant DNA technology are typically in the form of plasmids.
[0142] Recombinant expression vector can comprise this nucleic acid in the form suitable for expressing nucleic acid of the present invention in host cell, which means that recombinant expression vector comprises one or more regulating and controlling elements operably connected with the nucleic acid sequence to be expressed, and these regulating and controlling elements can be selected according to the host cell to be used for expression. In recombinant expression vector, "operably connected" refers to that the target nucleotide sequence is connected with one or more regulating and controlling elements in a manner that allows the expression of the nucleotide sequence (for example, in an in vitro transcription / translation system, or when the vector is introduced into a host cell, in a host cell). About recombination and cloning methods, U.S. Patent Application No. 10 / 815,730, disclosed as US2004-0171156A1 on September 2, 2004, is mentioned, and its contents are incorporated herein by reference in their entirety.
[0143] One or more vectors may include one or more regulatory elements, such as one or more promoters. One or more vectors may include a Cas coding sequence, and / or a single but may also include at least 3 or 8 or 16 or 32 or 48 or 50 guide RNA (e.g., sgRNA) coding sequences, such as 1-2, 1-3, 1-4, 1-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-8, 3-16, 3-30, 3-32, 3-48, 3-50 RNAs (e.g., sgRNAs). In a single vector, it is advantageous that when there are up to about 16 RNAs, each RNA (e.g., sgRNA) can have a promoter; and when a single vector provides more than 16 RNAs, one or more promoters can drive more than one RNA expression, for example, when there are 32 RNAs, each promoter can drive two RNA expressions, and when there are 48 RNAs, each promoter can drive three RNA expressions. Through simple arithmetic and mature cloning schemes and the teachings in the present disclosure, those skilled in the art can easily practice the present invention in terms of one or more RNAs for suitable exemplary vectors such as AAV and suitable promoters such as U6 promoters. For example, the packaging limit of AAV is about 4.7kb. The length of a single U6-gRNA (plus cloning restriction sites) is 361bp. Therefore, a technician can easily assemble about 12-16, for example, 13 U6-gRNA boxes in a single vector. It can be assembled by any suitable means, such as the golden gate strategy (golden gate strategy) (http: / / www.genome-engineering.org / taleffectors / ) for TALE assembly. The technician can also use a tandem guidance strategy to increase the number of U6-gRNA by about 1.5 times, for example, from 12-16, for example, 13 to about 18-24, for example, about 19 U6-gRNAs. Therefore, those skilled in the art can easily reach about 18-24, for example, about 19 promoter-RNAs, such as U6-gRNAs, in a single vector such as an AAV vector. Another means to increase the number of promoters and RNAs in a vector is to use a single promoter (e.g., U6) to express an RNA array separated by a cleavable sequence. Another means to increase the number of promoter-RNAs in a vector is to express promoter-RNA arrays separated by cleavable sequences in the introns of a coding sequence or gene; and in this case, it is advantageous to use a polymerase II promoter, which can increase expression and can transcribe long RNAs in a tissue-specific manner.(See, e.g., http: / / nar.oxfordjournals.org / content / 34 / 7 / e53.short, http: / / www.nature.com / mt / journal / v16 / n9 / abs / mt2008144a.html). In an advantageous embodiment, AAV can package U6 tandem gRNAs targeting up to about 50 genes. Thus, based on the knowledge in the art and the teachings of the present disclosure, a skilled artisan can readily prepare and use one or more vectors, e.g., a single vector expressing multiple RNAs or guides under control or operably or functionally linked to one or more promoters, without any undue experimentation, especially with respect to the number of RNAs or guides discussed herein.
[0144] One or more guide RNA coding sequences and / or Cas coding sequences can be functionally or operably connected to one or more regulatory elements, so that the one or more regulatory elements can drive expression. One or more promoters can be one or more constitutive promoters and / or conditional promoters and / or inducible promoters and / or tissue-specific promoters. The promoter can be selected from: RNA polymerase pol I, pol II, pol III, T7, U6, H1 type retrovirus Rous sarcoma virus (RSV) LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter and EF1α promoter. A favorable promoter is that the promoter is U6.
[0145] Aspects of the invention relate to the identification and engineering of novel effector proteins that associate with Class 2 CRISPR-Cas systems. In a preferred embodiment, the effector protein comprises a single subunit effector module. In a further embodiment, the effector protein can be used for in vitro, in vivo or ex vivo applications in prokaryotic or eukaryotic cells.
[0146] The term "nucleic acid targeting system" (wherein the nucleic acid is DNA or RNA, and in some aspects may also refer to a DNA-RNA hybrid or a derivative thereof) refers collectively to transcripts and other elements involved in the expression of ("Cas") genes associated with DNA or RNA targeting CRISPR or directing the activity of the gene, which may include sequences encoding DNA or RNA targeting Cas proteins and DNA or RNA targeting guide RNAs comprising CRISPR RNA (crRNA) sequences and (in some but not all systems) trans-activating CRISPR / Cas system RNA (tracrRNA) sequences, or other sequences and transcripts from DNA or RNA targeting CRISPR loci. Generally speaking, RNA targeting systems are characterized by having elements that promote the formation of DNA or RNA targeting complexes at the site of a target DNA or RNA sequence. In the case of forming a DNA or RNA targeting complex, a "target sequence" refers to a DNA or RNA sequence to which a DNA or RNA targeting guide RNA is designed to have complementarity, wherein hybridization between the target sequence and the RNA targeting guide RNA promotes the formation of an RNA targeting complex. In some embodiments, the target sequence is located in the nucleus or cytoplasm of a cell.
[0147] In one aspect of the present invention, the novel RNA targeting system is also referred to as RNA or RNA targeting CRISPR / Cas or CRISPR-Cas system. The RNA targeting system of the present application is based on the identified type VI-B Cas protein and does not require the production of customized proteins to target specific RNA sequences. Instead, a single enzyme can be programmed by RNA molecules to recognize specific RNA targeting. In other words, the RNA molecule can be used to recruit the enzyme to a specific RNA target.
[0148] In one aspect of the present invention, the novel DNA targeting system is also referred to as a DNA or DNA targeting CRISPR / Cas or CRISPR-Cas system. The RNA targeting system of the present application is based on the identified type VI-B Cas protein and does not require the production of customized proteins to target specific RNA sequences. Instead, a single enzyme can be programmed by RNA molecules to recognize specific DNA targeting. In other words, the RNA molecule can be used to recruit the enzyme to a specific DNA target.
[0149] The nucleic acid targeting systems, vector systems, vectors and compositions described herein can be used for a variety of nucleic acid targeting applications, including altering or modifying gene products such as protein synthesis, nucleic acid cleavage, nucleic acid editing, nucleic acid splicing; transport of target nucleic acids, tracking of target nucleic acids, separation of target nucleic acids, visualization of target nucleic acids, etc.
[0150] As used herein, Cas protein or CRISPR enzyme refers to any protein presented in the new classification of CRISPR-Cas systems.
[0151] Cas13b nuclease
[0152] The Cas13b effector protein of the present invention is from Figure 1 or Figure 1 The described protein, or comprises the protein, or consists essentially of the protein, or consists of the protein, or comprises the protein. Figure 1 The preferred protein is selected from oral Porphyromonas Cas13b (accession number WP_039434803), Prevotella P5-125 Cas13b (accession number WP_044065294), gingivalis Porphyromonas Cas13b (accession number WP_053444417), Porphyromonas COT-052OH4946 Cas13b (accession number WP_039428968), Bacteroides pyogenes Cas13b (accession number WP_034542281), and Riemerella anatipestifer Cas13b (accession number WP_004919755). Figure 1 The most preferred protein is selected from oral Porphyromonas Cas13b (accession number WP_039434803), Prevotella P5-125 Cas13b (accession number WP_044065294), gingival Porphyromonas Cas13b (accession number WP_053444417), Porphyromonas COT-052OH4946 Cas13b (accession number WP_039428968); and most particularly preferred is oral Porphyromonas Cas13b (accession number WP_039434803) or Prevotella P5-125 Cas13b (accession number WP_044065294). The present invention is intended to provide or relate to or include a protein from or as described herein, or consist essentially of the protein, or consist of the protein, including mutations or changes as described herein.
[0153] Thus, in some embodiments, the effector protein may be an RNA binding protein, such as a death Cas type effector protein, which may be optionally functionalized as described herein, for example, with a transcriptional activator or repressor domain, an NLS or other functional domain. In some embodiments, the effector protein may be an RNA binding protein that cleaves a single strand of RNA. If the bound RNA is ssRNA, the ssRNA is completely cleaved. In some embodiments, for example, if the effector protein comprises two RNase domains, it may be an RNA binding protein that cleaves a double strand of RNA. If the bound RNA is dsRNA, the dsRNA is completely cleaved.
[0154] RNase function in CRISPR systems is known, for example, mRNA targeting of certain type III CRISPR-Cas systems has been reported (Hale et al., 2014, Genes Dev, Vol. 28, 2432-2443; Hale et al., 2009, Cell, Vol. 139, 945-956; Peng et al., 2015, Nucleic acids research, Vol. 43, 406-417), and the reported mRNA targeting provides obvious advantages. Therefore, a CRISPR-Cas system, composition or method for targeting RNA via an effector protein of the present invention is provided.
[0155] The target RNA, i.e., the target RNA, is the RNA to be targeted by the present invention, resulting in recruitment to the target target site on the target RNA and binding of the effector protein at the target target site. The target RNA can be any suitable form of RNA. In some embodiments, this can include mRNA. In other embodiments, the target RNA can include tRNA or rRNA.
[0156] Cas13b guide
[0157] As used herein, the term "crRNA" or "guide RNA" or "single guide RNA" or "sgRNA" or "nucleic acid component(s)" of a Type VI CRISPR-Cas locus effector protein comprises any polynucleotide sequence that has sufficient complementarity to a target nucleic acid sequence to hybridize to the target nucleic acid sequence and to effect sequence-specific binding of the guide RNA targeting complex to the target RNA sequence.
[0158] In certain embodiments, the CRISPR system provided herein can utilize crRNA or similar polynucleotides comprising a guide sequence, wherein the polynucleotide is RNA, DNA, or a mixture of RNA and DNA, and / or wherein the polynucleotide comprises one or more nucleotide analogs. The sequence may comprise any structure, including but not limited to the structure of natural crRNA, such as a bulge, a hairpin, or a stem-loop structure. In certain embodiments, the polynucleotide comprising a guide sequence forms a duplex with a second polynucleotide sequence, and the second polynucleotide sequence may be an RNA or DNA sequence.
[0159] In certain embodiments, the guide of the present invention comprises non-naturally occurring nucleic acids and / or non-naturally occurring nucleotides and / or nucleotide analogs and / or chemical modifications. Non-naturally occurring nucleic acids may include, for example, a mixture of natural and non-naturally occurring nucleotides. Non-naturally occurring nucleotides and / or nucleotide analogs may be modified at ribose, phosphate and / or base moieties. In one embodiment of the present invention, the guide nucleic acid comprises ribonucleotides and non-ribonucleotides. In one such embodiment, the guide comprises one or more ribonucleotides and one or more deoxyribonucleotides. In one embodiment of the present invention, the guide comprises one or more non-naturally occurring nucleotides or nucleotide analogs, such as nucleotides with thiophosphate bonds, boric acid phosphate bonds, locked nucleic acids (LNA) nucleotides comprising a methylene bridge between the 2' and 4' carbons of the ribose ring, or bridged nucleic acids (BNA). Other examples of modified nucleotides include 2'-O-methyl analogs, 2'-deoxy analogs, 2-thiouridine analogs, N6-methyladenosine analogs, or 2'-fluoro analogs. Other examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromouridine, pseudouridine (Ψ), N1-methylpseudouridine (melΨ), 5-methoxyuridine (5moU), inosine, 7-methylguanosine. Examples of chemical modifications of guide RNAs include, but are not limited to, incorporation of 2'-O-methyl (M), 2'-O-methyl 3'thiophosphate (MS), S-constrained ethyl (cEt), or 2'-O-methyl 3'thiophosphonoacetate (MSP) at one or more terminal nucleotides. Such chemically modified guide RNAs may have increased stability and activity compared to unmodified guide RNAs, but on-target and off-target specificity cannot be predicted. (See Hendel, 2015, Nat Biotechnol. 33(9):985-9, doi:10.1038 / nbt.3290, published online on June 29, 2015; Allerson et al., J. Med. Chem. 2005, 48:901-904; Bramsen et al., Front. Genet., 2012, 3:154; Deng et al., PNAS, 2015, 112:11870-11875; Sharma et al., Med Chem Comm., 2014, 5:1454-1471; Li et al., Nature Biomedical Engineering, 2017, 1, 0066 DOI:10.1038 / s41551-017-0066).
[0160] In some embodiments, the 5' and / or 3' ends of the guide RNA are modified with a variety of functional moieties including fluorescent dyes, polyethylene glycol, cholesterol, proteins, or detection tags. (See Kelly et al., 2016, J. Biotech. 233: 74-83). In certain embodiments, the guide comprises ribonucleotides in the region that binds to the target RNA, and comprises one or more deoxyribonucleotides and / or nucleotide analogs in the region that binds to Cas13b. In one embodiment of the invention, deoxyribonucleotides and / or nucleotide analogs are incorporated into engineered guidance structures, such as, but not limited to, 5' and / or 3' ends, stem loop regions, and seed regions. In certain embodiments, the modification is not in the 3'-handle of the stem loop region. Chemical modifications in the 3'-handle of the stem loop region of the guide may eliminate its function. In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides of the guide are chemically modified. In some embodiments, 3-5 nucleotides at the 3' end or 5' end of the guide are chemically modified. In some embodiments, only minor modifications, such as 2'-F modifications, are introduced in the seed region. In certain embodiments, 2'-F modifications are introduced at the 5' end and / or 3' end of the guide. In some embodiments, 3 to 5 nucleotides at the 5' and / or 3' ends of the guide are chemically modified with 2'-O-methyl (M), 2'-O-methyl-3'-phosphorothioate (MS), S-constrained ethyl (cEt) or 2'-O-methyl-3'-phosphonothioate acetate (MSP). This modification can improve genome editing efficiency (see Hendel et al., Nat. Biotechnol. (2015) 33 (9): 985-989). In some embodiments, all phosphodiester bonds of the guide are replaced with phosphorothioate (PS) to enhance the level of gene disruption. In some embodiments, five or more nucleotides at the 5' and / or 3' ends of the guide are chemically modified with 2'-O-Me, 2'-F or S-constrained ethyl (cEt). This chemically modified guide can mediate enhanced gene disruption levels (see Ragdarm et al., 0215, PNAS, E7110-E7111). In one embodiment of the invention, the guide is modified to include a chemical moiety at its 3' end and / or 5' end. Such moieties include, but are not limited to, amines, azides, alkynes, thiols, dibenzocyclooctyne (DBCO), or rhodamine. In certain embodiments, the chemical moiety is conjugated to the guide via a linker such as an alkyl chain. In certain embodiments, the guide can be attached to another molecule, such as DNA, RNA, protein, or nanoparticle using the chemical moiety of the modified guide.Such chemically modified guides can be used to identify or enrich for cells that are commonly edited by the CRISPR system (see Lee et al., eLife, 2017, 6:e25312, DOI: 10.7554).
[0161] In some embodiments, the modification of the guide is a chemical modification, insertion, deletion or break. In some embodiments, the chemical modification includes but is not limited to the incorporation of 2'-O-methyl (M) analogs, 2'-deoxy analogs, 2-thiouridine analogs, N6-methyladenosine analogs, 2'-fluoro analogs, 2-aminopurine, 5-bromouridine, pseudouridine (Ψ), N1-methyl pseudouridine (melΨ), 5-methoxyuridine (5moU), inosine, 7-methylguanosine, 2'-O-methyl-3'-thiophosphate (MS), S-constrained ethyl (cEt), thiophosphate (PS) or 2'-O-methyl-3'-thiophosphonoacetate (MSP). In some embodiments, the guide comprises one or more thiophosphate modifications. In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 25 nucleotides of the guide are chemically modified. In certain embodiments, one or more nucleotides in the seed region are chemically modified. In certain embodiments, one or more nucleotides in the 5' end are chemically modified. In certain embodiments, no nucleotide in the 3'-handle is chemically modified. In some embodiments, the chemical modification in the seed region is a minor modification, such as incorporating a 2'-fluoro analog. In a specific embodiment, a nucleotide in the seed region is replaced with a 2'-fluoro analog. In some embodiments, 5 or 10 nucleotides in the 5' end are chemically modified. Such chemical modifications at the 5' end of Cas13b crRNA can improve gene cutting efficiency. In a specific embodiment, 5 nucleotides in the 5' end are replaced with 2'-fluoro analogs. In a specific embodiment, 10 nucleotides in the 5' end are replaced with 2'-fluoro analogs. In a specific embodiment, 5 nucleotides in the 5' end are replaced with 2'-O-methyl (M) analogs.
[0162] In some embodiments, the loop of the 3'-handle of the guide is modified. In some embodiments, the loop of the 3'-handle of the guide is modified to have a deletion, insertion, breakage, or chemical modification. In certain embodiments, the loop comprises 3, 4, or 5 nucleotides. In certain embodiments, the loop comprises the sequence UCUU, UUUU, UAUU, or UGUU.
[0163] On the one hand, the guide includes a part that is chemically connected or conjugated via a non-phosphodiester bond. On the one hand, in a non-limiting example, the guide includes a direct repeat sequence and a targeting sequence portion that are chemically connected or conjugated via a non-nucleotide ring. In some embodiments, these parts are connected via a non-phosphodiester covalent linker. The example of a covalent linker includes but is not limited to a chemical part selected from the following: carbamate, ether, ester, amide, imine, amidine, aminotriazine, hydrazone, disulfide, thioether, thioester, thiophosphate, dithiophosphate, sulfonamide, sulfonate, sulfone (fulfone), sulfoxide, urea, thiourea, hydrazide, oxime, triazole, light unstable key, CC bond forming group (such as, Diels-Alder cycloaddition pair or ring-closing metathesis pair and Michael reaction pair).
[0164] In some embodiments, the various portions of the guide are first synthesized using a standard phosphoramidite synthesis protocol (Herdewijn, P., ed., Methods in Molecular Biology Col 288, Oligonucleotide Synthesis: Methods and Applications, Humana Press, New Jersey (2012)). In some embodiments, the non-targeted guide portion can be functionalized to include a suitable functional group for attachment using standard protocols known in the art (Hermanson, GT, Bioconjugate Techniques, Academic Press (2013)). Examples of functional groups include, but are not limited to, hydroxyl, amine, carboxylic acid, carboxylic acid halide, carboxylic acid active ester, aldehyde, carbonyl, chlorocarbonyl, imidazolylcarbonyl, hydrazide, semicarbazide, thiosemicarbazide, thiol, maleimide, haloalkyl, sulfonyl, allyl, propargyl, diene, alkyne, and azide. Once the non-targeted portion of the guide is functionalized, a covalent chemical bond can be formed between the two oligonucleotides. Examples of chemical bonds include, but are not limited to, bonds based on carbamates, ethers, esters, amides, imines, amidines, aminotriazines, hydrazones, disulfides, thioethers, thioesters, phosphorothioates, phosphorodithioates, sulfonamides, sulfonates, sulfones, sulfoxides, ureas, thioureas, hydrazides, oximes, triazoles, photolabile bonds, C-C bond forming groups such as Diels-Alder cycloaddition pairs or ring-closing metathesis pairs and Michael reaction pairs.
[0165] In some embodiments, one or more portions of the guide can be chemically synthesized. In some embodiments, chemical synthesis uses an automated solid phase oligonucleotide synthesizer and utilizes 2'-acetoxyethyl orthoester (2'-ACE) (Scaringe et al., J. Am. Chem. Soc. (1998) 120: 11820-11821; Scaringe, Methods Enzymol. (2000) 317: 3-18) or 2'-thiocarbamate (2'-TC) chemistry (Dellinger et al., J. Am. Chem. Soc. (2011) 133: 11540-11546; Hendel et al., Nat. Biotechnol. (2015) 33: 985-989).
[0166] In some embodiments, the guidance moiety can be covalently attached via modification of sugars, internucleotide phosphodiester bonds, purine and pyrimidine residues using various bioconjugation reactions, rings, bridges, and non-nucleotide bonds. Sletten et al., Angew. Chem. Int. Ed. (2009) 48: 6974-6998; Manoharan, M., Curr. Opin. Chem. Biol. (2004) 8: 570-9; Behlke et al., Oligonucleotides (2008) 18: 305-19; Watts et al., Drug. Discov. Today (2008) 13: 842-55; Shukla et al., Chem Med Chem (2010) 5: 328-49.
[0167] In some embodiments, click chemistry can be used to covalently link the guide portion. In some embodiments, a triazole linker can be used to covalently link the guide portion. In some embodiments, the Huisgen 1,3-dipolar cycloaddition reaction involving alkynes and azides can be used to produce a highly stable triazole linker to covalently link the guide portion (He et al., ChemBioChem (2015) 17: 1809-1812; WO 2016 / 186745). In some embodiments, the guide portion is covalently linked by linking a 5'-hexyne portion and a 3'-azide portion. In some embodiments, one or both of the 5'-hexyne director moiety and the 3'-azide director moiety can be protected with a 2'-acetoxyethyl orthoester (2'-ACE) group, which can then be removed using the Dharmacon protocol (Scaringe et al., J. Am. Chem. Soc. (1998) 120: 11820-11821; Scaringe, Methods Enzymol. (2000) 317: 3-18).
[0168] In some embodiments, the guide moiety can be covalently linked via a linker (e.g., a non-nucleotide loop) comprising moieties such as spacers, attachments, bioconjugates, chromophores, reporter groups, dye-labeled RNAs, and non-naturally occurring nucleotide analogs. More specifically, suitable spacers for the purposes of the present invention include, but are not limited to, polyethers (e.g., polyethylene glycol, polyols, polypropylene glycol, or mixtures of ethylene and propylene glycol), polyamine groups (e.g., spermine, spermidine, and polymeric derivatives thereof), polyesters (e.g., poly(ethyl acrylate)), polyphosphodiester, alkylene groups, and combinations thereof. Suitable attachments include any moiety that can be added to the linker to add additional properties to the linker, such as, but not limited to, fluorescent labels. Suitable bioconjugates include, but are not limited to, peptides, glycosides, lipids, cholesterol, phospholipids, diacylglycerols and dialkylglycerols, fatty acids, hydrocarbons, enzyme substrates, steroids, biotin, digoxigenin, carbohydrates, polysaccharides. Suitable chromophores, reporter groups, and dye-labeled RNAs include, but are not limited to, fluorescent dyes (such as fluorescein and rhodamine), chemiluminescent, electrochemiluminescent, and bioluminescent labeling compounds. The design of exemplary linkers for conjugating two RNA components is also described in WO 2004 / 015075.
[0169] In some embodiments, the joint has a length equal to about 0-16 nucleotides. In some embodiments, the joint has a length equal to about 0-8 nucleotides. In some embodiments, the joint has a length equal to about 0-4 nucleotides. In some embodiments, the joint has a length equal to about 2 nucleotides. Example joint designs are also described in WO2011 / 008730.
[0170] In some embodiments, when optimally aligned using a suitable alignment algorithm, the degree of complementarity is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or more. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, an algorithm based on the Burrows-Wheeler transformation (e.g., Burrows WheelerAligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). The ability of a guide sequence (within an RNA targeting guide RNA or crRNA) to direct a nucleic acid targeting complex to bind sequence-specifically to a target nucleic acid sequence can be assessed by any suitable assay. For example, the preferential targeting (e.g., cleavage) in the target nucleic acid sequence can be evaluated, such as by transfection with a vector encoding a component of a nucleic acid targeting complex, and then the preferential targeting (e.g., cleavage) in the target nucleic acid sequence can be evaluated, and the RNA targeting CRISPR Cas13b system components (including the guide sequence to be tested) sufficient to form the nucleic acid targeting complex are provided to the host cell with the corresponding target nucleic acid sequence. Similarly, the target nucleic acid sequence, the components of the nucleic acid targeting complex (including the guide sequence to be tested and the control guide sequence different from the test guide sequence) can be provided, and the binding or cleavage rate at the target sequence can be compared between the test guide sequence and the control guide sequence reaction, and the cleavage of the target nucleic acid sequence can be evaluated in a test tube. Other determinations are also possible and are conceivable to those skilled in the art. The guide sequence can be selected and therefore RNA targeting guide RNA or crRNA can be selected to target any target nucleic acid sequence. The target sequence can be DNA. The target sequence can be any RNA sequence. In some embodiments, the target sequence can be a sequence within an RNA molecule selected from emissive RNA (mRNA), pre-mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), double-stranded RNA (dsRNA), non-coding RNA (ncRNA), long non-coding RNA (lncRNA) and small cytoplasmic RNA (scRNA). In some preferred embodiments, the target sequence can be a sequence within an RNA molecule selected from mRNA, pre-mRNA and rRNA.In some preferred embodiments, the target sequence may be a sequence within an RNA molecule selected from ncRNA and lncRNA. In some more preferred embodiments, the target sequence may be a sequence within an mRNA molecule or a pre-mRNA molecule.
[0171] In some embodiments, RNA targeting guide RNA or crRNA is selected to reduce the degree of secondary structure in RNA targeting guide RNA or crRNA. In some embodiments, when optimal folding is performed, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less nucleotides of RNA targeting guide RNA participate in self-complementary base pairing. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimum Gibbs free energy (Gibbs free energy). An example of such an algorithm is mFold, as described in Zuker and Stiegler (Nucleic Acids Res.9 (1981), 133-148). Another example of a folding algorithm is the online web server RNAfold, developed by the Institute of Theoretical Chemistry at the University of Vienna, which uses the centroid structure prediction algorithm (see, e.g., AR Gruber et al., 2008, Cell 106(1):23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12):1151-62).
[0172] In certain embodiments, the guide RNA or crRNA may comprise a forward repeat (DR) sequence and a guide sequence or a spacer sequence, consist essentially of the sequence, or consist of the sequence. In certain embodiments, the guide RNA or crRNA may comprise a forward repeat sequence fused or connected to a guide sequence or a spacer sequence, consist essentially of the sequence, or consist of the sequence. In certain embodiments, the forward repeat sequence may be located upstream (i.e., 5') of the guide sequence or the spacer sequence. In other embodiments, the forward repeat sequence may be located downstream (i.e., 3') of the guide sequence or the spacer sequence. In other embodiments, multiple DRs (such as double DRs) may be present.
[0173] In certain embodiments, the crRNA comprises a stem loop, preferably a single stem loop. In certain embodiments, the direct repeat sequence forms a stem loop, preferably a single stem loop.
[0174] In certain embodiments, the spacer length of the guide RNA is 15 to 35 nt. In certain embodiments, the spacer length of the guide RNA is at least 15 nucleotides. In certain embodiments, the spacer length is 15 to 17 nt (e.g., 15, 16 or 17 nt), 17 to 20 nt (e.g., 17, 18, 19 or 20 nt), 20 to 24 nt (e.g., 20, 21, 22, 23 or 24 nt), 23 to 25 nt (e.g., 23, 24 or 25 nt), 24 to 27 nt (e.g., 24, 25, 26 or 27 nt), 27 to 30 nt (e.g., 27, 28, 29 or 30 nt), 30 to 35 nt (e.g., 30, 31, 32, 33, 34 or 35 nt) or 35 nt or longer.
[0175] Interfering RNA (RNAi) and microRNA (miRNA)
[0176] In other embodiments, the target RNA may include interfering RNA, i.e., RNA that participates in RNA interference pathways in eukaryotes and prokaryotes, such as shRNA, siRNA, etc. In other embodiments, the target RNA may include microRNA (miRNA). Controlling interfering RNA or miRNA can help reduce off-target effects (OTEs) produced by those methods by reducing the life span of interfering RNA or miRNA in vivo or in vitro.
[0177] In certain embodiments, the target is not the miRNA itself, but rather a miRNA binding site of a miRNA target.
[0178] In certain embodiments, the miRNA may be sequestered (such as including subcellular relocalization). In certain embodiments, the miRNA may be cleaved, such as but not limited to, at a hairpin.
[0179] In certain embodiments, miRNA processing (such as including turnover) is increased or decreased.
[0180] If an effector protein and a suitable guide are selectively expressed (e.g., spatially or temporally, under the control of a suitable promoter, such as a tissue or cell cycle specific promoter and / or enhancer), this can be used to "protect" cells or systems (in vivo or in vitro) from RNAi in these cells. This may be useful in neighboring tissues or cells where RNAi is not desired, or when comparing cells or tissues that do and do not express an effector protein and a suitable guide (i.e., do not control and control RNAi, respectively). Effector proteins can be used to control or bind to molecules comprising or consisting of RNA, such as ribozymes, ribosomes, or riboswitches. In embodiments of the invention, RNA guides can recruit effector proteins to these molecules so that the effector proteins can bind to them.
[0181] In light of the present disclosure, the inventive inoculum system can be applied to the field of RNAi technology, including therapeutic, assay and other applications, without undue experimentation (see, e.g., Guidi et al., PLoS Negl Trop Dis 9(5):e0003801. doi: 10.1371 / journal.pntd; Crotty et al., In vivo RNAi screens: concepts and applications. Shane Crotty ... 2015, Elsevier Ltd., published by Elsevier Inc., Pesticide Biochemistry and Physiology (impact factor: 2.01). 01 / 2015; 120. DOI: 10.1016 / j.pestbp.2015.01.002 and Makkonen et al., Viruses 2015, 7(4), 2099-2125; doi: 10.3390 / v7042099), as the present application provides a basis for engineering the system in a well-informed manner.
[0182] Ribosomal RNA (rRNA)
[0183] For example, azalide antibiotics such as azithromycin are well known. They target and destroy the 50S ribosomal subunit. In some embodiments, the effector protein of the present invention can be recruited and bound to the 50S ribosomal subunit together with a suitable guide RNA targeting the 50S ribosomal subunit. Therefore, the effector protein of the present invention and a suitable guide for a ribosome (especially a 50s ribosomal subunit) target are provided. The use of such effector proteins and suitable guides for ribosomes (especially 50s ribosomal subunits) targets may include antibiotic uses. Specifically, antibiotic uses are similar to the effects of azalide antibiotics such as azithromycin. In some embodiments, prokaryotic ribosomal subunits such as 70S subunits in prokaryotes, the above-mentioned 50S subunits, 30S subunits, and 16S and 5S subunits can be targeted. In other embodiments, eukaryotic ribosomal subunits such as 80S subunits, 60S subunits, 40S subunits, and 28S, 18S, 5.8S and 5S subunits in eukaryotes can be targeted.
[0184] In some embodiments, the effector protein may be an RNA binding protein, optionally functionalized as described herein. In some embodiments, the effector protein may be an RNA binding protein that cleaves a single strand of RNA. In either case, but particularly where the RNA binding protein cleaves a single strand of RNA, ribosomal function may be modulated, particularly reduced or disrupted. This may apply to any ribosomal RNA and any ribosomal subunit, and the sequence of rRNA is well known.
[0185] Thus, it is contemplated that ribosomal activity is controlled by using the effector proteins of the invention together with suitable guides to ribosomal targets. This can be achieved by cleaving or binding to ribosomes. Specifically, it is contemplated that ribosomal activity is reduced. This may be useful for determining ribosomal function in vivo or in vitro, but can also be used as a means of controlling therapy based on ribosomal activity in vivo or in vitro. In addition, it is contemplated that protein synthesis is controlled (i.e., reduced) in an in vivo or in vitro system, such control includes antibiotic uses as well as research and diagnostic uses.
[0186] Riboswitch
[0187] A riboswitch (also known as an aptozyme) is a regulatory fragment of a messenger RNA molecule that binds a small molecule. This typically results in a change in the production of the protein encoded by the mRNA. Therefore, it is contemplated that the activity of a riboswitch is controlled by using an effector protein of the invention and a suitable guide to the riboswitch target. This can be achieved by cleaving or binding the riboswitch. Specifically, it is contemplated that the activity of a riboswitch is reduced. This may be useful for determining riboswitch function in vivo or in vitro, but may also be used as a means of controlling therapy based on riboswitch activity in vivo or in vitro. In addition, it is contemplated that protein synthesis is controlled (i.e., reduced) in an in vivo or in vitro system. For rRNA, such control may include antibiotic uses as well as research and diagnostic uses.
[0188] Ribozyme
[0189] Ribozymes are RNA molecules with catalytic properties, similar to enzymes (of course, proteins). Since both naturally occurring and engineered ribozymes contain RNA or consist of RNA, they can also be targeted by the RNA-binding effector proteins of the present invention. In some embodiments, the effector protein can be an RNA-binding protein that cleaves the ribozyme to inactivate it. Therefore, it is contemplated to control ribozyme activity by using the effector protein of the present invention and a suitable guide to the ribozyme target. This can be achieved by cleaving or binding the ribozyme. Specifically, it is contemplated to reduce ribozyme activity. This may be useful for determining ribozyme function in vivo or in vitro, but it can also be used as a means of controlling therapy based on ribozyme activity in vivo or in vitro.
[0190] Gene expression, including RNA processing
[0191] Effector proteins can also be used with suitable guides for targeted gene expression, including via control RNA processing. Controlling RNA processing can include RNA processing reactions such as RNA splicing, including alternative splicing via targeted RNApol; viral replication (particularly satellite viruses, bacteriophages and retroviruses, such as HBV, HBC and HIV and other viruses listed herein), including viroids in plants; and tRNA biosynthesis. Effector proteins and suitable guides can also be used to control RNA activation (RNAa). RNAa will promote gene expression, so control of gene expression can be achieved by destroying or reducing RNAa to reduce the promotion of gene expression. This will be discussed in more detail below.
[0192] RNAi screening
[0193] Biological pathways can be interrogated and components identified via RNAi screens by identifying gene products whose knockdown is associated with phenotypic changes. Controls can also be applied to these screens or during these screens using effector proteins and appropriate guides to remove or reduce the activity of RNAi in the screen, thereby restoring the activity of the (previously perturbed) gene product (by removing or reducing perturbation / repression).
[0194] Satellite RNA (satRNA) and satellite viruses can also be processed.
[0195] Control of RNase activity herein generally refers to reduction, negative disruption, or knockdown or knockout.
[0196] In vivo RNA applications
[0197] Inhibit gene expression
[0198] The target-specific RNAse provided herein allows very specific cleavage of target RNA. Since the genome is not modified, interference at the RNA level can be regulated in space and time and in a non-invasive manner.
[0199] It has been demonstrated that many diseases can be treated by mRNA targeting. Although most of these studies are related to the administration of siRNA, it should be clear that the RNA targeting effector proteins provided herein can be applied in a similar manner.
[0200] Examples of mRNA targets (and corresponding disease treatments) are VEGF, VEGF-R1 and RTP801 (in the treatment of AMD and / or DME), Caspase 2 (in the treatment of Naion), ADRB2 (in the treatment of intraocular pressure), TRPVI (in the treatment of dry eye syndrome), Syk kinase (in the treatment of asthma), Apo B (in the treatment of hypercholesterolemia or hypobetalipoproteinemia), PLK1, KSP and VEGF (in the treatment of solid tumors), Ber-Abl (in the treatment of CML) (Burnett and Rossi, Chem Biol. 2012, 19(1):60–71)). Likewise, RNA targeting has been shown to be effective in treating RNA virus-mediated diseases such as HIV (targeting HIV Tet and Rev), RSV (targeting RSV nucleocapsid), and HCV (targeting miR-122) (Burnett and Rossi, Chem Biol. 2012, 19(1):60–71).
[0201] It is further envisioned that the RNA targeting effector protein of the present invention can be used for mutation-specific or allele-specific knockdown. The guide RNA can be designed so that it specifically targets sequences containing mutation- or allele-specific sequences in the transcribed mRNA. This specific knockdown is particularly suitable for therapeutic applications of diseases associated with mutation- or allele-specific gene products. For example, most cases of familial hypobetalipoproteinemia (FHBL) are caused by mutations in the ApoB gene. The gene encodes two forms of apolipoprotein B protein: a short form (ApoB-48) and a long form (ApoB-100). Several ApoB gene mutations that cause FHBL result in two forms of ApoB being abnormally short. Specific targeting and knockdown of mutant ApoB mRNA transcripts with the RNA targeting effector protein of the present invention may be beneficial for the treatment of FHBL. As another example, Huntington's disease (HD) is caused by the expansion of CAG triplet repeat sequences in the gene encoding Huntingtin protein, resulting in protein abnormalities. Specific targeting and knockdown of mutant or allele-specific mRNA transcripts encoding Huntingtin protein using the RNA targeting effector protein of the present invention may be beneficial for the treatment of HD.
[0202] It should be noted that in this case, and more generally, for various applications described herein, it is conceivable to use a broken version of the RNA targeting effector protein. In fact, this can not only increase specificity, but also may be beneficial for delivery. In the sense that the two parts of the Cas13b enzyme essentially contain a functional Cas13b, Cas13b is broken. Ideally, the break should always leave one or more catalytic domains unaffected. Cas13b can act as a nuclease, or it can be a dead Cas13b, which is essentially an RNA binding protein with little or no catalytic activity due to the presence of one or more mutations in its catalytic domain.
[0203] Each half of the broken Cas13b can be fused with a dimerization partner. For example, but not limited to, a chemically inducible broken Cas13b can be produced using a rapamycin-sensitive dimerization domain to temporarily control the activity of Cas13b. Therefore, Cas13b can be made chemically inducible by dividing it into two fragments, and the rapamycin-sensitive dimerization domain can be used for the controlled recombination of Cas13b. The two parts of the broken Cas13b can be regarded as the N' terminal part and the C' terminal part of the broken Cas13b. Fusion is usually at the breakpoint of Cas13b. In other words, the C' end of the N' terminal part of the broken Cas13b is fused to half of the two half dimers, and the N' end of the C' terminal part is fused to the other half dimer.
[0204] In the sense of newly formed fractures, Cas13b does not have to be fractured. Breakpoints are usually designed on a computer and cloned into a construct. The two parts of the fractured Cas13b, i.e., the N' end and the C' end, form a complete Cas13b together, which comprises preferably at least 70% or more wild-type amino acids (or nucleotides encoding them), preferably at least 80% or more, preferably at least 90% or more, preferably at least 95% or more, most preferably at least 99% or more wild-type amino acids (or nucleotides encoding them). Some modifications can be made, and mutants are envisioned. Non-functional domains can be completely removed. It is important that the two parts can be put together, and the desired Cas13b function can be restored or reconstructed. The dimer can be a homodimer or a heterodimer.
[0205] In certain embodiments, the Cas13b effectors described herein can be used for mutation-specific or allele-specific targeting, such as for mutation-specific or allele-specific knockdown.
[0206] Furthermore, RNA-targeting effector proteins can be fused with another functional RNAse domain such as a nonspecific RNase or Argonaute 2, which act synergistically to increase RNAse activity or ensure further degradation of the message.
[0207] Regulating gene expression by modulating RNA function
[0208] In addition to directly affecting gene expression by cracking mRNA, RNA targeting can also be used to affect specific aspects of RNA processing in cells, so that gene expression can be more finely regulated. Generally speaking, regulation can be mediated, for example, by interfering with the binding of proteins to RNA, such as blocking the binding of proteins or recruiting RNA binding proteins. In fact, regulation can be ensured at different levels (such as the splicing, transport, positioning, translation and conversion of mRNA). Similarly, in the case of treatment, it is conceivable to solve (pathogenic) dysfunction at each level in these levels by using RNA-specific targeting molecules. In these embodiments, in many cases, it is preferred that RNA targeting proteins are "dead" Cas13b that loses the ability to cut RNA targets but maintains its ability to bind RNA targets, such as mutant forms of Cas13b as described herein.
[0209] A) Alternative splicing
[0210] Many human genes express multiple mRNAs due to alternative splicing. It has been shown that different diseases are associated with abnormal splicing, which results in loss of function or gain of function of the expressed genes. Although some of these diseases are caused by mutations that cause splicing defects, many diseases are not. A therapeutic option is to directly target the splicing mechanism. The RNA targeting effector protein described herein can, for example, be used to block or promote splicing, include or exclude exons and affect the expression of specific isoforms and / or stimulate the expression of alternative protein products. Such applications are described in more detail below.
[0211] RNA targeting effector protein binding to target RNA can spatially block splicing factors from approaching RNA sequences. RNA targeting effector protein targeting splicing sites can block splicing at the site, optionally redirecting splicing to adjacent sites. For example, RNA targeting effector protein binding to the 5' splicing site can block the recruitment of the U1 component of the spliceosome, thereby facilitating the skipping of the exon. Alternatively, RNA targeting effector protein targeting splicing enhancer or silencer can prevent trans-regulatory splicing factors from binding at the target site and effectively block or promote splicing. Exon exclusion can be further achieved by recruiting ILF2 / 3 to pre-mRNA near the exon by the RNA targeting effector protein described herein. As another example, a glycine-rich domain can be attached for recruiting hnRNP A1 and exon exclusion (Del Gatto-Konczak et al. Mol Cell Biol. 1999 January; 19(1): 251-60).
[0212] In certain embodiments, through appropriate selection of gRNA, specific splice variants can be targeted while other splice variants are not targeted.
[0213] In some cases, RNA targeting effector proteins can be used to promote splicing (e.g., in cases where splicing is defective). For example, RNA targeting effector proteins can be associated with effectors that can stabilize splicing regulatory stem loops to further splicing. RNA targeting effector proteins can be linked to common binding site sequences of specific splicing factors to recruit proteins to target DNA or RNA.
[0214] Examples of diseases associated with abnormal splicing include, but are not limited to, paraneoplastic opsoclonus-myoclonus ataxia (or POMA) due to the absence of the Nova protein (which regulates the splicing of proteins that function in synapses), and cystic fibrosis due to defective splicing of the cystic fibrosis transmembrane conductance regulator (resulting in the production of non-functional chloride channels). In other diseases, abnormal RNA splicing can lead to gain of function. This is the case, for example, in myotonic dystrophy, which is caused by an expansion of the CUG triplet repeat sequence (50 to more than 1500 repeats) in the 3'UTR of the mRNA, resulting in splicing defects.
[0215] RNA targeting effector proteins can be used to include exons by recruiting splicing factors (such as U1) to the 5' splice site to promote the excision of introns surrounding the desired exon. This recruitment can be mediated by fusion with an arginine / serine-rich domain that acts as a splicing activator (Gravely BR and Maniatis T, Mol Cell. 1998 (5): 765-71).
[0216] It is envisioned that RNA targeting effector proteins can be used to block the splicing apparatus at the desired site, thereby preventing exon recognition and expression of different protein products. An example of a treatable disease is Duchenne muscular dystrophy (DMD), which is caused by mutations in the gene encoding dystrophin. Almost all DMD mutations cause frameshifts, resulting in impaired translation of dystrophin. RNA targeting effector proteins can be paired with splicing junctions or exonic splicing enhancers (ESEs), thereby preventing exon recognition, resulting in partial functional protein translation. This converts the lethal Duchenne phenotype into a less severe Becker phenotype.
[0217] B) RNA modification
[0218] RNA editing is a natural process by which the diversity of gene products of a given sequence is increased by making minor modifications in RNA. Typically, the modification involves the conversion of adenosine (A) to inosine (I), thereby producing a sequence different from the RNA sequence encoded by the genome. RNA modification is generally ensured by ADAR enzymes, whereby the precursor RNA target is formed into an imperfect duplex RNA by base pairing between the exons and intron non-coding elements containing the adenosine to be edited. A classic example of AI editing is the glutamate receptor GluR-B mRNA, whereby this change causes the conductance characteristics of the channel to be modified (Higuchi M et al. Cell. 1993; 75: 1361-70).
[0219] According to the present invention, enzymatic methods are used to induce conversion (A<->G or C<->U changes) or transversion (any purine to any pyrimidine, and vice versa) in the RNA base of a given transcript. The conversion can be directly induced by using adenosine deaminase (ADAR1 / 2) or cytosine deaminase (APOBEC, AID) that converts A to I or C to U, respectively. The conversion can be indirectly induced by positioning a cluster of reactive oxygen molecules to damage the target base, which will result in chemical modifications being added to the affected bases, such as converting guanine to oxoguanine. Oxoguanine is considered to be T, so it will be paired with adenine bases, resulting in translation being affected. Proteins that can be recruited for ROS-mediated base damage include APEX and mini-SOG. Both methods can fuse these effectors with catalytically inactive Cas13b and recruit them to sites on transcripts that require these types of mutations.
[0220] In humans, heterozygous non-functional mutations in the ADAR1 gene lead to a skin disease, human pigmented dermatosis (Miyamura Y et al. Am J Hum Genet. 2003; 73: 693-9). It is envisioned that the RNA targeting effector proteins of the present invention can be used to correct dysfunctional RNA modifications.
[0221] It is further contemplated that RNA adenosine methylase (N(6)-methyladenosine) can be fused to the RNA targeting effector protein of the present invention and targeted to the target transcript. This methylase causes reversible methylation, has a regulatory effect, and can affect gene expression and cell fate determination by regulating multiple RNA-related cellular pathways (Fu et al., Nat Rev Genet. 2014; 15(5): 293-306).
[0222] C) Polyadenylation
[0223] Polyadenylation of mRNA is important for nuclear transport, translation efficiency and stability of mRNA, all of which, as well as the polyadenylation process, depend on specific RBPs. Most eukaryotic mRNAs receive a 3'poly(A) tail of about 200 nucleotides after transcription. Polyadenylation involves different RNA-binding protein complexes that stimulate the activity of poly(A) polymerase (Minvielle-Sebastia L et al. Curr Opin Cell Biol. 1999; 11: 352–7). It is envisioned that the RNA targeting effector proteins provided herein can be used to interfere with or promote the interaction between RNA-binding proteins and RNA.
[0224] An example of a disease associated with a defective protein involved in polyadenylation is oculopharyngeal muscular dystrophy (OPMD) (Brais B et al. Nat Genet. 1998; 18: 164-7).
[0225] D) RNA export
[0226] After pre-mRNA processing, mRNA is exported from the nucleus to the cytoplasm. This process is ensured by a cellular machinery involving the generation of a carrier complex, which is then transported through the nuclear pores and releases the mRNA in the cytoplasm, followed by recycling of the carrier.
[0227] Overexpression of proteins that function in RNA export, such as TAP, has been found to increase the export of transcripts that are inefficiently exported in Xenopus (Katahira J et al. EMBO J. 1999; 18: 2593-609).
[0228] E) mRNA localization
[0229] mRNA localization can ensure that the production of proteins is regulated spatially. Transcript localization to specific regions of cells can be ensured by localization elements. In specific embodiments, it is envisioned that the effector proteins described herein can be used to target the localization elements to the target RNA. Effector proteins can be designed to bind to target transcripts and shuttle these effector proteins to a position in the cell determined by the peptide signal tag of the target transcript. More specifically, for example, RNA targeting effector proteins fused to one or more nuclear localization signals (NLS) and / or one or more nuclear export signals (NES) can be used to change RNA localization.
[0230] Other examples of localization signals include zipcode binding protein (ZBP1) (ensuring β-actin localization to the cytoplasm in several asymmetric cell types), KDEL retention sequence (localization to the endoplasmic reticulum), nuclear export signal (localization to the cytoplasm), mitochondrial targeting signal (localization to mitochondria), peroxisome targeting signal (localization to peroxisomes), and m6A marker / YTH DF2 (localization to p bodies). Other approaches envisioned are to fuse RNA targeting effector proteins to proteins of known localization (e.g., membrane, synapse).
[0231] Alternatively, the effector protein according to the invention can be used, for example, for localization-dependent knockdown. By fusing the effector protein to a suitable localization signal, the effector can be targeted to a specific cell compartment. Only target RNAs located in this compartment can be effectively targeted, while other identical targets (but located in different cell compartments) will not be targeted, thereby establishing localization-dependent knockdown.
[0232] F) Translation
[0233] The RNA targeting effector proteins described herein can be used to enhance or repress translation. It is envisioned that upregulating translation is a very reliable way to control cellular circuits. In addition, for functional studies, protein translation screens may be superior to transcriptional upregulation screens, the latter of which have the disadvantage that upregulation of transcripts does not translate into increased protein production.
[0234] It is contemplated that the RNA targeting effector proteins described herein can be used to bring translation initiation factors such as EIF4G to the vicinity of the 5' untranslated repeat sequence (5'UTR) of the target messenger RNA, thereby driving translation (e.g., De Gregorio et al. EMBO J. 1999; 18(17): 4865-74, for non-reprogrammable RNA binding proteins). As another example, the cytoplasmic poly (A) polymerase GLD2 can be recruited to the target mRNA by the RNA targeting effector protein. This will allow the target mRNA to undergo directional polyadenylation, thereby stimulating translation.
[0235] Similarly, the RNA targeting effector proteins envisioned herein can be used to block translation repressors of mRNA, such as ZBP1 (Huttelmaier S et al. Nature. 2005; 438: 512–5). By binding to the translation start site of the target RNA, translation can be directly affected.
[0236] Alternatively, fusing RNA-targeting effector proteins to proteins that stabilize mRNA, for example by preventing its degradation by agents such as RNase inhibitors, can increase protein production of the target transcript.
[0237] It is contemplated that the RNA targeting effector proteins described herein can be used to repress translation by binding in the 5'UTR region of RNA transcripts and preventing ribosome formation and initiation of translation.
[0238] Furthermore, RNA-targeting effector proteins can be used to recruit Caf1, a component of the CCR4-NOT deadenylase complex, to target mRNAs, leading to deadenylation or target transcripts and inhibition of protein translation.
[0239] For example, the RNA targeting effector protein of the present invention can be used to increase or decrease the translation of therapeutically relevant proteins. Examples of therapeutic applications in which RNA targeting effector proteins can be used to downregulate or upregulate translation are amyotrophic lateral sclerosis (ALS) and cardiovascular disease. It is reported that the level of glial glutamate transporter EAAT2 in ALS motor cortex and spinal cord is reduced, and multiple abnormal EAAT2 mRNA transcripts are present in ALS brain tissue. Loss of EAAT2 protein and function is considered to be the main cause of excitotoxicity in ALS. Restoring EAAT2 protein levels and function can provide therapeutic benefits. Therefore, RNA targeting effector proteins can be beneficially used to upregulate the expression of EAAT2 protein, for example, by blocking translation repressors or stabilizing mRNA as described above. Apolipoprotein A1 is the main protein component of high-density lipoprotein (HDL), and ApoA1 and HDL are generally believed to have anti-atherosclerotic effects. It is envisioned that RNA targeting effector proteins can be beneficially used to upregulate the expression of ApoA1, for example, by blocking translation repressors or stabilizing mRNA as described above.
[0240] G) mRNA conversion
[0241] Translation is closely related to mRNA conversion and regulated mRNA stability. Specific proteins have been described to be related to the stability of transcripts, such as ELAV / Hu proteins in neurons (Keene JD, 1999, Proc Natl Acad Sci U SA. 96: 5–7) and tristetraprolin (TTP). These proteins stabilize target mRNA by protecting information from degradation in the cytoplasm (Peng SS et al., 1988, EMBO J. 17: 3461-70).
[0242] It is conceivable that the RNA targeting effector protein of the present invention can be used to interfere with or promote the activity of proteins that act to stabilize mRNA transcripts, thereby affecting mRNA conversion. For example, the use of RNA targeting effector proteins to recruit human TTP to target RNA will allow translation repression and target degradation mediated by elements rich in adenylate-uridylate (AU-rich elements). AU-rich elements have been found in the 3'UTR of many mRNAs encoding proto-oncogenes, nuclear transcription factors, and cytokines, which promote RNA stability. As another example, the RNA targeting effector protein can be fused with another mRNA stabilizing protein HuR (Hinman MN and Lou H, Cell Mol Life Sci 2008; 65: 3168-81), and recruited to the target transcript to extend its lifespan or stabilize short-lived mRNA.
[0243] It is further contemplated that the RNA targeting effector proteins described herein can be used to promote degradation of target transcripts. For example, m6A methyltransferases can be recruited to target transcripts to localize the transcripts to P bodies, thereby resulting in target degradation.
[0244] As yet another example, the RNA targeting effector protein described herein can be fused to the non-specific endonuclease domain PilT N-terminus (PIN) to recruit it to the target transcript and degrade it.
[0245] Patients with paraneoplastic neurological disorder (PND)-associated encephalomyelitis and neuropathy are patients who produce autoantibodies against Hu proteins in tumors outside the central nervous system (Szabo A et al. 1991, Cell.; 67:325–33), which then cross the blood-brain barrier. It is conceivable that the RNA targeting effector proteins of the present invention can be used to interfere with the binding of autoantibodies to mRNA transcripts.
[0246] Patients with dystrophy type 1 (DM1) caused by (CUG)n expansion in the 3'UTR of the dystrophin myotonic protein kinase (DMPK) gene are characterized by accumulation of such transcripts in the nucleus. It is envisioned that RNA targeting effector proteins of the invention fused to an endonuclease targeting the (CUG)n repeat sequence can inhibit this accumulation of aberrant transcripts.
[0247] H) Interaction with multifunctional proteins
[0248] Some RNA binding proteins bind to multiple sites on many RNAs to play a role in a variety of processes. For example, the hnRNP A1 protein has been found to bind to exonic splicing silencer sequences (thus antagonizing splicing factors), associate with telomeric ends (thus stimulating telomeric activity), and bind miRNAs to promote Drosha-mediated processing, thereby affecting maturation. It is contemplated that the RNA binding effector proteins of the present invention can interfere with the binding of RNA binding proteins at one or more locations.
[0249] I) RNA folding
[0250] RNA adopts a defined structure to perform its biological activity. Conformation transitions between alternative tertiary structures are essential for most RNA-mediated processes. However, there may be several problems with RNA folding. For example, RNA may have a tendency to fold into an inappropriate alternative conformation and remain in that conformation, and / or the correct tertiary structure may not have sufficient thermodynamic advantages compared to the alternative structure. The RNA targeting effector protein of the present invention, particularly the cleavage-defective or dead RNA targeting protein, can be used to guide (m) RNA folding and / or capture its correct tertiary structure.
[0251] Use of RNA-targeting effector proteins in regulating cellular states
[0252] In certain embodiments, Cas13b in a complex with crRNA is activated upon binding to a target RNA, subsequently cleaving any nearby ssRNA targets (i.e., a "collateral" or "bystander" effect). Once Cas13b is primed by a homologous target, it can cleave other (non-complementary) RNA molecules. This promiscuous RNA cleavage may cause cytotoxicity or otherwise affect cell physiology or cell state.
[0253] Therefore, in certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce cell dormancy. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce cell cycle arrest. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to reduce cell growth and / or cell proliferation. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce cell incapacity. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce apoptosis. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce cell necrosis. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce cell death. In certain embodiments, the non-naturally occurring or engineered compositions, carrier systems or delivery systems described herein are used or used to induce programmed cell death.
[0254] In certain embodiments, the present invention relates to a method for inducing cell dormancy, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the present invention relates to a method for inducing cell cycle arrest, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the present invention relates to a method for reducing cell growth and / or cell proliferation, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the present invention relates to a method for inducing cell incapacity, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the present invention relates to a method for inducing apoptosis, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the present invention relates to a method for inducing cell necrosis, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the present invention relates to a method for inducing cell death, comprising introducing or inducing a non-naturally occurring or engineered composition, carrier system, or delivery system as described herein. In certain embodiments, the invention relates to a method for inducing programmed cell death comprising introducing or inducing a non-naturally occurring or engineered composition, vector system, or delivery system described herein.
[0255] The methods and uses described herein can be therapeutic or preventive, and can target specific cells, cell (sub) populations or cell / tissue types. Specifically, the methods and uses described herein can be therapeutic or preventive, and can target specific cells, cell (sub) populations or cell / tissue types expressing one or more target sequences such as one or more specific target RNAs (e.g., ssRNA). In a non-limiting manner, the target cell can be, for example, a cancer cell expressing a specific transcript, such as a given class of neurons, (immune) cells causing, for example, autoimmunity, or cells infected by a specific (e.g., virus) pathogen, etc.
[0256] Therefore, in certain embodiments, the present invention relates to a method for treating a pathological condition characterized by the presence of undesirable cells (host cells), comprising introducing or inducing a non-naturally occurring or engineered composition, vector system, or delivery system as described herein. In certain embodiments, the present invention relates to the use of a non-naturally occurring or engineered composition, vector system, or delivery system as described herein for treating a pathological condition characterized by the presence of undesirable cells (host cells). In certain embodiments, the present invention relates to a non-naturally occurring or engineered composition, vector system, or delivery system as described herein for treating a pathological condition characterized by the presence of undesirable cells (host cells). It should be understood that preferably the CRISPR-Cas system targets targets that are specific to undesirable cells. In certain embodiments, the present invention relates to the use of a non-naturally occurring or engineered composition, vector system, or delivery system as described herein for treating, preventing, or alleviating cancer. In certain embodiments, the present invention relates to a non-naturally occurring or engineered composition, vector system, or delivery system as described herein for treating, preventing, or alleviating cancer. In certain embodiments, the present invention relates to a method for treating, preventing, or alleviating cancer, comprising introducing or inducing a non-naturally occurring or engineered composition, vector system, or delivery system as described herein. It should be understood that preferably the CRISPR-Cas system targets targets that are specific to cancer cells. In certain embodiments, the present invention relates to non-naturally occurring or engineered compositions, vector systems or delivery systems described herein for treating, preventing or alleviating cell infections caused by pathogens. In certain embodiments, the present invention relates to non-naturally occurring or engineered compositions, vector systems or delivery systems described herein for treating, preventing or alleviating cell infections caused by pathogens. In certain embodiments, the present invention relates to a method for treating, preventing or alleviating cell infections caused by pathogens, comprising introducing or inducing non-naturally occurring or engineered compositions, vector systems or delivery systems described herein. It should be understood that preferably the CRISPR-Cas system targets targets that are specific to cells infected by pathogens (e.g., pathogen-derived targets). In certain embodiments, the present invention relates to non-naturally occurring or engineered compositions, vector systems or delivery systems described herein for treating, preventing or alleviating autoimmune diseases. In certain embodiments, the present invention relates to non-naturally occurring or engineered compositions, vector systems or delivery systems described herein for treating, preventing or alleviating autoimmune diseases. In certain embodiments, the present invention relates to a method for treating, preventing, or alleviating an autoimmune disease, comprising introducing or inducing a non-naturally occurring or engineered composition, vector system, or delivery system described herein.It will be appreciated that preferably the CRISPR-Cas system targets targets that are specific for cells that cause autoimmune diseases (e.g., specific immune cells).
[0257] Use of RNA-targeting effector proteins in RNA detection or protein detection
[0258] It is further envisioned that the RNA targeting effector protein can be used to detect nucleic acids or proteins in biological samples. The sample can be composed of cells or lack cells.
[0259] It is further contemplated that RNA targeting effector proteins can be used in Northern blot analysis. Northern blotting involves the use of electrophoresis to separate RNA samples by size. RNA targeting effector proteins can be used to specifically bind and detect target RNA sequences.
[0260] RNA targeting effector protein can also be fused with fluorescent protein (such as GFP) and used to track RNA localization in living cells. More specifically, RNA targeting effector protein can be inactivated because it no longer cleaves RNA. In a specific embodiment, it is envisioned that a fractured RNA targeting effector protein can be used, whereby the signal depends on the combination of two subproteins to ensure more accurate visualization. Alternatively, a fractured fluorescent protein can be used, and when multiple RNA targeting effector protein complexes are bound to the target transcript, the fluorescent protein is reconstructed. It is further envisioned that transcripts are targeted at multiple binding sites along mRNA, so that the fluorescent signal can amplify the real signal and allow focused identification. As another alternative, the fluorescent protein can be reconstructed to form a fractured intein.
[0261] RNA targeting effector proteins are suitable for determining the localization of RNA or specific splice variants, the level of mRNA transcripts, the upregulation or downregulation of transcripts, and disease-specific diagnosis. RNA targeting effector proteins can be used to visualize RNA in, for example, (living) cells using, for example, fluorescence microscopy or flow cytometry (such as fluorescence activated cell sorting (FACS), which can perform high-throughput screening of cells and recover living cells after cell sorting). In addition, the expression levels of different transcripts can be evaluated simultaneously under stress (e.g., using molecular inhibitors or hypoxic conditions to inhibit cancer cell growth). Another application is the use of two-photon microscopy to track the localization of transcripts to synaptic connections during neural stimulation.
[0262] In certain embodiments, the components or complexes according to the invention described herein can be used together with, for example, (fluorescently) labeled Cas13b effectors for multiplex error-corrected fluorescence in situ hybridization (MERFISH; Chen et al. Science; 2015; 348(6233)).
[0263] In vitro vertex labeling
[0264] Cellular processes depend on a network of molecular interactions between proteins, RNA, and DNA. Accurate detection of protein-DNA and protein-RNA interactions is key to understanding such processes. In vitro proximity labeling techniques use affinity tags combined with, for example, photoactivatable probes to label polypeptides and RNAs near target proteins or RNAs in vitro. After ultraviolet light irradiation, the photoactivatable groups react with proteins and other molecules near the labeled molecules, thereby labeling them. The labeled interacting molecules can then be recovered and identified. The RNA targeting effector protein of the present invention can, for example, be used to target the probe to a selected RNA sequence.
[0265] These applications can also be applied in animal models for in vivo imaging of disease-relevant applications or difficult-to-culture cell types.
[0266] The present invention provides reagents and methods for diagnosing and monitoring health conditions (including testing risks and guiding targeted RNA therapies) by non-invasive sampling of cell-free RNA, and can be used for occasions where rapid administration of therapy is important for treatment outcomes. In one embodiment, the present invention provides cancer detection methods and reagents for circulating tumor RNA (including for monitoring the recurrence and / or development of common drug resistance mutations). In another embodiment, the present invention provides detection methods and reagents for directly detecting and / or identifying bacterial species from blood or serum to monitor, for example, disease progression and sepsis. In one embodiment of the present invention, Cas13b proteins and derivatives are used to distinguish and diagnose common diseases such as rhinovirus or upper respiratory tract infections from more serious infections such as bronchitis.
[0267] The present invention provides methods and reagents for rapid genotyping for emergency pharmacogenomics, including guidance for administration of anticoagulants during treatment of myocardial infarction or stroke based on, for example, VKORC1, CYP2C9, and CYP2C19 genotyping.
[0268] The present invention provides reagents and methods for monitoring food contamination caused by bacteria at all points in the food production and distribution chain. In another embodiment, the present invention provides quality control and monitoring, such as by identifying the source of food and determining purity. In a non-limiting example, the present invention can be used to identify or confirm the source of food, such as the type of animal meat and seafood.
[0269] In another embodiment, the present invention is used for forensic identification, such as crime scene samples containing blood or other body fluids. In one embodiment of the present invention, the present invention is used to identify nucleic acid samples from fingerprints.
[0270] Use of RNA targeting effector proteins in RNA origami / in vitro assembly lines - modular
[0271] RNA origami refers to a nanoscale folded structure that uses RNA as an integrated template to form a two-dimensional or three-dimensional structure. The folded structure is encoded in RNA, so the shape of the resulting RNA is determined by the synthetic RNA sequence (Geary et al. 2014. Science, 345 (6198). Pages 799-804). RNA origami can serve as a scaffold for arranging other components such as proteins into a complex. The RNA targeting effector protein of the present invention can, for example, be used to target a target protein to RNA origami using a suitable guide RNA.
[0272] Use of RNA targeting effector proteins in RNA isolation or purification, enrichment or depletion
[0273] It is further contemplated that the RNA targeting effector protein can be used to separate and / or purify RNA in complex with RNA. The RNA targeting effector protein can be fused, for example, with an affinity tag, which can be used to separate and / or purify the RNA-RNA targeting effector protein complex. Such applications can be used, for example, to analyze gene expression profiles in cells. In certain embodiments, it is contemplated that the RNA targeting effector protein can be used to target specific non-coding RNA (ncRNA), thereby blocking its activity, thereby providing a useful functional probe. In certain embodiments, the effector proteins described herein can be used to specifically enrich for specific RNAs (including but not limited to increasing stability, etc.), or alternatively to specifically deplete specific RNAs (such as but not limited to, for example, specific splice variants, isoforms, etc.).
[0274] Probing the functions of lincRNAs and other nuclear RNAs
[0275] The disadvantage of current RNA knockdown strategies such as siRNA is that they are mainly limited to targeting cytoplasmic transcripts because the protein device is cytoplasmic. The RNA targeting effector protein of the present invention is an exogenous system that is not essential for cellular function, and the advantage is that it can be used in any compartment of the cell. By fusing the NLS signal with the RNA targeting effector protein, it can be directed to the nucleus, thereby targeting nuclear RNA. For example, it is envisioned to detect the function of lincRNA. Long intergenic noncoding RNA (lincRNA) is an area that has not been fully studied. So far, most lincRNAs have unknown functions and can be studied using the RNA targeting effector protein of the present invention.
[0276] Identification of RNA-binding proteins
[0277] Identifying proteins that bind to specific RNAs may help understand the role of many RNAs. For example, many lincRNAs are associated with transcriptional and epigenetic regulators to control transcription. Understanding what proteins bind to a given lincRNA can help elucidate the components in a given regulatory pathway. The RNA targeting effector protein of the present invention can be designed to recruit biotin ligase to a specific transcript in order to label locally bound proteins with biotin. The protein can then be pulled down and identified by mass spectrometry.
[0278] Complex assembly on RNA and substrate shuttling
[0279] The RNA targeting effector protein of the present invention can also be used to assemble complexes on RNA. This can be achieved by functionalizing the RNA targeting effector protein with a variety of related proteins (e.g., components of a specific synthetic pathway). Alternatively, a variety of RNA targeting effector proteins can be functionalized with such different related proteins and targeted to the same or adjacent target RNA. Useful applications of assembling complexes on RNA are, for example, promoting substrate shuttling between proteins.
[0280] Synthetic Biology
[0281] The development of biological systems has a wide range of uses, including for clinical applications. It is contemplated that the programmable RNA targeting effector proteins of the present invention can be used in fusion with a cleavage protein of a toxic domain of targeted cell death, for example using cancer-linked RNA as a target transcript. In addition, pathways involving protein-protein interactions may be affected in synthetic biological systems having, for example, fusion complexes (with suitable effectors, such as kinases or other enzymes).
[0282] Protein splicing: inteins
[0283] Protein splicing is a post-translational process in which an intervening polypeptide (called an intein) catalyzes self-excision from a polypeptide (called an extein) flanking it, and subsequent extein ligation. The assembly of two or more RNA targeting effector proteins described herein on a target transcript can be used to guide the release of the fragmented intein (Topilina and Mills, MobDNA. 2014 Feb 4; 5(1):5), thereby allowing direct calculation of the presence of mRNA transcripts and subsequent release of protein products, such as metabolic enzymes or transcription factors (for downstream activation of transcriptional pathways). This application may be of great significance in synthetic biology (see above) or large-scale bioproduction (producing products only under specific conditions).
[0284] Inducible, quantitative, and self-inactivating system
[0285] In one embodiment, the fusion complex comprising the RNA targeting effector protein of the invention and the effector component is designed to be inducible, such as light-inducible or chemical-inducible. This inducibility allows the effector component to be activated at the desired time.
[0286] For example, light inducibility is achieved by designing fusion complexes in which the CRY2PHR / CIBN pairing is used for fusion. This system is particularly useful for light-induced protein interactions in living cells (Konermann S et al. Nature. 2013; 500: 472–476).
[0287] For example, chemical inducibility can be provided by designing a fusion complex in which the fusion is performed using a FKBP / FRB (FK506 binding protein / FKBP rapamycin binding) pairing. Using this system, rapamycin is required for protein binding (Zetsche et al. Nat Biotechnol. 2015; 33(2): 139-42 describes the use of this system in Cas9).
[0288] In addition, the RNA targeting effector protein of the present invention, when introduced into cells as DNA, can be regulated by inducible promoters such as tetracycline or doxycycline-controlled transcriptional activation (Tet-On and Tet-Off expression systems), hormone-inducible gene expression systems (such as ecdysone-inducible gene expression systems), and arabinose-inducible gene expression systems. When the RNA targeting effector protein is delivered as RNA, its expression can be regulated via a riboswitch that can sense small molecules such as tetracycline (as described in Goldfless et al. Nucleic Acids Res. 2012; 40(9): e64).
[0289] In one embodiment, the delivery of the RNA targeting effector protein of the invention can be modulated to alter the amount of protein or crRNA in the cell, thereby changing the magnitude of the desired effect or any undesired off-target effects.
[0290] In one embodiment, the RNA targeting effector proteins described herein can be designed to be self-inactivating. When they are delivered to cells as RNA, mRNA, or as replicating RNA therapeutics (Wrobleska et al., Nat Biotechnol. 2015 August; 33(8): 839-841), they can self-inactivate expression and subsequent effects by destroying their own RNA, thereby reducing retention and potential undesirable effects.
[0291] For other in vivo applications of the RNA targeting effector proteins described herein, reference is made to Mackay JP et al. (Nat Struct Mol Biol. 2011 Mar; 18(3):256-61), Nelles et al. (Bioessays. 2015 Jul; 37(7):732-9), and Abil Z and Zhao H (Mol Biosyst. 2015 Oct; 11(10):2658-65), which are incorporated herein by reference. Specifically, the following applications are contemplated in certain embodiments of the invention, preferably in certain embodiments using catalytically inactive Cas13b: enhancing translation (e.g., Cas13b-translation promoting factor fusion (e.g., eIF4 fusion)); repressing translation (e.g., gRNA targeting ribosome binding sites); exon skipping (e.g., gRNA targeting splicing donor and / or acceptor sites); exon inclusion (e.g., targeting specific exon splicing donor and / or acceptor sites to be included or with spliceosomal components (e.g., U1 snRNA) fusion or gRNA of Cas13b that recruits this spliceosomal component); access RNA localization (e.g., Cas13b-tag fusion (e.g., EGFP fusion)); change RNA localization (e.g., Cas13b-localization signal fusion (e.g., NLS or NES fusion)); RNA degradation (in this case, if the activity of Cas13b is relied upon, a catalytically inactive Cas13b is not used, alternatively, a broken Cas13b can be used to increase specificity); inhibition of non-coding RNA function (e.g., miRNA), such as by degrading the gRNA or causing it to bind to a functional site (potentially by repositioning it at a specific site through a Cas13b-signal sequence fusion).
[0292] Cas13b function is robust to 5' or 3' extension of crRNA and extension of crRNA loop. Therefore, it is envisioned that the MS2 loop and other recruitment domains can be added to crRNA without affecting complex formation and binding to target transcripts. Such modification of crRNA to recruit various effector domains can be applicable to the use of the above-mentioned RNA targeting effector proteins.
[0293] Cas13b can mediate resistance to RNA phages. Therefore, it is envisioned that Cas13b can be used to immunize, for example, animals, humans, and plants against RNA-only pathogens (including but not limited to retroviruses (e.g., slow viruses, such as HIV), HCV, Ebola virus, and Zika virus).
[0294] In certain embodiments, Cas13b can process (crack) its own array. This applies to wild-type Cas13b proteins and mutant Cas13b proteins containing one or more mutant amino acid residues discussed herein. Therefore, it is envisioned that multiple crRNAs designed for different target transcripts and / or applications can be delivered as a single pre-crRNA or as a single transcript driven by a promoter. The advantage of this delivery method is that it is significantly more compact, easier to synthesize and easier to deliver in a viral system. It should be understood that for the orthologs of Cas13b herein, the exact amino acid position can be varied, which can be appropriately determined by protein alignment, as known in the art and as described elsewhere herein. Aspects of the present invention also encompass compositions and systems described herein in genome engineering, for example, for use in prokaryotic or eukaryotic cells in vitro, in vivo or in vitro to change or manipulate the expression of one or more genes or one or more gene products and uses.
[0295] Aspects of the invention also encompass methods and uses of the compositions and systems described herein in genome or transcriptome engineering, such as genome or transcriptome engineering. Methods and uses for altering or manipulating (protein) expression of one or more genes or one or more gene products in prokaryotic or eukaryotic cells, such as in vitro, in vivo or ex vivo in prokaryotic or eukaryotic cells.
[0296] On the one hand, the invention provides methods and compositions for regulating, for example, reducing the (protein) expression of a target RNA in a cell. In the subject method, a Cas13b system of the invention is provided, which interferes with the transcription, stability and / or translation of RNA.
[0297] In certain embodiments, an effective amount of Cas13b system is used to crack RNA or otherwise inhibit RNA expression. In this regard, the system has purposes similar to siRNA and shRNA, so such methods can also be substituted. The method includes but is not limited to using Cas13b system as a substitute for, for example, interfering ribonucleic acid (such as siRNA or shRNA) or its transcription template (such as DNA encoding shRNA). For example, the system is introduced into target cells by applying the Cas13b system to mammals including target cells.
[0298] Advantageously, the Cas13b system of the present invention has specificity. For example, although interfering with ribonucleic acid (such as siRNA or shRNA) polynucleotide systems are subject to design and stability problems and off-target binding, the Cas13b system of the present invention can be designed to have high specificity.
[0299] Destabilized Cas13b
[0300] In certain embodiments, the effector protein (CRISPR enzyme; Cas13b) according to the present invention described herein is associated or fused with a destabilizing domain (DD). In some embodiments, the DD is ER50. In some embodiments, the corresponding stabilizing ligand of the DD is 4HT. Thus, in some embodiments, one of at least one DD is ER50, and its stabilizing ligand is 4HT or CMP8. In some embodiments, the DD is DHFR50. In some embodiments, the corresponding stabilizing ligand of the DD is TMP. Thus, in some embodiments, one of at least one DD is DHFR50, and its stabilizing ligand is TMP. In some embodiments, the DD is ER50. In some embodiments, the corresponding stabilizing ligand of the DD is CMP8. Thus, CMP8 can be an alternative stabilizing ligand for 4HT in the ER50 system. Although it is possible that CMP8 and 4HT can / should be used in competition events, some cell types may be more susceptible to one or the other of the two ligands, and based on the present disclosure and the knowledge in the art, the skilled person can use CMP8 and / or 4HT.
[0301] In some embodiments, one or two DDs may be fused to the N-terminus of the CRISPR enzyme, and one or two DDs may be fused to the C-terminus of the CRISPR enzyme. In some embodiments, the at least two DDs are associated with the CRISPR enzyme, and these DDs are the same DD, i.e., the DDs are homologous. Thus, both (or two or more) DDs may be ER50 DDs. This is preferred in some embodiments. Alternatively, the two (or two or more) DDs may be DHFR50 DDs. This is also preferred in some embodiments. In some embodiments, the at least two DDs are associated with the CRISPR enzyme, and these DDs are different DDs, i.e., the DDs are heterologous. Thus, one DD may be ER50, and one or more DDs or any other DD may be DHFR50. Having two or more heterologous DDs may be advantageous because this will provide a higher level of degradation control. Fusion of more than one DD in tandem at the N-terminus or C-terminus may enhance degradation; and such tandem fusions may be, for example, ER50-ER50-Cas13b or DHFR-DHFR-Cas13b. It is envisioned that high levels of degradation will occur in the absence of any stabilizing ligand, moderate levels of degradation will occur in the absence of one stabilizing ligand and in the presence of the other (or another) stabilizing ligand, and low levels of degradation will occur in the presence of two (or more) stabilizing ligands. Control may also be given by having an N-terminal ER50 DD and a C-terminal DHFR50 DD.
[0302] In some embodiments, the CRISPR enzyme fused to the DD comprises a linker between the DD and the CRISPR enzyme. In some embodiments, the linker is a GlySer linker. In some embodiments, the DD-CRISPR enzyme further comprises at least one nuclear export signal (NES). In some embodiments, the DD-CRISPR enzyme comprises two or more NES. In some embodiments, the DD-CRISPR enzyme comprises at least one nuclear localization signal (NLS). This may be in addition to the NES. In some embodiments, the CRISPR enzyme comprises, consists essentially of, or consists of a localization (nuclear import or export) signal as a linker between the CRISPR enzyme and the DD or as part of the linker. HA or Flag tags are also within the scope of the invention as linkers. Applicants use NLS and / or NES as linkers, and also use as short as GS to as high as (GGGGS) 3 The glycine-serine linker.
[0303] A general use of destabilizing domains is to confer instability to various proteins; see, e.g., Miyazaki, J Am Chem Soc. 2012 Mar 7; 134(9):3942-3945, which is incorporated herein by reference. CMP8 or 4-hydroxytamoxifen can be a destabilizing domain. More generally, a temperature-sensitive mutant of mammalian DHFR (DHFRt) (destabilizing residues according to the N-terminal rule) was found to be stable at the permissive temperature but unstable at 37°C. Addition of methotrexate, a high-affinity ligand for mammalian DHFR, to cells expressing DHFRt partially inhibited degradation of the protein. This is an important demonstration that small molecule ligands can stabilize proteins that are otherwise targeted for degradation in cells. Rapamycin derivatives were used to stabilize unstable mutants of the FRB domain of mTOR (FRB*) and restore function of the fusion kinase GSK-3β. 6,7 This system demonstrates that ligand-dependent stability represents an attractive strategy for regulating the function of specific proteins in complex biological environments. When ubiquitin complementation occurs due to rapamycin-induced dimerization of FK506 binding protein and FKBP12, the system for controlling protein activity can involve DD to function. Mutants of human FKBP12 or ecDHFR proteins can be engineered to be metabolically unstable in the absence of their high-affinity ligands Shield-1 or trimethoprim (TMP), respectively. These mutants are some possible destabilizing domains (DD) that can be used to practice the present invention, and the instability of DD when fused to the CRISPR enzyme causes the entire fusion protein to be degraded by the proteasome CRISPR protein. Shield-1 and TMP bind to and stabilize DD in a dose-dependent manner. The estrogen receptor ligand binding domain (ERLBD, residues 305-549 of ERS1) can also be engineered as a destabilizing domain. Since the estrogen receptor signaling pathway is associated with a variety of diseases such as breast cancer, the pathway has been extensively studied, and many agonists and antagonists of the estrogen receptor have been developed. Therefore, compatible pairs of ERLBD and drugs are known. There are some ligands that bind to mutants of ERLBD but not to its wild-type form. By using one of these mutant domains encoding three mutations (L384M, M421G, G521R), ligands that do not interfere with the endogenous estrogen-sensitive network can be used to modulate the stability of the ERLBD-derived DD. Additional mutations (Y537S) can be introduced to further destabilize the ERLBD and construct it into a potential DD candidate. This quadruple mutant is a favorable DD development. The mutant ERLBD can be fused to the CRISPR enzyme and a ligand can be used to modulate or interfere with its stability so that the CRISPR enzyme has a DD.Another DD can be a 12-kDa (107 amino acids) tag based on a mutant FKBP protein, stabilized by the Shield 1 ligand. See, e.g., Nature Methods 5, (2008). For example, the DD can be a modified FK506 binding protein 12 (FKBP12) that binds to and is reversibly stabilized by the synthetic biologically inert small molecule Shield-1. See, e.g., Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ. A rapid, reversible, and tunable method to regulate protein function inliving cells using synthetic small molecules. Cell. 2006; 126:995–1004; Banaszynski LA, Sellmyer MA, Contag CH, Wandless TJ, Thorne SH. Chemical control of protein stability and function. and Rodriguez, Chem. Biol. 2012 Mar 23;19(3):391-398, all of which are incorporated herein by reference and may be used in the practice of the present invention in a selected DD to be associated with a CRISPR enzyme in the practice of the present invention.It can be seen that the knowledge in the art includes many DDs, and DDs can be associated with CRISPR enzymes, for example, advantageously fused thereto using a linker, whereby the DD can be stabilized in the presence of a ligand, and when the ligand is not present, the DD can be destabilized, whereby the CRISPR enzyme is completely destabilized, or the DD can be stabilized in the absence of a ligand, and when the ligand is present, the DD can be destabilized; the DD enables the CRISPR enzyme and therefore the CRISPR-Cas complex or system to be regulated or controlled (turned on or off, so to speak), thereby providing a means for regulating or controlling the system, for example, in an in vivo or in vitro environment. For example, when a protein of interest is expressed as a fusion with a DD tag, it is destabilized and rapidly degraded in the cell, for example, by the proteasome. Therefore, the lack of a stabilizing ligand results in the degradation of the D-associated Cas. When a new DD is fused to a protein of interest, its instability is imparted to the protein of interest, resulting in rapid degradation of the entire fusion protein. Peak activity of Cas is sometimes beneficial for reducing off-target effects. Therefore, short bursts of high activity are preferred. The present invention is able to provide such peaks. In some senses, the system is inducible. In some other sense, the system is repressed in the absence of a stabilizing ligand and derepressed in the presence of a stabilizing ligand.
[0304] Application of RNA-targeted CRISPR systems in plants and yeast
[0305] definition:
[0306] In general, the term "plant" relates to any of the various photosynthetic, eukaryotic, unicellular or multicellular organisms of the kingdom Plantae, characterized by growth by cell division, containing chloroplasts, and having a cell wall composed of cellulose. The term "plant" encompasses monocots and dicots. In particular, these plants are intended to include, but are not limited to, angiosperms and gymnosperms such as acacia, alfalfa, amaranth, apple, apricot, artichoke, ash, asparagus, avocado, banana, barley, beans, beets, birch, beech, blackberries, blueberries, broccoli, Brussels sprouts, cabbage, rapeseed, cantaloupe, carrots, cassava, cauliflower, cedar, cereals, celery, chestnuts, cherries, Chinese cabbage, citrus, clementines, clover, coffee, corn, cotton, cowpea, cucumber, cypress, eggplant, elm, chicory, eucalyptus, fennel, fig, fir, geranium, grape, grapefruit, peanut, ground cherry, gum hemlock, hickory, kale, kiwi, cabbage, larch, lettuce, leek, lemon, lime, acacia, pine, cosmos, corn, mango, maple, melon, millet, mushroom, mustard, nuts, oak, oats, oil palm, okra, onion, orange, ornamental plants or flowers or trees, papaya, palm, parsley, parsnip, peas, peach, peanut, pear, peat, pepper, persimmon, pigeon pea, pineapple, plantain, plum, pomegranate, potato, pumpkin, chicory, radish, rapeseed, raspberry, rice, rye, sorghum, safflower, yellow willow, soybean, spinach, spruce, pumpkin fruit, strawberry, sugar beet, sugar cane, sunflower, sweet potato, sweet corn, tangerine, tea, tobacco, tomato, tree, triticale, lawn grass, turnip, vine, walnut, watercress, watermelon, wheat, yam, yew and zucchini. The term "plant" also encompasses algae, which are primarily photoautotrophs, their common feature being primarily the lack of roots, leaves, and other organs that characterize higher plants.
[0307] Methods for regulating gene expression using RNA targeting systems described herein can be used to confer desired traits to substantially any plant. Using the nucleic acid constructs disclosed herein and the various transformation methods described above, a wide variety of plants and plant cell systems can be engineered for the desired physiological and agronomic characteristics described herein. In preferred embodiments, target plants and plant cells for engineering include, but are not limited to, those monocots and dicots, such as crops, including cereal crops (e.g., wheat, corn, rice, millet, barley), fruit crops (e.g., tomatoes, apples, pears, strawberries, oranges), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrots, potatoes, beets, yams), leafy vegetable crops (e.g., lettuce, spinach); flowering plants (e.g., petunias, roses, chrysanthemums), conifers and pines (e.g., pine, spruce); plants for phytoremediation (e.g., heavy metal accumulation plants); oil crops (e.g., sunflowers, rapeseed) and plants for experimental purposes (e.g., Arabidopsis). Thus, these methods and CRISPR-Cas systems can be used in a wide range of plants, such as with dicotyledonous plants belonging to the following orders: Magniolales, Illiciales, Laurales, Piperales, Aristochiales, Nymphaeales, Ranunculales, Papeverales, Sarraceniaceae, Trochodendrales, Hamamelidales, Eucomiales, Leitneriales, Myricales, Fagales, Casuarinas, Casuarinales), Caryophyllales, Batales, Polygonales, Plumbaginales, Dilleniales, Theales, Malvales, Urticales, Lecythidales, Violales, Salicales, Capparales, Ericales, Diapensales, Ebenales, Primulales, Rosales, Fabales, Podostemales,Haloragales, Myrtales, Cornales, Proteales, Santales, Rafflesiales, Celastrales, Euphorbiales, Rhamnales, Sapindales, Juglandales, Geraniales, Polygalales, Umbellales, Gentianales, Polemoniales, Lamiales, Plantaginales, Scrophulariales, Campanulales, Rubiales, Dipsacales, and Asterales; these methods and CRISPR-C The as system can be used with monocots such as those belonging to the following orders: Alismatales, Hydrocharitales, Najadales, Triuridales, Commelinales, Eriocaulales, Restionales, Poales, Juncales, Cyperales, Typhales, Bromeliales, Zingiberales, Arecales, Cyclanthales, Pandanales, Arales, Lilliales, and Orchidales. ales, or with plants belonging to the gymnosperms, such as those belonging to the orders Pinales, Ginkgoales, Cycadales, Araucariales, Cupressales, and Gnetales.
[0308] The RNA-targeted CRISPR systems and methods of use described herein can be used in a wide range of plant species, which are included in the following non-limiting list of dicot, monocot or gymnosperm genera: Atropa, Alseodaphne, Anacardium, Arachis, Beilschmiedia, Brassica, Carthamus, Cocculus, Croton, Cucumis, Citrus ... Citrullus, Capsicum, Catharanthus, Cocos, Coffea, Cucurbita, Daucus, Duguetia, Eschscholzia, Ficus, Fragaria, Glaucium, Glycine, Gossypium, Helianthus, Hevea, Hyoscyamus oscyamus), Lactuca, Landolphia, Linum, Litsea, Lycopersicon, Lupinus, Manihot, Majorana, Malus, Medicago, Nicotiana, Olea, Parthenium, Papaver, Persea, Phaseolus, Pistacia (Pistacia), Pisum, Pyrus, Prunus, Raphanus, Ricinus, Senecio, Sinomenium, Stephania, Sinapis, Solanum, Theobroma, Trifolium, Trigonella, Vicia, Vinca, Vilis, and Vigna;and the following genera: Allium, Andropogon, Aragrostis, Asparagus, Avena, Cynodon, Elaeis, Festuca, Festulolium, Heterocallis, Hordeum, Lemna, Lolium, Musa Musa), Oryza, Panicum, Pannesetum, Phleum, Poa, Secale, Sorghum, Triticum, Zea, Abies, Cunninghamia, Ephedra, Picea, Pinus, and Pseudotsuga.
[0309] These RNA targeting CRISPR systems and methods of use can also be used with a wide range of "algae" or "algal cells", including, for example, algae selected from a variety of eukaryotic phyla, including Rhodophyta (red algae), Chlorophyta (green algae), Phaeophyta (brown algae), Bacillariophyta (diatoms), Eustigmatophyta, and dinoflagellates, as well as the prokaryotic phylum Cyanobacteria (blue-green algae). The term "algae" includes, for example, algae selected from the genera Amphora, Anabaena, Anikstrodesmis, Botryococcus, Chaetoceros, Chlamydomonas, Chlorella, Chlorococcum, Cyclotella, Cylindrotheca, Dunaliella, Emiliana, Euglena, Hematococcus, Isochrysis, Monochrysis, Monoraphidium, Nannochloris, Nannnochloropsis, Navicula, Nephrochloris, Nephroselmis, Nitzschia, Nodularia, Nostoc, Oochromonas, Oocystis, Oscillartoria, Pavlova, Phaeodactylum, Playtmonas, Pleurochrysis, Porhyra, Pseudoanabaena, Pyramimonas, Stichococcus, Synechococcus, Synechocystis, Tetraselmis, Thalassiosira and Trichodesmium.
[0310] A part of a plant, i.e., a "plant tissue", can be treated according to the methods of the invention to produce an improved plant. Plant tissue also encompasses plant cells. The term "plant cell" as used herein refers to an individual unit of a living plant, whether in an intact whole plant or in an isolated form grown in in vitro tissue culture, on a culture medium or agar, in a suspension in a growth medium or buffer, or as part of a higher organization complex such as a plant tissue, a plant organ, or a whole plant.
[0311] "Protoplast" refers to a plant cell that has been formed into a biochemically functional complete unit of a living plant by complete or partial removal of the protective cell wall, such as by mechanical or enzymatic means, the cell wall of which can be modified, so that it can proliferate and, under appropriate growth conditions, regenerate and grow into a whole plant.
[0312] The term "transformation" refers broadly to the process of genetically modifying a plant host by introducing DNA using Agrobacterium or a variety of chemical or physical methods. As used herein, the term "plant host" refers to a plant, including any cell, tissue, organ or progeny of a plant. Many suitable plant tissues or plant cells can be transformed, including but not limited to protoplasts, somatic embryos, pollen, leaves, seedlings, stems, callus, runners, test tube tubers and buds. Plant tissue also refers to any clone of this plant, seed, progeny, propagule (whether sexual or asexual reproduction) and any of these offspring (such as cuttings or seeds).
[0313] The term "conversion" as used herein refers to cells, tissues, organs or organisms into which exogenous DNA molecules such as constructs have been introduced. The DNA molecules introduced can be integrated into the genomic DNA of the recipient cells, tissues, organs or organisms so that the introduced DNA molecules are passed to subsequent progeny. In these embodiments, "conversion" or "transgenic" cells or plants may also include progeny of cells or plants, and progeny produced by breeding programs that utilize such transformed plants as hybrid parents and show phenotypic changes due to the presence of the introduced DNA molecules. Preferably, transgenic plants are fertile and can pass the introduced DNA to progeny through sexual reproduction.
[0314] The term "progeny" such as progeny of a transgenic plant is a progeny born, produced or derived from a plant or transgenic plant. An introduced DNA molecule may also be transiently introduced into a recipient cell such that the introduced DNA molecule is not inherited by subsequent progeny and is therefore not considered "transgenic". Thus, as used herein, a "non-transgenic" plant or plant cell is a plant that does not contain exogenous DNA stably integrated into its genome.
[0315] The term "plant promoter" as used herein is a promoter capable of initiating transcription in a plant cell, whether or not its origin is a plant cell. Exemplary suitable plant promoters include, but are not limited to, promoters obtained from plants, plant viruses, and bacteria (such as Agrobacterium or Rhizobium) containing genes expressed in plant cells.
[0316] As used herein, "fungal cell" refers to any type of eukaryotic cell within the kingdom Fungi. Gates within the kingdom Fungi include Ascomycota, Basidiomycota, Blastocladiomycota, Chytridiomycota, Glomeromycota, Microsporidia, and Neocallimastigomycota. Fungal cells may include yeasts, molds, and filamentous fungi. In some embodiments, the fungal cell is a yeast cell.
[0317] As used herein, the term "yeast cell" refers to any fungal cell within the Ascomycota and Basidiomycota. Yeast cells can include budding yeast cells, fission yeast cells, and mold cells. Not limited to these organisms, many types of yeast used in laboratory and industrial settings are part of the Ascomycota. In some embodiments, the yeast cell is a Saccharomyces cerevisiae, Kluyveromyces marxianus, or Issatchenkia orientalis cell. Other yeast cells can include, but are not limited to, Candida spp. (e.g., Candida albicans), Yarrowia spp. (e.g., Yarrowia lipolytica), Pichia spp. (e.g., Pichia pastoris), Kluyveromyces spp. (e.g., Kluyveromyces lactis and Kluyveromyces marxianus), Neurospora spp. (e.g., Neurospora crassa), Fusarium spp. (e.g., Fusarium oxysporum), and Issatchenkia spp. (e.g., Issatchenkia orientalis, also known as Pichia kudriavzki), kudriavzevii and thermophilic Candida (Candida acidothermophilum). In some embodiments, the fungal cell is a filamentous fungal cell. As used herein, the term "filamentous fungal cell" refers to any type of fungal cell that grows in a filament, i.e., hyphae or mycelium. Examples of filamentous fungal cells may include, but are not limited to, Aspergillus spp. (e.g., Aspergillus niger), Trichoderma spp. (e.g., Trichoderma reesei), Rhizopus spp. (e.g., Rhizopus oryzae), and Mortierella spp. (e.g., Mortierella isabellina).
[0318] In some embodiments, the fungal cell is an industrial strain. As used herein, "industrial strain" refers to any fungal cell strain used in an industrial process (e.g., producing a product on a commercial or industrial scale) or separated from an industrial process. Industrial strains may refer to fungal species commonly used in industrial processes, or may refer to isolated bacteria of fungal species that may also be used for non-industrial purposes (e.g., laboratory research). Examples of industrial processes may include fermentation (e.g., in the production of food or beverage products), distillation, biofuel production, compound production, and polypeptide production. Examples of industrial strains may include, but are not limited to, JAY270 and ATCC4124.
[0319] In some embodiments, fungal cells are polyploid cells. As used herein, "polyploid" cells may refer to any cell whose genome exists in more than one copy. Polyploid cells may refer to naturally found cell types in a polyploid state, or may refer to cells that have been induced to exist in a polyploid state (e.g., by specific regulation, change, inactivation, activation or modification of meiosis, cytokinesis or DNA replication). Polyploid cells may refer to cells whose entire genome is polyploid, or may refer to cells that are polyploid in a specific target genome locus. Without wishing to be bound by theory, it is believed that the abundance of guide RNA may be more often a rate-limiting component in the genome engineering of polyploid cells than in haploid cells, and therefore the method using the Cas13b CRISPR system described herein can utilize the use of a certain fungal cell type.
[0320] In some embodiments, fungal cell is a diploid cell.As used herein, "diploid" cell may refer to any cell whose genome exists with two copies.Diploid cell may refer to a cell type naturally found to be in a diploid state, or may refer to a cell induced to exist in a diploid state (e.g., by specific regulation, change, inactivation, activation or modification to meiosis, cytokinesis or DNA replication).For example, saccharomyces cerevisiae strain S228C may be maintained in a haploid or diploid state.Diploid cell may refer to a cell whose entire genome is a diploid, or may refer to a cell that is a diploid in a specific target genome locus.In some embodiments, fungal cell is a haploid cell.As used herein, "haploid" cell may refer to any cell whose genome exists with a copy.Haploid cell may refer to a cell type naturally found to be in a haploid state, or may refer to a cell induced to exist in a haploid state (e.g., by specific regulation, change, inactivation, activation or modification to meiosis, cytokinesis or DNA replication). For example, Saccharomyces cerevisiae strain S228C can be maintained in a haploid or diploid state. A haploid cell can refer to a cell whose entire genome is haploid, or can refer to a cell that is haploid in a particular genomic locus of interest.
[0321] As used herein, "yeast expression vector" refers to a nucleic acid comprising one or more sequences encoding RNA and / or polypeptides, and may also include any desired elements for controlling the expression of one or more nucleic acids, and any elements capable of replicating and maintaining the expression vector inside a yeast cell. Many suitable yeast expression vectors and their characteristics are known in the art; for example, different vectors and techniques are shown in Yeast Protocols, 2nd edition, Xiao, W. ed. (Humana Press, New York, 2007) and Buckholz, RG and Gleeson, MA (1991) Biotechnology (NY) 9 (11): 1067-72. Yeast vectors may include, but are not limited to, centromere (CEN) sequences, autonomously replicating sequences (ARS), promoters (such as RNA polymerase III promoters) operably linked to a target sequence or gene, terminators (such as RNA polymerase III terminators), origins of replication, and marker genes (e.g., auxotrophic markers, antibiotic markers or other selective markers). Examples of expression vectors for yeast may include plasmids, yeast artificial chromosomes, 2μ plasmids, yeast integrating plasmids, yeast replicating plasmids, shuttle vectors, and episomal plasmids.
[0322] Stable integration of RNA-targeted CRISP system components into the genomes of plants and plant cells
[0323] In certain embodiments, polynucleotides encoding components of a targeting RNA CRISPR system are envisioned for stable integration into the genome of a plant cell. In these embodiments, the design of the transformation vector or expression system can be adjusted based on when, where, and under what conditions one or more guide RNAs and / or RNA targeting genes are expressed.
[0324] In a specific embodiment, it is contemplated that components of the RNA-targeting CRISPR system are stably introduced into the genomic DNA of a plant cell. Additionally or alternatively, it is contemplated that components of the RNA-targeting CRISPR system are introduced to stably integrate into the DNA of a plant organelle, such as, but not limited to, a plastid, mitochondria, or chloroplast.
[0325] An expression system for stable integration into the genome of a plant cell may comprise one or more of the following elements: a promoter element, which can be used to express the guide RNA and / or RNA targeting enzyme in the plant cell; a 5' untranslated region to enhance expression; an intron element to further enhance expression in certain cells, such as monocot cells; a multiple cloning site to provide convenient restriction sites for insertion of one or more guide RNA and / or RNA targeting gene sequences and other desired elements; and a 3' untranslated region to efficiently terminate the expressed transcript.
[0326] These elements of the expression system can be on one or more circular expression constructs (such as plasmids or transformation vectors) or non-circular constructs (such as linear double-stranded DNA).
[0327] In a specific embodiment, the RNA targeting CRISPR expression system comprises at least:
[0328] (a) a nucleotide sequence encoding a guide RNA (gRNA) that hybridizes to a target sequence in a plant, wherein the guide RNA comprises a guide sequence and a direct repeat sequence, and
[0329] (b) a nucleotide sequence encoding an RNA targeting protein,
[0330] Wherein components (a) or (b) are located on the same or different constructs, and thus the different nucleotide sequences may be controlled by the same or different regulatory elements operable in plant cells.
[0331] One or more DNA constructs comprising components of the RNA-targeted CRISPR system and template sequences (where applicable) can be introduced into the genome of a plant, plant part or plant cell by a variety of conventional techniques. The process generally comprises the following steps: selecting a suitable host cell or host tissue, introducing one or more constructs into the host cell or host tissue, and regenerating the plant cell or plant therefrom. In a specific embodiment, the DNA construct can be introduced into the plant cell using techniques such as, but not limited to, electroporation of plant cell protoplasts, microinjection, aerosol beam injection, or bioprojectiles such as DNA particle bombardment can be used to introduce the DNA construct directly into plant tissue (see also Fu et al., Transgenic Res, February 2000; 9(1): 11-9). The basis of particle bombardment is to accelerate the particles coated with the target gene toward the cell so that the particles penetrate the protoplasm and are generally stably integrated into the genome. (See, e.g., Klein et al., Nature (1987); Klein et al., Bio / Technology (1992); Casas et al., Proc. Natl. Acad. Sci. USA (1993)).
[0332] In a specific embodiment, a DNA construct containing components of an RNA-targeted CRISPR system can be introduced into a plant by Agrobacterium-mediated transformation. The DNA construct can be combined with a suitable T-DNA flanking region and introduced into a conventional Agrobacterium tumefaciens host vector. Exogenous DNA can be incorporated into the plant genome by infecting the plant or by incubating plant protoplasts with Agrobacterium bacteria containing one or more Ti (tumor-inducing) plasmids. (See, for example, Fraley et al., (1985); Rogers et al., (1987); and U.S. Patent No. 5,563,055).
[0333] Plant promoter
[0334] To ensure proper expression in plant cells, the components of the Cas13b CRISPR system described herein are generally placed under the control of a plant promoter, i.e., a promoter operable in plant cells. The use of different types of promoters is contemplated.
[0335] A constitutive plant promoter is a promoter that is capable of expressing an open reading frame (ORF) that it controls (referred to as "constitutive expression") in all or nearly all plant tissues at all or nearly all developmental stages of a plant. A non-limiting example of a constitutive promoter is the cauliflower mosaic virus 35S promoter. The present invention contemplates methods for modifying RNA sequences, and therefore also contemplates regulating the expression of plant biomolecules. Therefore, in a particular embodiment of the present invention, it is advantageous to place one or more elements of the RNA-targeting CRISPR system under the control of a promoter that can be regulated. "Regulatable promoter" refers to a promoter that directs gene expression non-constitutively but in a temporally and / or spatially regulated manner, and includes tissue-specific, tissue-preferred, and inducible promoters. Different promoters can direct gene expression in different tissues or cell types or at different developmental stages or in response to different environmental conditions. In a particular embodiment, one or more RNA-targeting CRISPR components are expressed under the control of a constitutive promoter such as the cauliflower mosaic virus 35S promoter. Tissue-preferred promoters can be used to target enhanced expression in certain cell types within specific plant tissues (e.g., vascular cells of leaves or roots) or specific cells of seeds. Examples of specific promoters for RNA-targeted CRISPR systems can be found in Kawamata et al., (1997) Plant Cell Physiol 38:792-803; Yamamoto et al., (1997) Plant J 12:255-65; Hire et al., (1992) Plant Mol Biol 20:207-18; Kuster et al., (1995) Plant Mol Biol 29:759-72; and Capana et al., (1994) Plant Mol Biol 25:681-91.
[0336] Examples of promoters that can be induced and allow spatiotemporal control of gene editing or gene expression can use energy forms.Energy forms may include, but are not limited to, acoustic energy, electromagnetic radiation, chemical energy, and / or thermal energy.Examples of inducible systems include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule dual hybrid transcriptional activation systems (FKBP, ABA, etc.), or light-inducible systems (photochromes, LOV domains, or cryptochromes), such as light-inducible transcriptional effectors (LITEs) that guide changes in transcriptional activity in a sequence-specific manner.Components of light-inducible systems may include RNA-targeted CRISPR enzymes, light-responsive cytochrome heterodimers (e.g., from Arabidopsis thaliana), and transcriptional activation / repression domains.Other examples of inducible DNA binding proteins and methods of use thereof are provided in US 61 / 736465 and US 61 / 721,283, which are hereby incorporated by reference in their entirety.
[0337] In a specific embodiment, transient or inducible expression can be achieved by using, for example, a chemically regulated promoter (i.e., using exogenous chemicals to induce gene expression). Regulation of gene expression can also be obtained by chemically repressible promoters (wherein chemical substances are used to repress gene expression). Chemically inducible promoters include, but are not limited to, the corn ln2-2 promoter (De Veylder et al., (1997) Plant Cell Physiol 38:568-77) activated by benzenesulfonamide herbicide safeners, the corn GST promoter (GST-11-27, WO93 / 01294) activated by hydrophobic electrophilic compounds used as pre-emergence herbicides, and the tobacco PR-1a promoter (Ono et al., (2004) Biosci Biotechnol Biochem 68:803-7) activated by salicylic acid. Promoters regulated by antibiotics such as tetracycline-inducible and tetracycline-repressible promoters (Gatz et al., (1991) Mol Gen Genet 227:229-37; and US Pat. Nos. 5,814,618 and 5,789,156) can also be used herein.
[0338] Translocation to and / or expression in specific plant organelles
[0339] The expression system may comprise elements for translocation to and / or expression in specific plant organelles.
[0340] Chloroplast targeting
[0341] In certain embodiments, it is contemplated that the expression and / or translation of chloroplast genes is specifically modified or expression in chloroplasts is ensured using RNA-targeted CRISPR systems. To this end, chloroplast transformation methods are used or RNA-targeted CRISPR components are compartmentalized to enter the chloroplasts. For example, the introduction of genetic modifications in the plastid genome can reduce biosafety issues, such as gene flow through pollen.
[0342] Chloroplast transformation methods are known in the art and include particle bombardment, PEG treatment and microinjection. In addition, methods involving translocation of the transformation cassette from the nuclear genome to the plastid as described in WO2010061186 may be used.
[0343] Alternatively, it is envisioned that one or more RNA targeting CRISPR components are targeted to plant chloroplasts. This is achieved by incorporating a sequence encoding a chloroplast transit peptide (CTP) or a plastid transit peptide in the expression construct (which is operably linked to the 5' region of the sequence encoding the RNA targeting protein). CTP is removed in the processing step during translocation to the chloroplast. Chloroplast targeting of the expressed protein is well known to those skilled in the art (see, for example, Protein Transport into Chloroplasts, 2010, Annual Review of Plant Biology, Vol. 61: 157-180). In such embodiments, it is also desirable to target one or more guide RNAs to plant chloroplasts. Methods and constructs for making guide RNA translocation into chloroplasts by means of chloroplast localization sequences are described in, for example, US20040142476, which is incorporated herein by reference. Such variants of the construct can be incorporated into the expression system of the present invention to effectively translocate one or more RNA targeting guide RNAs.
[0344] A polynucleotide encoding a CRISPR-RNA targeting system is introduced into algal cells.
[0345] Transgenic algae (or other plants, such as rapeseed) may be particularly useful in producing vegetable oils or biofuels such as alcohols (especially methanol and ethanol) or other products. They can be engineered to express or overexpress high levels of oil or alcohol for use in the oil or biofuel industry.
[0346] US 8945839 describes a method for engineering microalgae (Chlamydomonas reinhardtii cells) using Cas9. Using similar tools, the methods of the RNA targeting CRISPR system described herein can be applied to Chlamydomonas species and other algae. In a specific embodiment, one or more RNA targeting proteins and guide RNAs are introduced into algae expressed by a vector expressing the RNA targeting protein under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2-tubulin. Optionally, a vector containing a T7 promoter is used to deliver the guide RNA. Alternatively, RNA targeting mRNA and in vitro transcribed guide RNA can be delivered to algae cells. Electroporation protocols are available to technicians, such as standard recommended protocols derived from the GeneArt Chlamydomonas Engineering kit.
[0347] Introducing a polynucleotide encoding an RNA targeting component into yeast cells
[0348] In a specific embodiment, the present invention relates to the use of RNA-targeted CRISPR systems for RNA editing in yeast cells. Methods for transforming yeast cells that can be used to introduce polynucleotides encoding RNA-targeted CRISPR system components are well known to those skilled in the art and are reviewed in Kawai et al., 2010, Bioeng Bugs. 2010 November to December; 1(6): 395-403. Non-limiting examples include transforming yeast cells by lithium acetate treatment (which may also include carrier DNA and PEG treatment), bombardment or electroporation.
[0349] Transient expression of RNA-targeted CRISPR system components in plants and plant cells
[0350] In certain embodiments, it is contemplated that the guide RNA and / or RNA targeting gene is transiently expressed in plant cells. In these embodiments, the RNA targeting CRISPR system ensures modification of the RNA target molecule only when both the guide RNA and the RNA targeting protein are present in the cell, thereby further controlling gene expression. Since the expression of the RNA targeting enzyme is transient, plants regenerated from such plant cells generally do not contain exogenous DNA. In certain embodiments, the RNA targeting enzyme is stably expressed by the plant cell and the guide sequence is transiently expressed.
[0351] In a particularly preferred embodiment, plant viral vectors can be used to introduce RNA-targeted CRISPR system components into plant cells (Scholthof et al., 1996, Annu Rev Phytopathol. 1996; 34: 299-323). In another specific embodiment, the viral vector is a vector from a DNA virus. For example, a geminivirus (e.g., cabbage leaf curl virus, bean yellow dwarf virus, wheat dwarf virus, tomato leaf curl virus, corn streak virus, tobacco leaf curl virus, or tomato golden mosaic virus) or a dwarf virus (e.g., broad bean necrotic yellows virus). In other specific embodiments, the viral vector is a vector from an RNA virus. For example, tobacco rattle virus (e.g., tobacco rattle virus, tobacco mosaic virus), potato virus (e.g., potato virus X) or barley virus (e.g., barley stripe mosaic virus). The replicating genome of the plant virus is a non-integrating vector, which is meaningful in avoiding the production of transgenic plants.
[0352] In a specific embodiment, the vector used for transient expression of RNA targeting CRISPR constructs is, for example, a pEAQ vector, which is customized for Agrobacterium-mediated transient expression in protoplasts (Sainsbury F. et al., Plant Biotechnol J., 2009 September; 7(7): 682-93). The precise targeting of genomic locations was demonstrated using a modified cabbage leaf curl virus (CaLCuV) vector to express gRNA in stable transgenic plants expressing CRISPR enzymes (Scientific Reports 5, article number: 14926 (2015), doi: 10.1038 / srep14926).
[0353] In certain embodiments, double-stranded DNA fragments encoding guide RNA and / or RNA targeting genes can be transiently introduced into plant cells. In such embodiments, the amount of double-stranded DNA fragments introduced is sufficient to modify one or more RNA molecules in the cell, but will not persist after the expected period of time or after one or more cell divisions. Methods for directly transferring DNA into plants are known to the skilled person (see, e.g., Davey et al., Plant Mol Biol. 1989 September; 13(3): 273-85.)
[0354] In other embodiments, an RNA polynucleotide encoding an RNA targeting protein is introduced into a plant cell and then translated and processed by the host cell to produce a protein (in the presence of at least one guide RNA) sufficient to modify the RNA molecule in the cell, but the protein produced does not persist after the expected period of time or after one or more cell divisions. Methods for introducing mRNA into plant protoplasts for transient expression are known to the skilled person (see, for example, Gallie, Plant Cell Reports (1993), 13; 119-122). Combinations of the above different methods are also contemplated.
[0355] Delivery of RNA-targeted CRISPR components to plant cells
[0356] In a specific embodiment, it is meaningful to deliver one or more components of the RNA targeting CRISPR system directly to the plant cell. This is particularly meaningful for producing non-transgenic plants (see below). In a specific embodiment, one or more RNA targeting components are prepared outside the plant or plant cell and delivered to the cell. For example, in a specific embodiment, the RNA targeting protein is prepared in vitro before being introduced into the plant cell. The RNA targeting protein can be prepared by a variety of methods known to those skilled in the art, including recombinant production. After expression, the RNA targeting protein is isolated, refolded if necessary, purified and optionally treated to remove any purification tags, such as His tags. Once an unprocessed, partially purified or more completely purified RNA targeting protein is obtained, the protein can be introduced into a plant cell.
[0357] In certain embodiments, the RNA targeting protein is mixed with a guide RNA that targets a target RNA to form a preassembled ribonucleoprotein.
[0358] Individual components or preassembled ribonucleoproteins can be introduced into plant cells via electroporation, by bombardment with particles coated with RNA targeting-related gene products, by chemical transfection, or by some other means of translocation across the cell membrane. For example, it has been demonstrated that transfection of plant protoplasts with preassembled CRISPR ribonucleoproteins can ensure targeted modification of plant genomes (as described in Woo et al. Nature Biotechnology, 2015; DOI: 10.1038 / nbt.3389). These methods can be improved to achieve targeted modification of RNA molecules in plants.
[0359] In a specific embodiment, nanoparticles are used to introduce RNA targeting CRISPR systems into plant cells. These components can be loaded onto nanoparticles as proteins or nucleic acids or in combination thereof or packaged into nanoparticles and applied to plants (such as described in WO 2008042156 and US20130185823). Specifically, embodiments of the present invention include nanoparticles loaded or packaged together with one or more DNA molecules encoding RNA targeting proteins, DNA molecules encoding guide RNAs, and / or separated guide RNAs, as described in WO2015089419.
[0360] Another means of introducing one or more components of the RNA targeting CRISPR system into plant cells is by using a cell penetrating peptide (CPP). Thus, in particular, embodiments of the present invention include compositions comprising a cell penetrating peptide linked to an RNA targeting protein. In certain embodiments of the invention, the RNA targeting protein and / or one or more guide RNAs are linked to one or more CPPs for efficient transport into plant protoplasts (Ramakrishna (2014, Genome Res. 2014 Jun; 24(6): 1020-7 (for Cas9 in human cells)). In other embodiments, the RNA targeting gene and / or one or more guide RNAs are encoded by one or more circular or non-circular DNA molecules that are linked to one or more CPPs for plant protoplast delivery. The plant protoplasts are then regenerated into plant cells and further regenerated into plants. CPPs are generally described as short peptides of less than 35 amino acids derived from proteins or chimeric sequences that are capable of transporting biomolecules across cell membranes in a receptor-independent manner. CPPs can be cationic peptides, peptides with hydrophobic sequences, amphipathic peptides, peptides with proline-rich and antimicrobial sequences, and chimeric or bipartite peptides (Pooga and Langel 2005). CPPs are able to penetrate biological membranes and thus trigger the movement of various biomolecules across the cell membrane into the cytoplasm and improve their intracellular routes, thereby promoting the interaction between biomolecules and targets. Examples of CPPs include, among others: Tat (a nuclear transcription activator protein required for HIV type 1 viral replication), penetratin, Kaposi fibroblast growth factor (FGF) signal peptide sequence, integrin β3 signal peptide sequence; polyarginine peptide Args sequence, guanine-rich molecular transporter, sweet arrow peptide, etc.
[0361] Target RNAs envisioned for plant, algae or fungal applications
[0362] Target RNA, i.e., target RNA, is the RNA to be targeted by the present invention, so as to cause recruitment to the target target site on the target RNA and the RNA targeting protein to bind at the target target site. The target RNA can be any suitable form of RNA. In some embodiments, this can include mRNA. In other embodiments, the target RNA can include transfer RNA (tRNA) or ribosomal RNA (rRNA). In other embodiments, the target RNA can include interfering RNA (RNAi), microRNA (miRNA), microswitch, microenzyme, satellite RNA and RNA virus. The target RNA can be located in the cytoplasm of a plant cell, or in a nucleus or a plant cell organelle (such as mitochondria, chloroplasts or plastids).
[0363] In certain embodiments, RNA-targeting CRISPR systems are used to cleave RNA or otherwise inhibit RNA expression.
[0364] Use of RNA-targeted CRISPR systems to regulate plant gene expression via RNA regulation
[0365] RNA targeting proteins can also be used together with suitable guide RNAs for targeted gene expression via controlling RNA processing. Controlling RNA processing can include RNA processing reactions (such as RNA splicing, including alternative splicing) or specific targeting of certain splice variants or isotypes; viral replication (especially plant viruses, including viroids and tRNA biosynthesis in plants). RNA targeting proteins can also be combined with suitable guide RNAs for controlling RNA activation (RNAa). RNAa will promote gene expression, so control of gene expression can be achieved by destroying or reducing RNAa to reduce the promotion of gene expression.
[0366] The RNA targeting effector protein of the present invention can also be used for antiviral activity in plants, particularly against RNA viruses. Suitable guide RNAs that are selective for selected viral RNA sequences can be used to target the effector protein to viral RNA. Specifically, the effector protein can be an active nuclease that cleaves RNA such as single-stranded RNA. Therefore, the use of the RNA targeting effector protein of the present invention as an antiviral agent is provided. Examples of viruses that can be resisted in this way include, but are not limited to, tobacco mosaic virus (TMV), tomato spotted wilt virus (TSWV), cucumber mosaic virus (CMV), potato virus Y (PVY), cauliflower mosaic virus (CaMV) (RT virus), plum pox virus (PPV), bromegrass mosaic virus (BMV) and potato virus X (PVX).
[0367] Also described herein are examples of modulating RNA expression in plants, algae or fungi as an alternative to targeted gene modification.
[0368] Of particular interest is the regulatory control of gene expression by regulating the cleavage of mRNA. This can be achieved by placing the RNA targeting element under the control of a regulatable promoter as described herein.
[0369] Use of the RNA-targeting CRISPR system to restore the function of tRNA molecules.
[0370] Pring et al. described RNA editing in plant mitochondria and chloroplasts, which can change the mRNA sequence to encode proteins different from DNA. (Plant Mol. Biol. (1993) 21 (6): 1163-1170. doi: 10.1007 / BF00023611). In a specific embodiment of the present invention, elements of the RNA targeting CRISPR system that specifically targets mitochondrial and chloroplast mRNA can be introduced into plants or plant cells to mimic the process that occurs in vivo to express different proteins in such plant cell organelles.
[0371] Use of RNA-targeted CRISPR systems as an alternative to RNA interference to inhibit RNA expression.
[0372] RNA targeting CRISPR system has uses similar to RNA suppression or RNA interference, and therefore can also replace such methods. In a specific embodiment, the method of the present invention includes using RNA targeting CRISPR as a substitute for, for example, interfering ribonucleic acid (such as siRNA or shRNA or dsRNA). Examples of suppressing RNA expression in plants, algae or fungi are also described herein as an alternative to targeted gene modification.
[0373] Use of RNA-targeting CRISPR systems to control RNA interference.
[0374] Controlling interfering RNA or miRNA can help reduce off-target effects (OTEs) produced by those methods by reducing the life span of interfering RNA or miRNA in vivo or in vitro. In specific embodiments, the target RNA may include interfering RNA, i.e., RNA involved in the RNA interference pathway, such as shRNA, siRNA, etc. In other embodiments, the target RNA may include microRNA (miRNA) or double-stranded RNA (dsRNA).
[0375] In other specific embodiments, if an RNA targeting protein and one or more suitable guide RNAs are selectively expressed (e.g., spatially or temporally under the control of a regulatable promoter, such as a tissue or cell cycle specific promoter and / or enhancer), this can be used to "protect" cells or systems (in vivo or in vitro) from RNAi in these cells. This may be useful in adjacent tissues or cells where RNAi is not desired, or when comparing cells or tissues that do and do not express an effector protein and a suitable guide (i.e., do not control and control RNAi, respectively). RNA targeting proteins can be used to control or bind to molecules comprising or consisting of RNA, such as ribozymes, ribosomes, or riboswitches. In embodiments of the invention, the guide RNA can recruit the RNA targeting protein to these molecules so that the RNA targeting protein can bind to them.
[0376] According to the present disclosure, the RNA targeting CRISPR system of the present invention can be applied to the field of plant RNAi technology without undue experimentation, including pest management, plant disease management and herbicide resistance management, as well as plant assays and other applications (see, for example, Kim et al., Pesticide Biochemistry and Physiology (Impact Factor: 2.01), 01 / 2015; 120.DOI: 10.1016 / j.pestbp.2015.01.002; Sharma et al., Academic Journals (2015), Vol. 12(18), pp. 2303-2312); Green JM, Pest Management Science, Vol. 70(9), pp. 1351-1357), because the present application provides a basis for engineering the system in a well-informed manner.
[0377] Use of RNA-targeted CRISPR systems to modify riboswitches and control metabolic regulation in plants, algae, and fungi
[0378] Riboswitches (also called aptazymes) are regulatory segments of messenger RNA that bind small molecules and thereby regulate gene expression. This mechanism enables cells to sense the intracellular concentration of these small molecules. A particular riboswitch typically regulates a gene by altering the transcription, translation, or splicing of its neighboring gene. Therefore, in a particular embodiment of the invention, it is contemplated that riboswitch activity is controlled by using an RNA targeting protein in combination with a suitable guide RNA to target the riboswitch. This can be achieved by cleaving or binding the riboswitch. In a particular embodiment, it is contemplated that riboswitch activity is reduced. Recently, riboswitches that bind thiamine pyrophosphate (TPP) have been characterized and found to regulate thiamine biosynthesis in plants and algae. In addition, this element appears to be an important regulator of plant primary metabolism (Bocobza and Aharoni, Plant J, August 2014; 79(4): 693-703. doi: 10.1111 / tpj.12540. Electronic version of June 17, 2014). TPP riboswitches are also present in certain fungi such as Neurospora crassa, which control alternative splicing to conditionally generate upstream open reading frames (uORFs), thereby affecting the expression of downstream genes (Cheah MT et al., (2007) Nature 447(7143):497-500, doi:10.1038 / nature05769). The RNA-targeted CRISPR system described herein can be used to manipulate endogenous riboswitch activity in plants, algae or fungi, and thus change the expression of downstream genes controlled by them. In specific embodiments, the RNA-targeted CRISPR system can be used to determine riboswitch function in vivo or in vitro, and to study its relevance to metabolic networks. In specific embodiments, the RNA-targeted CRISPR system can potentially be used to engineer riboswitches into metabolite sensors in plants and platforms for gene control.
[0379] Use of RNA-targeted CRISPR systems for RNAi screening in plants, algae, or fungi
[0380] By identifying the gene product whose knockdown is associated with a phenotypic change, biological pathways can be interrogated and components can be identified via RNAi screening. In a specific embodiment of the invention, the activity of RNAi in the screening can also be removed or reduced by using Cas13b proteins as described herein and suitable guide RNAs to control these screenings or during these screenings, thereby restoring the activity of the (previously disturbed) gene product (by removing or reducing interference / repression).
[0381] Use of RNA targeting proteins for visualizing RNA molecules in vivo and in vitro
[0382] In a specific embodiment, the present invention provides a nucleic acid binding system. In situ hybridization of RNA with complementary probes is a powerful technique. Typically, fluorescent DNA oligonucleotides are used to detect nucleic acids by hybridization. Efficiency has been improved by certain modifications such as locked nucleic acids (LNA), but there is still a need for effective and versatile alternatives. Therefore, the labeling elements of the RNA targeting system can be used as an alternative to an effective and suitable system for in situ hybridization.
[0383] Other applications of RNA-targeted CRISPR systems in plants and yeast
[0384] Application of RNA-targeted CRISPR systems in biofuel production
[0385] As used herein, the term "biofuel" is an alternative fuel made from the source of plants and plant sources. Renewable biofuels can be extracted from organic matter that obtains its energy through a carbon fixation process, or made by using or converting biomass. The biomass can be used directly for biofuels, or it can be converted into a convenient energy-containing substance by thermal conversion, chemical conversion and biochemical conversion. This biomass conversion can produce fuels in solid, liquid or gaseous form. There are two types of biofuels: bioethanol and biodiesel. Bioethanol is mainly produced by the sugar fermentation process of cellulose (starch), and cellulose (starch) is mainly derived from corn and sugarcane. On the other hand, biodiesel is mainly produced by oil crops such as rapeseed, palm and soybean. Biofuel is mainly used for transportation.
[0386] Enhancing plant traits for biofuel production
[0387] In a specific embodiment, the methods described herein using RNA targeting CRISPR systems are used to change the properties of the cell wall so that key hydrolyzing agents can enter, thereby more efficiently releasing sugars for fermentation. In a specific embodiment, the biosynthesis of cellulose and / or lignin is modified. Cellulose is the main component of the cell wall. The biosynthesis of cellulose and lignin is co-regulated. By reducing the proportion of lignin in the plant, the proportion of cellulose can be increased. In a specific embodiment, the methods described herein are used to down-regulate the biosynthesis of lignin in the plant, thereby increasing fermentable carbohydrates. More specifically, the methods described herein are used to downregulate at least a first lignin biosynthesis gene selected from 4-coumarate 3-hydroxylase (C3H), phenylalanine ammonia lyase (PAL), cinnamate 4-hydroxylase (C4H), hydroxycinnamoyltransferase (HCT), caffeic acid O-methyltransferase (COMT), caffeoyl-CoA 3-O-methyltransferase (CCoAOMT), ferulic acid 5-hydroxylase (F5H), cinnamyl alcohol dehydrogenase (CAD), cinnamoyl-CoA-reductase (CCR), 4-coumarate-CoA ligase (4CL), monolignol-lignin-specific glycosyltransferase and aldehyde dehydrogenase (ALDH), as disclosed in WO2008064289 A2.
[0388] In certain embodiments, the methods described herein are used to produce plant matter that produces lower levels of acetic acid during fermentation (see also WO 2010096488).
[0389] Modifying yeast for biofuel production
[0390] In a specific embodiment, bioethanol is produced by recombinant microorganisms using RNA targeting enzymes provided herein. For example, RNA targeting enzymes can be used to engineer microorganisms such as yeast to produce biofuels or biopolymers from fermentable sugars, and optionally can degrade plant-derived lignocellulose derived from agricultural waste as a source of fermentable sugars. More specifically, the present invention provides methods for modifying the expression of endogenous genes required for biofuel production and / or modifying endogenous genes that can interfere with biofuel synthesis using RNA targeting CRISPR complexes. More specifically, these methods involve stimulating one or more nucleotide sequences encoding enzymes involved in the conversion of pyruvic acid into ethanol or another target product to be expressed in microorganisms such as yeast. In a specific embodiment, these methods ensure that stimulation allows the expression of one or more enzymes such as cellulases that allow microbial degradation of cellulose. In another embodiment, RNA targeting CRISPR complexes are used to suppress endogenous metabolic pathways that compete with biofuel production pathways.
[0391] Modifying algae and plants for production of vegetable oils or biofuels
[0392] For example, transgenic algae or other plants such as rapeseed may be particularly useful in producing vegetable oils or biofuels such as alcohols (especially methanol and ethanol). They can be engineered to express or overexpress high levels of oil or alcohol for use in the oil or biofuel industry.
[0393] US 8945839 describes a method for engineering microalgae (Chlamydomonas reinhardtii cells) using Cas9. Using similar tools, the method of the RNA targeting CRISPR system described herein can be applied to Chlamydomonas species and other algae. In a specific embodiment, RNA targeting effector protein and guide RNA are introduced into algae expressed by a vector expressing RNA targeting effector protein under the control of a constitutive promoter such as Hsp70A-RbcS2 or Beta2-tubulin. A vector containing a T7 promoter will be used to deliver guide RNA. Alternatively, guide RNA transcribed in vitro can be delivered to algae cells. The electroporation protocol follows the standard recommended protocol derived from the GeneArt Chlamydomonas Engineering kit.
[0394] Specific applications of RNA-targeted enzymes in plants
[0395] In certain embodiments, the present invention can be used as a therapy for removing viruses in plant systems due to its ability to cleave viral RNA. Previous studies in human systems have shown that the single-stranded RNA virus hepatitis C was successfully targeted using CRISPR (A. Price et al., Proc. Natl. Acad. Sci, 2015). These methods can also be adapted to use the RNA targeting CRISPR system in plants.
[0396] Improved plants
[0397] The present invention also provides plants and yeast cells obtainable and obtained by the methods provided herein. The improved plants obtained by the methods described herein can be used in food or feed production by modifying, for example, the expression of genes that ensure tolerance to plant pests, herbicides, drought, low or high temperatures, excess water, etc.
[0398] The modified plants, especially crops and algae obtained by the methods described herein can be used in food or feed production by expressing, for example, higher protein, carbohydrate, nutrient or vitamin levels than normally seen in the wild type. In this regard, modified plants, especially beans and tubers are preferred.
[0399] For example, modified algae or other plants such as rapeseed may be particularly useful in producing vegetable oils or biofuels such as alcohols (especially methanol and ethanol). They can be engineered to express or overexpress high levels of oil or alcohol for use in the oil or biofuel industry.
[0400] The present invention also provides improved parts of plants. Plant parts include, but are not limited to, leaves, stems, roots, tubers, seeds, endosperms, ovules and pollen. The plant parts contemplated herein can be viable, non-viable, reproducible and / or non-reproducible.
[0401] Also contemplated herein are plant cells and plants produced according to the methods of the present invention. Gametes, seeds, embryos (zygotes or somatic cells), progeny or hybrids of plants comprising genetic modifications produced by traditional breeding methods are also included within the scope of the present invention. Such plants may comprise heterologous or exogenous DNA sequences that insert or replace the target sequence. Alternatively, such plants may only comprise changes (mutations, deletions, insertions, substitutions) in one or more nucleotides. Therefore, the difference between such plants and their ancestral plants will only be the presence of specific modifications.
[0402] In one embodiment of the present invention, the Cas13b system is used to engineer pathogen-resistant plants, for example, by producing resistance to diseases caused by bacteria, fungi or viruses. In certain embodiments, pathogen resistance can be achieved by engineering crops to produce a Cas13b system that will be ingested by pests, causing their death. In one embodiment of the present invention, the Cas13b system is used to engineer abiotic stress tolerance. In another embodiment, the Cas13b system is used to engineer drought stress tolerance or salt stress tolerance or cold stress tolerance or heat stress tolerance. Younis et al. 2014, Int. J. Biol. Sci. 10; 1150 reviewed potential targets for plant breeding methods, all of which can be corrected or improved by using the Cas13b system described herein. Some non-limiting target crops include rice (Oryza sativa L), European plum (Prunus domestica L), upland cotton (Gossypium hirsutum), yellow tobacco (Nicotiana rustica), corn (Zea mays), alfalfa (Medicago sativa), Nicotiana benthamiana, and Arabidopsis thaliana.
[0403] In one embodiment of the present invention, the Cas13b system is used to manage crop pests. For example, a Cas13b system operable in crop pests can be expressed from a plant host or directly transferred to a target, for example, using a viral vector.
[0404] In one embodiment, the present invention provides a method for efficiently generating a homozygous organism from a heterozygous non-human starting organism. In one embodiment, the present invention is used in plant breeding. In another embodiment, the present invention is used in animal breeding. In such embodiments, recombination is prevented or inhibited by interfering with at least one target gene involved in double-strand breaks, chromosome pairing and / or strand exchange, thereby preparing a homozygous organism, such as a plant or animal.
[0405] Application of Cas13b protein in an optimized functional RNA targeting system
[0406] On the one hand, the present invention provides a system for specifically delivering functional components to an RNA environment. This can be ensured using a CRISPR system comprising an RNA targeting effector protein of the present invention that allows specific targeting of different components to RNA. More specifically, such components include activators or repressors, such as activators or repressors of RNA translation, degradation, etc. The application of this system is described elsewhere herein.
[0407] According to one aspect, the present invention provides a non-naturally occurring or engineered composition comprising a guide RNA, the guide RNA comprising a guide sequence capable of hybridizing with a target sequence in a target genomic locus in a cell, wherein the guide RNA is modified by inserting one or more different RNA sequences bound to an adapter protein. In a specific embodiment, the RNA sequence can be bound to two or more adapter proteins (e.g., aptamers), and wherein each adapter protein is associated with one or more functional domains. It is shown that the guide RNA of the Cas13b enzyme described herein can modify the guide sequence. In a specific embodiment, the guide RNA is modified by inserting one or more different RNA sequences in the 5', 3' of the forward repeat sequence, or in the forward repeat sequence. When there are more than one functional domain, these functional domains may be identical or different, such as two functional domains are identical, or the activators or repressors of the two functional domains are different. In one aspect, the invention provides a composition as discussed herein, wherein one or more functional domains are attached to an RNA targeting enzyme such that, when bound to a target RNA, the functional domain is in a spatial orientation that allows the functional domain to function in accordance with its attribute function; In one aspect, the invention provides a composition as discussed herein, wherein the composition comprises a CRISPR-Cas complex having at least three functional domains, at least one functional domain is associated with an RNA targeting enzyme, and at least two functional domains are associated with a gRNA.
[0408] Thus, in one aspect, the invention provides a non-naturally occurring or engineered CRISPR-Cas13b composite composition comprising a guide RNA discussed herein and Cas13b as an RNA targeting enzyme, wherein optionally the RNA targeting enzyme comprises at least one mutation such that the nuclease activity of the RNA targeting enzyme is no more than 5% of the enzyme without the at least one mutation, and optionally one or more comprises at least one or more nuclear localization sequences. In a specific embodiment, the guide RNA is additionally or alternatively modified so as to still ensure binding of the RNA targeting enzyme, but to prevent cleavage by the RNA targeting enzyme (as described in detail elsewhere herein).
[0409] In a particular embodiment, the RNA targeting enzyme is a Cas13b enzyme whose nuclease activity is reduced by at least 97% or 100% compared to a Cas13b enzyme without at least one mutation. In one aspect, the invention provides a composition as discussed herein, wherein the Cas13b enzyme comprises two or more mutations, as further discussed herein.
[0410] In a specific embodiment, an RNA targeting system as described above comprising two or more functional domains is provided. In a specific embodiment, the two or more functional domains are heterologous functional domains. In a specific embodiment, the system comprises an adapter protein, which is a fusion protein comprising a functional domain, the fusion protein optionally comprising a linker between the adapter protein and the functional domain. In a specific embodiment, the linker comprises a GlySer linker. Additionally or alternatively, one or more functional domains are attached to the RNA effector protein via a linker, optionally a GlySer linker. In a specific embodiment, one or more functional domains are attached to the RNA targeting enzyme via one or two HEPN domains.
[0411] In one aspect, the invention provides a composition as discussed herein, wherein the one or more functional domains associated with the adaptor protein or RNA targeting enzyme are domains capable of activating or repressing RNA translation. In one aspect, the invention provides a composition as discussed herein, wherein at least one of the one or more functional domains associated with the adaptor protein has one or more activities, including methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, DNA integration activity, RNA cleavage activity, DNA cleavage activity or nucleic acid binding activity, or molecular switch activity or chemical inducibility or light inducibility.
[0412] In one aspect, the invention provides a composition as discussed herein comprising an aptamer sequence. In a specific embodiment, the aptamer sequence is two or more aptamer sequences specific for the same adapter protein. In one aspect, the invention provides a composition as discussed herein, wherein the aptamer sequence is two or more aptamer sequences specific for different adapter proteins. In one aspect, the invention provides a composition as discussed herein, wherein the adapter protein comprises MS2, PP7, Qβ, F2, GA, fr, JP501, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, φCb5, φCb8r, φCb12r, φCb23r, 7s, PRR1. Thus, in a specific embodiment, the aptamer is selected from a binding protein that specifically binds to any of the above adapter proteins. In one aspect, the invention provides a composition as discussed herein, wherein the cell is a eukaryotic cell. In one aspect, the invention provides a composition as discussed herein, wherein the eukaryotic cell is a mammalian cell, a plant cell or a yeast cell, whereby the mammalian cell is optionally a mouse cell. In one aspect, the invention provides a composition as discussed herein, wherein the mammalian cell is a human cell.
[0413] In one aspect, the invention provides a composition as discussed herein above, wherein there is more than one gRNA, and these gRNAs target different sequences, whereby when the composition is used, there is multiplexing. In one aspect, the invention provides a composition, wherein there is more than one gRNA, which are modified by inserting one or more different RNA sequences that bind to one or more adapter proteins.
[0414] In one aspect, the invention provides a composition as herein discussed, wherein there is one or more adaptor proteins associated with one or more functional domains, and these adaptor proteins bind to different RNA sequences inserted into the guide RNA.
[0415] In one aspect, the invention provides a composition discussed herein, wherein the guide RNA is modified to have at least one non-coding functional loop; for example, wherein at least one non-coding functional loop is repressive; for example, wherein at least one non-coding functional loop comprises Alu.
[0416] In one aspect, the invention provides a method for modifying gene expression comprising administering to a host or expressing in vivo in a host one or more compositions discussed herein.
[0417] In one aspect, the invention provides methods discussed herein comprising delivering the composition or one or more nucleic acid molecules encoding it, wherein the one or more nucleic acid molecules are operably linked to one or more regulatory sequences and expressed in vivo. In one aspect, the invention provides methods discussed herein, wherein in vivo expression is via lentivirus, adenovirus or AAV.
[0418] In one aspect, the invention provides a mammalian cell line of a cell as discussed herein, wherein the cell line is optionally a human cell line or a mouse cell line. In one aspect, the invention provides a transgenic mammalian model, optionally a mouse, wherein the model is transformed with a composition as discussed herein, or the model is a progeny of the transformant.
[0419] In one aspect, the present invention provides nucleic acid molecules encoding guide RNA or RNA targeting CRISPR-Cas complexes or compositions discussed herein. In one aspect, the present invention provides a vector comprising: a nucleic acid molecule encoding a guide RNA (gRNA), the guide RNA comprising a guide sequence capable of hybridizing to a target sequence in a target genomic locus in a cell, wherein the direct repeat sequence of the gRNA is modified by inserting one or more different RNA sequences that bind to two or more adapter proteins, and wherein each adapter protein is associated with one or more functional domains; or, wherein the gRNA is modified to have at least one non-coding functional loop. In one aspect, the present invention provides one or more vectors comprising one or more nucleic acid molecules encoding the following substances: a non-naturally occurring or engineered CRISPR-Cas complex composition comprising a gRNA discussed herein, and an RNA targeting enzyme, wherein optionally the RNA targeting enzyme includes at least one mutation such that the nuclease activity of the RNA targeting enzyme is no more than 5% of the RNA targeting enzyme without the at least one mutation, and optionally one or more comprises at least one or more nuclear localization sequences. In one aspect, the vector may further comprise one or more regulatory elements operable in a eukaryotic cell, which are operably linked to a nucleic acid molecule encoding a guide RNA (gRNA) and / or a nucleic acid molecule encoding an RNA targeting enzyme and / or one or more optional nuclear localization sequences.
[0420] In one aspect, the invention provides a kit comprising one or more components described herein above. In some embodiments, the kit comprises a vector system as described above and instructions for using the kit.
[0421] In one aspect, the present invention provides a method for screening for gain of function (GOF) or loss of function (LOF) or for screening non-coding RNA or potential regulatory regions (e.g., enhancers, repressors), comprising cells of the herein-discussed or cell line model discussed herein containing or expressing an RNA targeting enzyme and introducing a composition discussed herein into the cells of the cell line or model, whereby the gRNA comprises an activator or a repressor, and monitoring GOF or LOF for those cells in which the introduced gRNA comprises an activator or for those cells in which the introduced gRNA comprises a repressor, respectively.
[0422] In one aspect, the present invention provides a library of non-naturally occurring or engineered compositions, each comprising: an RNA-targeting CRISPR guide RNA (gRNA), the guide RNA comprising a target RNA sequence capable of hybridizing to a target RNA sequence in a cell; an RNA-targeting enzyme, wherein the RNA-targeting enzyme comprises at least one mutation such that the nuclease activity of the RNA-targeting enzyme is no more than 5% of the RNA-targeting enzyme without the at least one mutation, wherein the gRNA is modified by inserting one or more different RNA sequences that bind to one or more adapter proteins, and wherein the adapter protein is associated with one or more functional domains, wherein the composition comprises one or more or two or more adapter proteins, wherein each protein is associated with one or more functional domains, wherein the gRNA comprises a whole genome library, the library comprising a plurality of RNA-targeting guide RNAs (gRNAs). In one aspect, the present invention provides a library as discussed herein, wherein the nuclease activity of the RNA-targeting enzyme targeting the RNA is reduced by at least 97% or 100% compared to the RNA-targeting enzyme without the at least one mutation. In one aspect, the present invention provides a library as discussed herein, wherein the adapter protein is a fusion protein comprising a functional domain. On the one hand, the invention provides libraries discussed herein, wherein gRNA is not modified by inserting one or more different RNA sequences that bind to one or two or more adapter proteins. On the one hand, the invention provides libraries discussed herein, wherein one or two or more functional domains are associated with RNA targeting enzymes. On the one hand, the invention provides libraries discussed herein, wherein the cell population of cells is a eukaryotic cell population. On the one hand, the invention provides libraries discussed herein, wherein eukaryotic cells are mammalian cells, plant cells or yeast cells. On the one hand, the invention provides libraries discussed herein, wherein mammalian cells are human cells. On the one hand, the invention provides libraries discussed herein, wherein the cell population is an embryonic stem (ES) cell population.
[0423] On the one hand, the invention provides libraries discussed herein, wherein about 100 or more RNA sequences are targeted. On the one hand, the invention provides libraries discussed herein, wherein about 1000 or more RNA sequences are targeted. On the one hand, the invention provides libraries discussed herein, wherein about 20,000 or more sequences are targeted. On the one hand, the invention provides libraries discussed herein, wherein the entire transcriptome is targeted. On the one hand, the invention provides libraries discussed herein, wherein the target is a group of target sequences for a related or desired pathway. On the one hand, the invention provides libraries discussed herein, wherein the pathway is an immune pathway. On the one hand, the invention provides libraries discussed herein, wherein the pathway is a cell division pathway.
[0424] In one aspect, the present invention provides a method for producing a model eukaryotic cell comprising a gene with modified expression. In some embodiments, the disease gene is any gene associated with an increased risk of suffering from or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors encoding the components of the system described above into a eukaryotic cell, and (b) binding the CRISPR complex to a target polynucleotide to modify the expression of the gene, thereby producing a model eukaryotic cell comprising modified gene expression.
[0425] The structural information provided herein allows the interaction of guide RNA with target RNA and RNA targeting enzyme to be interrogated, thereby allowing the guide RNA structure to be engineered or altered to optimize the function of the entire RNA targeting CRISPR-Cas system. For example, the guide RNA can be extended by inserting an adaptor protein that can bind to the RNA without interfering with the RNA targeting protein. These adaptor proteins can also recruit effector proteins or fusions containing one or more functional domains.
[0426] One aspect of the invention is to include the above elements in a single composition or in separate compositions. These compositions can be advantageously applied to a host to induce a functional effect at the genomic level.
[0427] The skilled artisan will appreciate that modifications to the guide RNA that allow the adapter + functional domain to bind but fail to properly position the adapter + functional domain (e.g., due to steric hindrance within the three-dimensional structure of the CRISPR complex) are undesirable modifications. The one or more modified guide RNAs may be modified by inserting one or more different RNA sequences 5' to the direct repeat sequence, within the direct repeat sequence, or 3' to the direct repeat sequence.
[0428] The modified guide RNA, the inactivated RNA targeting enzyme (with or without a functional domain), and the binding protein with one or more functional domains can be individually included in the composition and administered to the host individually or jointly. Alternatively, these components can be provided in the form of a single composition for administration to the host. Administration to the host can be performed via a viral vector (e.g., a lentiviral vector, an adenoviral vector, an AAV vector) known to the technician or described herein for delivery to the host. As described herein, the use of different selective markers (e.g., for lentiviral gRNA selection) and gRNA concentrations (e.g., depending on whether multiple gRNAs are used) may be beneficial to the effect of eliciting improvements.
[0429] Using the provided compositions, those skilled in the art can advantageously and specifically target single or multiple loci with the same or different functional domains, thereby initiating one or more genomic events. These compositions can be used in various methods for screening in libraries in cells and for functional modeling in vivo (e.g., identification of gene activation and function of lincRNA; gain of function modeling; loss of function modeling; establishment of cell lines and transgenic animals using the compositions of the invention for optimization and screening purposes).
[0430] The present invention includes the use of the compositions of the present invention to establish and utilize conditional or inducible CRISPR RNA targeting events. (See, e.g., Platt et al., Cell (2014), http: / / dx.doi.org / 10.1016 / j.cell.2014.09.014; or PCT patent publications cited herein, such as WO 2014 / 093622 (PCT / US2013 / 074667), which are not considered to be prior to the present invention or the present application). For example, the target cell conditionally or inducibly comprises an RNA targeting CRISPR enzyme (e.g., in the form of a Cre-dependent construct) and / or conditionally or inducibly comprises an adapter protein, and when the vector introduced into the target cell is expressed, the vector expresses in the target cell conditions that induce or generate expression of the s RNA targeting enzyme and / or adapter expression. Inducible gene expression affected by a functional domain is also an aspect of the present invention by applying the teachings and compositions of the present invention together with known methods for forming a CRISPR complex. Alternatively, the adaptor protein can be provided as a conditional or inducible element together with the conditional or inducible sRNA targeting enzyme to provide an efficient model for screening purposes, which advantageously requires only minimal design and administration of specific gRNA for a large number of applications.
[0431] Guide RNA comprising a dead guide sequence according to the present invention
[0432] In one aspect, the invention provides guide sequences modified in such a manner that the formation of a CRISPR complex and successful binding to a target are allowed, while at the same time not allowing successful nuclease activity (i.e., no nuclease activity / no insertion and deletion activity). For purposes of explanation, such modified guide sequences are referred to as "dead guides" or "dead guide sequences". In terms of nuclease activity, these dead guides or dead guide sequences may be considered to be catalytically inactive or conformationally inactive. In fact, the dead guide sequence may not be sufficient to participate in productive base pairing in terms of the ability to promote catalytic activity or to distinguish between on-target and off-target binding activity. Briefly, the assay involves synthesizing a CRISPR target RNA and a guide RNA that contains mismatches with the target RNA, combining these substances with an RNA targeting enzyme and cleaving based on gel analysis based on the presence of bands produced by the cleavage products, and quantitatively cleaving based on relative band intensities.
[0433] Thus, in a related aspect, the present invention provides a non-naturally occurring or engineered composition RNA targeting CRISPR-Cas system comprising a functional RNA targeting system as described herein and a guide RNA (gRNA), wherein the gRNA comprises a dead guide sequence, whereby the gRNA is capable of hybridizing with a target sequence, such that the RNA targeting CRISPR-Cas system is directed to a target genomic locus in a cell without detectable RNA cleavage activity of a non-mutated RNA targeting enzyme of the system. It should be understood that any gRNA described elsewhere herein according to the present invention may be used as a dead gRNA / gRNA comprising a dead guide sequence as described below. Any methods, products, compositions and uses described elsewhere herein are equally applicable to the dead gRNA / gRNA comprising a dead guide sequence as further described below. By further guidance, the following specific aspects and embodiments are provided.
[0434] The ability of the death guide sequence to guide the CRISPR complex to sequence-specific binding with the RNA target sequence can be assessed by any suitable assay. For example, the CRISPR system components (including the death guide sequence to be tested) sufficient to form the CRISPR complex can be provided to a host cell with the corresponding target sequence, such as by transfection with a vector encoding the components of the CRISPR sequence, and then the preferential cleavage within the target sequence is assessed. For example, the cleavage of the target RNA polynucleotide sequence can be assessed in a test tube by providing a target sequence, components of the CRISPR complex (including the death guide sequence to be tested and a control guide sequence different from the test death guide sequence), and comparing the binding or cleavage rate at the target sequence between the test guide sequence and the control guide sequence reaction. Other assays are also possible and are conceivable to those skilled in the art. The death guide sequence can be selected to target any target sequence. In some embodiments, the target sequence is a sequence within the cell genome.
[0435] As further explained herein, a variety of structural parameters allow for the appropriate framework to arrive at such dead guides. Dead guide sequences are typically shorter than corresponding guide sequences that cause active RNA cleavage. In specific embodiments, the dead guide is 5%, 10%, 20%, 30%, 40%, 50% shorter than the corresponding guide pointing to the dead guide sequence.
[0436] As explained below and known in the art, one aspect of gRNA-RNA targeting specificity is the forward repeat sequence that will be appropriately connected to this type of guide. Specifically, this means that the design of the forward repeat sequence depends on the source of the RNA targeting enzyme. Therefore, the structural data that can be used for the verified death guide sequence can be used to design Cas13b specific equivalents. For example, the structural similarity between the orthologous nuclease domain HEPN of two or more Cas13b effector proteins can be used to transfer the design of equivalent death guides. Therefore, the death guide sequence herein can be appropriately modified in length and sequence to reflect such Cas13b specific equivalents, thereby allowing the formation of CRISPR complexes and successfully binding to the target RNA, while not allowing successful nuclease activity.
[0437] The use of dead guides herein and in the context of the prior art provides a surprising and unexpected platform for network biology and / or systems biology in in vitro, ex vivo, and in vivo applications, allowing multiplexed gene targeting, in particular bidirectional multiplexed gene targeting. Prior to the use of dead guides, addressing multiple targets has been challenging and in some cases impossible. By using dead guides, multiple targets, and therefore multiple activities, can be addressed, for example, in the same cell, in the same animal, or in the same patient. This multiplexing can occur simultaneously or staggered, for a desired period of time.
[0438] For example, the dead guide allows the use of gRNA as a means of gene targeting, but ultimately does not have nuclease activity, and simultaneously provides a means of guiding activation or repression. The guide RNA comprising the dead guide can be modified in a certain way to also include elements that allow activation or repression of gene activity, particularly protein adapters (e.g., aptamers) that allow functional placement of gene effectors (e.g., activators or repressors of gene activity) as described elsewhere herein. An example is the incorporation of aptamers, as explained herein and in the prior art. Multiple different effector domains can be assembled by engineering the gRNA comprising the dead guide to incorporate aptamers that interact with proteins (Konermann et al., "Genome-scale transcription activation by an engineered CRISPR-Cas9 complex," doi: 10.1038 / nature14136, incorporated herein by reference). It can be modeled after the natural process.
[0439] General Provisions
[0440] In one aspect, the present invention provides a nucleic acid binding system. In situ hybridization of RNA with complementary probes is a powerful technique. Typically, fluorescent DNA oligonucleotides are used to detect nucleic acids by hybridization. Efficiency has been improved by certain modifications such as locked nucleic acids (LNA), but there is still a need for effective and versatile alternatives. The present invention provides an effective, adjustable system for in situ hybridization.
[0441] In embodiments of the present invention, the terms guide sequence and guide RNA are used interchangeably, as in the literature cited above, such as WO 2014 / 093622 (PCT / US2013 / 074667). In general, a guide sequence is any polynucleotide sequence that has sufficient complementarity to a target polynucleotide sequence to hybridize with the target sequence and guide the CRISPR complex to sequence-specific binding to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or more when optimally aligned using a suitable alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, an algorithm based on the Burrows-Wheeler transformation (e.g., Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the length of the guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or less nucleotides. Preferably, the length of the guide sequence is 10-30 nucleotides. The ability of the guide sequence to guide the CRISPR complex to bind sequence-specifically to the target sequence can be assessed by any suitable assay. For example, the CRISPR system components (including the guide sequence to be tested) sufficient to form the CRISPR complex can be provided to a host cell with the corresponding target sequence, such as by transfecting a vector encoding a component of the CRISPR sequence, and then assessing the preferential cleavage within the target sequence, such as by the Surveyor assay described herein. Similarly, the cleavage of the target polynucleotide sequence can be assessed in a test tube by providing a target sequence, components of the CRISPR complex (including a guide sequence to be tested and a control guide sequence different from the test guide sequence), and comparing the binding or cleavage rate at the target sequence between the test guide sequence and the control guide sequence reaction.Other assays are also possible and are within the scope of those skilled in the art. A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within the genome of a cell. Exemplary target sequences include sequences that are unique in the target genome.
[0442] Generally speaking, throughout the specification, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been connected. Vectors include, but are not limited to, single-stranded, double-stranded or partially double-stranded nucleic acid molecules; nucleic acid molecules comprising one or more free ends, not comprising free ends (e.g., in a circular shape); nucleic acid molecules comprising DNA, RNA or both; and other polynucleotide variants known in the art. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop, in which other DNA fragments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, in which a DNA or RNA sequence of viral origin is present in the vector for packaging into a virus (e.g., a retrovirus, a replication-defective retrovirus, an adenovirus, a replication-defective adenovirus, and an adeno-associated virus). Viral vectors also include polynucleotides carried by viruses for transfection into host cells. Certain vectors are capable of autonomous replication in host cells into which they are introduced (e.g., bacterial vectors and episomal mammalian vectors having a bacterial replication origin). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, thereby replicating with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "expression vectors". Vectors used for and resulting in expression in eukaryotic cells may be referred to herein as "eukaryotic expression vectors". Universal expression vectors useful in recombinant DNA technology are generally in the form of plasmids.
[0443] The recombinant expression vector may contain the nucleic acid of the present invention in a form suitable for expressing the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory elements operably linked to the nucleic acid sequence to be expressed, which regulatory elements may be selected based on the host cell to be used for expression. Within a recombinant expression vector, "operably linked" means that the target nucleotide sequence is linked to one or more regulatory elements in a manner that allows the expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system, or in a host cell when the vector is introduced into a host cell).
[0444] The term "regulatory element" refers to a promoter, an enhancer, an internal ribosome entry site (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). For example, such regulatory elements are described in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include regulatory elements that direct nucleotide sequences to direct constitutive expression in many types of host cells and regulatory elements that direct nucleotide sequences (e.g., tissue-specific regulatory sequences) to be expressed only in certain host cells. Tissue-specific promoters can direct expression primarily in desired target tissues, such as muscle, neurons, bones, skin, blood, specific organs (e.g., liver, pancreas), or specific cell types (e.g., lymphocytes). Regulatory elements can also direct expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue or cell type specific. In some embodiments, the vector comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5 or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5 or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5 or more pol I promoters), or a combination thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with CMV enhancer) [see, e.g., Boshart et al., Cell, 41: 521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. The term "regulatory element" also includes enhancer elements, such as WPRE; CMV enhancer; R-U5' fragment in the LTR of HTLV-I (Mol. Cell. Biol., Vol. 8 (1), pp. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78 (3), pp. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the desired expression level, etc.The vector can be introduced into a host cell to produce a transcript, protein or peptide, including a fusion protein or peptide (e.g., a clustered regularly interspaced short palindromic repeat (CRISPR) transcript, protein, enzyme, mutant form thereof, fusion protein thereof, etc.) encoded by a nucleic acid described herein.
[0445] Advantageous vectors include lentiviruses and adeno-associated viruses, and the type of such vectors may also be selected for targeting a particular type of cell.
[0446] As used herein, the term "crRNA" or "guide RNA" or "single guide RNA" or "sgRNA" or "nucleic acid component(s)" of a Type V or Type VI CRISPR-Cas locus effector protein comprises any polynucleotide sequence that has sufficient complementarity to a target nucleic acid sequence to hybridize to the target nucleic acid sequence and guide sequence-specific binding of a nucleic acid-targeting complex to the target nucleic acid sequence.
[0447] In certain embodiments, the CRISPR system provided herein can utilize crRNA or similar polynucleotides comprising a guide sequence, wherein the polynucleotide is RNA, DNA, or a mixture of RNA and DNA, and / or wherein the polynucleotide comprises one or more nucleotide analogs. The sequence may comprise any structure, including but not limited to the structure of natural crRNA, such as a bulge, a hairpin, or a stem-loop structure. In certain embodiments, the polynucleotide comprising a guide sequence forms a duplex with a second polynucleotide sequence, and the second polynucleotide sequence may be an RNA or DNA sequence.
[0448] In certain embodiments, a chemically modified guide RNA is used. Examples of chemical modifications of guide RNAs include, but are not limited to, incorporation of 2'-O-methyl (M), 2'-O-methyl 3' phosphorothioate (MS) or 2'-O-methyl 3' phosphothioate acetate (MSP) at one or more terminal nucleotides. Compared to unmodified guide RNAs, the stability and activity of such chemically modified guide RNAs may be increased, but on-target and off-target specificity cannot be predicted. (See Hendel, 2015, Nat Biotechnol. 33 (9): 985-9, doi: 10.1038 / nbt.3290, published online on June 29, 2015). Chemically modified guide RNAs also include, but are not limited to, RNAs having phosphorothioate bonds and locked nucleic acid (LNA) nucleotides containing a methylene bridge between the 2' and 4' carbons of the ribose ring.
[0449] In some embodiments, the degree of complementarity is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or more when optimally aligned using a suitable alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, an algorithm based on the Burrows-Wheeler transformation (e.g., Burrows WheelerAligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). The ability of a guide sequence (within a nucleic acid-targeting guide RNA) to direct sequence-specific binding of a nucleic acid-targeting complex to a target nucleic acid sequence can be assessed by any suitable assay. For example, a nucleic acid targeting CRISPR system component (including a guide sequence to be tested) sufficient to form a nucleic acid targeting complex can be provided to a host cell having a corresponding target nucleic acid sequence, such as by transfection with a vector encoding a component of a nucleic acid targeting complex, and then the preferential targeting (e.g., cleavage) within the target nucleic acid sequence can be assessed, such as by the Surveyor assay described herein. Similarly, the cleavage of the target nucleic acid sequence can be assessed in a test tube by providing a target nucleic acid sequence, components of a nucleic acid targeting complex (including a guide sequence to be tested and a contro...
Claims
1. A method for modifying a target locus of interest in a eukaryotic cell, preferably a mammalian cell, the method comprising delivering a non-naturally occurring or engineered composition comprising a Cas13b effector protein, optionally fused to one or more localization signals, and one or more nucleic acid components to the locus, wherein at least the one or more nucleic acid components are engineered, the one or more nucleic acid components direct the complex to the target of interest, and the effector protein forms a complex with the one or more nucleic acid components, and the complex binds to the target locus of interest.
2. A non-naturally occurring or engineered composition comprising a Cas13b effector protein, optionally fused to one or more localization signals, and one or more nucleic acid components, wherein at least the one or more nucleic acid components are engineered for modifying a target locus of interest in a eukaryotic cell, the one or more nucleic acid components directing the complex to the target of interest, and the effector protein forms a complex with the one or more nucleic acid components, and the complex binds to the target locus of interest.
3. Use of a non-naturally occurring or engineered composition, the non-naturally occurring or engineered composition comprising a Cas13b effector protein optionally fused to one or more localization signals and one or more nucleic acid components, wherein at least the one or more nucleic acid components are engineered for modifying a target locus of interest in a eukaryotic cell, the one or more nucleic acid components direct the complex to the target of interest, and the effector protein forms a complex with the one or more nucleic acid components, and the complex binds to the target locus of interest.
4. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein has at least 80% homology or identity with a wild-type Cas13b effector protein of a prokaryotic organism selected from Porphyromonas, Prevotella, Bacteroides, Riemerella, Bergeyella, Alternaria, Fragrant Fungus, Capnocytophaga and Flavobacterium.
5. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein has at least 80% homology or identity with a wild-type Cas13b effector protein of a prokaryotic organism selected from Porphyromonas oralis, Prevotella species, Porphyromonas gingivalis, Bacteroides pyogenes, Riemerella anatipestifer, Bergeyella zoohelcum, Prevotella intermedia, Prevotella buccalis, Alternaria species, Prevotella aurantifolia, Flavobacterium spp., Capnocytophaga canimorsus, Flavobacterium branchiophyllum and Flavobacterium columnaris.
6. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein is selected from oral Porphyromonas Cas13b (accession number WP_039434803), Prevotella species P5-125 Cas13b (accession number WP_044065294), gingival Porphyromonas Cas13b (accession number WP_053444417), Porphyromonas species COT-052OH4946 Cas13b (accession number WP_039428968), Bacteroides pyogenes Cas13b (accession number WP_034542281), Riemerella anatipestifer Cas13b (accession number WP_004919755), Bergeyella zoohelcum Cas13b (accession number WP_002664492), Prevotella intermedia Cas13b (accession number WP_036860899), Prevotella buccalis Cas13b (accession number WP_004343973), Porphyromonas gingivalis Cas13b (accession number WP_012458151), ZOR0009 Cas13b (accession number WP_047447901), Prevotella species MA2016 The wild-type Cas13b effector proteins of Cas13b (accession number WP_036929175), Prevotella aurantiaca Cas13b (accession number WP_025000926), CCUG 10230Cas13b (accession number EHO06562), Prevotella intermedia Cas13b (accession number WP_061868553), Capnocytophaga canimorsus Cas13b (accession number WP_013997271), Flavobacterium gillophilum Cas13b (accession number WP_014084666), Flavobacterium spicata Cas13b (accession number WP_058700060), Flavobacterium columnaris Cas13b (accession number WP_065213424) and Prevotella intermedia Cas13b (accession number WP_050955369) have at least 80% homology or identity.
7. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein has at least 80% homology to a wild-type Cas13b effector protein selected from Porphyromonas oralis Cas13b (Accession No. WP_039434803), Prevotella species P5-125 Cas13b (Accession No. WP_044065294), Porphyromonas gingivalis Cas13b (Accession No. WP_053444417), Porphyromonas species COT-052OH4946 Cas13b (Accession No. WP_039428968), Bacteroides pyogenes Cas13b (Accession No. WP_034542281) and Riemerella anatipestifer Cas13b (Accession No. WP_004919755).
8. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein has at least 80% homology to a wild-type Cas13b effector protein selected from Porphyromonas oralis Cas13b (Accession No. WP_039434803) and Prevotella sp. P5-125 Cas13b (Accession No. WP_044065294).
9. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein is a protein comprising a sequence having at least 70% sequence identity to one or more of the sequences consisting of DKHXFGAFLNLARHN (SEQ ID NO: 1), GLLFFVSLFLDK (SEQ ID NO: 2), SKIXGFK (SEQ ID NO: 3), DMLNELXRCP (SEQ ID NO: 4), RXZDRFPYFALRYXD (SEQ ID NO: 5) and LRFQVBLGXY (SEQ ID NO: 6).
10. The method, composition or use of any one of the preceding claims, wherein the target locus of interest comprises RNA.
11. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein is fused to at least one localization signal, and wherein the localization signal is a nuclear localization signal (NLS) or a nuclear export signal (NES), preferably a NES.
12. The method, composition or use of any preceding claim, wherein modification of the target locus of interest comprises strand breaks.
13. The method, composition or use of any one of the preceding claims, wherein the Cas13b effector protein is codon-optimized for expression in mammalian cells.
14. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein is associated with one or more functional domains; and optionally the effector protein contains one or more mutations, such as R116A, H121A, R1177A, H1182A (wherein the amino acid positions correspond to the amino acid positions of the Cas13b protein derived from Bergeyella zoohelcum ATCC 43767), optionally within the HEPN domain, whereby the complex can deliver an epigenetic modifier or a transcriptional or translational activation or repression signal.
15. The method, composition or use of any one of the preceding claims, wherein the functional domain modifies the transcription or translation of the target locus.
16. The method, composition or use of any preceding claim, wherein the target locus of interest is contained in a nucleic acid molecule within a cell.
17. The method, composition or use of any one of the preceding claims, wherein the modification is in vivo or ex vivo.
18. The method, composition or use of any of the preceding claims, wherein the one or more nucleic acid components, when complexed with the effector protein, are capable of effecting sequence-specific binding of the complex to a target sequence of the target locus of interest.
19. The method, composition or use of any one of the preceding claims, wherein the one or more nucleic acid components comprise a double direct repeat sequence.
20. The method, composition or use of any of the preceding claims, wherein the effector protein and the one or more nucleic acid components are provided via one or more polynucleotide molecules encoding the polypeptide and / or the one or more nucleic acid components, and wherein the one or more polynucleotide molecules are operably configured to express the polypeptide and / or the one or more nucleic acid components.
21. A method, composition or use as claimed in claim 20, wherein the one or more polynucleotide molecules comprise one or more regulatory elements operably configured to express the polypeptide and / or the one or more nucleic acid components, optionally wherein the one or more regulatory elements comprise one or more promoters or one or more inducible promoters.
22. The method, composition or use of claim 20 or 21, wherein the one or more polynucleotide molecules are contained within one or more vectors.
23. The method, composition or use of claim 20 or 21, wherein the one or more polynucleotide molecules are contained in a vector.
24. The method, composition or use of claim 22 or 23, wherein the one or more vectors comprise a viral vector.
25. The method, composition or use of claim 24, wherein the one or more viral vectors comprise one or more retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors or herpes simplex viral vectors.
26. The method, composition or use of claim 20 or 21, wherein the one or more polynucleotide molecules are contained in a delivery system, or the method, composition or use of claim 22 or 23, wherein the one or more vectors are contained in a delivery system, or the method, composition or use of any of the preceding claims, wherein the assembled complex is contained in a delivery system.
27. The method, composition or use of any of the preceding claims, wherein the non-naturally occurring or engineered composition is delivered via a delivery vehicle comprising one or more liposomes, one or more particles, one or more exosomes, one or more microvesicles, a gene gun, or one or more viral vectors.
28. A method, composition or use as claimed in any one of the preceding claims, wherein the composition comprises an auxiliary protein that enhances the activity of the Cas13b effector protein, preferably a csx28 protein.
29. A method, composition or use as claimed in any one of the preceding claims, wherein the composition comprises an auxiliary protein that suppresses the activity of the Cas13b effector protein, preferably a csx27 protein.
30. The method, composition or use of any of the preceding claims, wherein the Cas13b effector protein is linked to at least one functional domain; wherein the Cas13b effector protein comprises one or more mutations in the HEPN domain; and wherein the Cas13b effector protein is truncated at its C-terminus, the truncation being optionally selected from Δ1053-1090, Δ1026-1090, Δ984-1090, Δ934-1090, Δ884-1090, Δ834-1090, Δ784-1090 and Δ734-1090 corresponding to amino acid positions of Prevotella sp. P5-125 Cas13b protein.
31. A mammalian cell modified according to the method, or engineered to optionally inducibly or constitutively comprise or express a composition or component thereof as claimed in any preceding or subsequent claim.
32. The mammalian cell of claim 31, wherein the modification results in: - the cell comprises a transcriptional or translational alteration of at least one RNA product; - the cell comprises a transcriptional or translational alteration of at least one RNA product, wherein expression of the at least one product is increased; or - said cell comprises a transcriptional or translational alteration of at least one RNA product, wherein the expression of said at least one product is reduced.
33. A non-naturally occurring or engineered composition as claimed or referred to in any one of claims 1 to 30 for use in vivo or ex vivo in a eukaryotic cell, preferably a mammalian cell: - RNA sequence-specific interference, - RNA sequence-specific gene regulation, - Screening of RNA or RNA products or lincRNA or non-coding RNA, or nuclear RNA or mRNA, - mutagenesis, - Fluorescence in situ hybridization, - Breeding, - Induce cell dormancy in vitro or in vivo, - Induce cell cycle arrest in vitro or in vivo, - Reduction of cell growth and / or cell proliferation in vitro or in vivo, - Inducing cell anergy in vitro or in vivo, - Induce apoptosis in vitro or in vivo, - Induce cell necrosis in vitro or in vivo, - Induce cell death in vitro or in vivo, or - Induction of programmed cell death in vitro or in vivo.
34. A cell line which is a cell line of or comprises the cell according to claim 31 or 32 or its progeny.
35. A eukaryotic organism, preferably a mammal, comprising one or more cells according to claim 31 or 32.
36. A eukaryotic model, preferably a mammalian model, comprising one or more cells according to claim 31 or 32; the one or more cells optionally inducibly or constitutively expressing a composition or component thereof as claimed in any one of the preceding claims.
37. A product derived from a cell as claimed in claim 31 or 32, or a cell line or organism as claimed in claim 34 or 35, or a mammalian model as claimed in claim 36; wherein the one or more cells of the mammal of the cell line or the mammalian model optionally inducibly or constitutively express a composition or component thereof as claimed in any one of the preceding claims.
38. An assay, screening method or mutagenesis method comprising the method, composition or use as claimed in any one of claims 1 to 30.
39. An RNA-based assay, screening method or mutagenesis method wherein the improvement comprises not using RNA, the method comprising using a non-naturally occurring or engineered composition as claimed or referred to in any one of claims 1 to 30, wherein optionally the RNA-based assay, screening method or mutagenesis method is RNAi or fluorescence in situ hybridization method.
40. A method for regulating translation of a eukaryotic target locus of interest, the method comprising delivering a non-naturally occurring or engineered composition as claimed or referred to in any one of claims 1 to 30 to the locus, and wherein the Cas13b effector protein is fused to a (heterologous) translation regulator such as a translation activator or a translation repressor, and optionally to one or more localization signals; wherein at least the one or more nucleic acid components are engineered, the one or more nucleic acid components direct the complex to the target of interest, and the effector protein forms a complex with the one or more nucleic acid components, and the complex binds to the target locus of interest, preferably wherein the heterologous domain is EIF4, such as EIF4E.
41. A method for detecting a target RNA in a sample, comprising (a) incubating the sample with a non-naturally occurring or engineered composition as claimed or referred to in any one of claims 1 to 30 and an RNA-based cleavage-inducible reporter that can be non-specifically and detectably cleaved by the effector protein, (b) detecting the target RNA based on a signal generated by cleavage of the RNA-based cleavage-inducible reporter.
42. The method of claim 41, wherein the RNA-based cleavage-inducible reporter construct comprises a fluorescent dye and a quencher.
43. The method of claim 41 or 42, wherein the target RNA comprises a pathogen RNA.
44. The method of claim 43, wherein the pathogen comprises a virus, a bacterium, a fungus, or a parasite.
45. The method of any one of claims 41 to 44, comprising a guide RNA designed to detect a single nucleotide polymorphism in a splice variant of a target RNA or RNA transcript.
46. The method of any one of claims 41 to 45, wherein the guide RNA comprises one or more nucleotides that are mismatched with the target RNA.
47. The method of any one of claims 41 to 46, wherein the guide RNA binds to a target molecule that is diagnostic of a disease state.
48. The method of claim 47, wherein the disease state comprises cancer.
49. The method of claim 47, wherein the disease state comprises an autoimmune disease.
50. A ribonucleic acid (RNA) detection system comprising a) a non-naturally occurring or engineered composition as claimed or referred to in any one of claims 1 to 30, and c) an RNA-based cleavage-inducible reporter that can be non-specifically and detectably cleaved by the effector protein.
Citation Information
Patent Citations
Crispr-CAS systems and methods for altering expression of gene products
EP2764103A2
Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP2771468B1
Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP2784162B1
Recombinant virus and preparations thereof
US11332719B2
Regulation of endogenous gene expression in cells using zinc finger proteins
US20030087817A1
